14th annual biotech in europe investor forumsachs associates are delighted to welcome you to the...

EXHIBITORSORGANISERS

SUPPORTING ORGANISATIONSPRESENTING COM

PANIESW

ELCOME

SPEAKERS

14th Annual

BIOTECH IN EUROPE INVESTOR FORUM

www.sachsforum.com

30th September – 1st October 2014Congress Center · Basel · Switzerland

Conference Guide

BI

OT

EC

H

IN

E

UR

OP

E

IN

VE

ST

OR

F

OR

UM



PANIESW

ELCOME

SPEAKERS

t back :: next u

Welcome

Request for PresentationsPlease use the agenda to mark off presentations that you are interested in and email your request to [email protected] after the conference. We will endeavour to send you the requested presentations as soon as we have been granted permission to do so by that specific presenter. Please note that we DO NOT have copies of the slides that are shown during the conference.

Sachs Associates are delighted to welcome you to the:

14th Annual

Biotech in EuropeInvestor ForumFor Global Partnering & Investment30th September – 1st October 2014Congress Center Basel, Switzerland

General InformationThe registration desk will be open from 8am on September 30th and from 8am on October 1st although you are welcome to join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session.

Networking at the Forum is facilitated by our online 1-2-1 meeting system, which is available to all participants.

There will be a Networking Lunch.

Coffee stations will be set up in the rooms and the presentation rooms throughout the event.

Sachs Associates are delighted to welcome you to the 14th Annual Biotech in Europe Investor Forum. Following the success of previous years, the forum once again provides access to an exciting cross-section of venture-funded and small-cap companies with leading investors and pharmas.

This Forum is highly transactional and is comprised of a series of panels and presentations from leading investment, pharmaceutical and biotech companies, each one providing an expert outlook on growth and investment activity in Europe’s Biotech industry.

The programme highlights the current issues surrounding the evolving M&A market, the Private Equity & Venture Capital environment and a special session on major trends in Partnering. Plus, this year’s programme features more than 100 company presentations from a range of publicly listed and private life science companies looking to raise finance and/or find partners.



PANIESW

ELCOME

SPEAKERS

t back :: next u

Events Diary

2nd Annual MedTech & Diagnostics Innovations Summit13th November 2014 • Düsseldorf • Germany

The 2nd Annual MedTech & Diagnostics Innovations Summit is once again being held to coincide with the leading annual international tradeshow Medica with its anticipated 135,000 visitors. The Summit is designed to bring together a specialist audience from leading and growth companies focused on M+A, alliances and Investment. The program will feature keynotes from industry leaders and plenary panels on industry acquisitions; public markets, venture investment and growth, company finance, connected health, device and diagnostics. The subjects of regulation and reimbursement will also be covered.

There will be many networking breaks and a conference cocktail reception. There is a 1-to-1 online meeting system with meeting rooms provided. Participation will be limited and presentations by invitation. Financial Investors will receive complimentary passes. We plan an audience of 150 -200 delegates.

3rd Annual Cancer Bio Partnering and Investment ForumPromoting Public & Private Sector, Collaboration & Investment in Drug Development23rd February 2015 • New York • USA

The 2nd Annual Sachs Cancer Bio Partnering Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding/investment. We expect around 300 delegates and there is an online meeting system and meeting facilities to make the event transactional. There will also be a track of presentations by research institutes, patient advocacy groups, pharmaceutical companies on partnering and biotech’s seeking licensing/investment.The Forum will feature an online one-to-one meeting system with designated meeting space available to all attendees.

The Forum will cover the following topics in the program: • Advances in Translational Research • Strategies for Small Molecule and Biologicals Drug Development • Deal Making • Public & Private Partnerships • Diagnostics • Immunotherapies and Cancer Vaccines • Case Study

8th Annual European Life Science CEO Forum & ExhibitionPartnering & Investing in Biotech & Pharma Industry3rd – 4th March 2015 • Zurich • Switzerland

Back for its eighth year, this exclusive and highly transactional partnering event is a must for companies wishing to meet with their peers, engage with leading investors and forge new partnerships.

Building on the success of this year’s event, the forum will provide an excellent platform to gain insight into partnering and investment trends in the Biotech and Pharma industry. Networking at the Forum is facilitated by our online 1-2-1 meeting system, which is available to all participants.

The conference will feature up to 80 presentations by large to mid size pharmaceutical companies looking for strategic alliances/partners.

Do not miss out on this great opportunity to meet emerging companies, leading global investors and Big Pharma representatives!

For regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events please contact Mina Order on [email protected]


SUPPORTING ORGANISATIONS

Speakers

PRESENTING COMPANIES

WELCOM

ESPEAKERS

t back :: next u

Adrian Mills, Chief Business Officer, Novimmune SA

Adrian Mills joined Novimmune in July 2014 after an extensive career with GSK. Most recently he was their EU Commercial Director in the Rare & Critical Diseases Business Unit where he was responsible for launching new orphan medicines for neuromuscular disorders, metabolic diseases and immuno-deficiencies, as well as leading the European rare diseases sales and marketing teams promoting a portfolio of orphan and critical care medicines.

Adrian’s professional background includes launching new medicines and negotiating market access and pricing hurdles in Europe, Japan, Latin America and North America.

With over 20 years experience in life sciences, Adrian has led commercial functions in both R&D, strategy development and commercial operations.

Prior to GSK, he worked in consulting (Booz & Co) and investment banking (Schroders) advising life sciences companies.

Adrian holds an M.A. (Hons) in Engineering from Queens’ College, Cambridge, and an MBA from the London Business School.

Alain Huriez, Venture Partner, Advent Life Sciences

Alain Huriez joined Advent in 2012 bringing 22 years of experience in management, drug development and financing in the life sciences sector, including CEO of TcLand (TcLand Expression & Effimune) and Neovacs, Associate Partner at Truffle Capital and Vice President at Quintiles. Alain is a medical doctor and holds an MBA and a Masters of Pharmaco-Economics from Paris La Sorbonne University. Prior to joining the industry, he was head of the emergency room in a large teaching hospital and practiced as a General Practitioner for two years.

Alain has been responsible for several initiatives in Europe within the areas of personalized medicine, biomarkers and high value diagnostics through his work as chairman of EPEMED, the European Personalised Medicine Association. As an entrepreneur, and in addition to TcLand he also co-founded four biotechnology companies.

Aleš Štrancar, CEO & CBO, BIA Separations

Ales Strancar, the CEO of the BIA Separations and one of the main inventors of the CIM Convective Interaction Media® (new generation of chromatographic support).

Ales Strancar is author or co-author of more than 70 scientific papers dealing with separation and purification technologies. He is a co-author of 5 granted USA patents and their foreign equivalents in the field of biomolecule separations and purification. As well he is a co-author of several book chapters dealing with novel chromatography technologies for biomolecule separation.

Ales Strancar holds a position of Assistant Professor at Biotechnical Faculty of University of Ljubljana.

Anders M. Hinsby, CEO, Orphazyme ApS

Anders is the CEO of Orphazyme ApS, a company he co-founded in 2009 and joined full-time in 2010. Orphazyme develops heat shock protein-based therapies for degenerative diseases and has a special focus on lysosomal storage diseases. Orphazyme is currently planning to take its lead project into Phase II/III clinical development for Niemann Pick disease type C, a debilitating and ultimately fatal lysosomal storage disease. Prior to Orphazyme Anders worked for several years in a major Danish life science venture fund where he became a Partner in 2009.

Before joining the industry Anders was an Assistant Professor in systems biology at the Danish Technical University in the group of Professor Søren Brunak. His work focused on identifying functional protein networks with relevance to physiological and pathological processes. Anders holds a master’s degree in Human Biology and a Ph.D. in Medicine.



Speakers


WELCOM

ESPEAKERS

t back :: next u

André Choulika, Chairman and CEO, Cellectis

André Choulika is the Chairman, CEO, and founder of Cellectis. Dr Choulika is a pioneer in the analysis and use of meganucleases to modify complex genomes. After receiving his PhD in molecular virology from the University of Paris VI (Pierre et Marie Curie), he completed a research fellowship in the Harvard Medical School Department of Genetics. Later, while working in the Division of Molecular Medicine at Boston Children’s Hospital, he developed the first approaches to meganuclease-based human gene therapy.

Dr Choulika also has management training from the HEC (Challenge+).

Andrew Mackie, Lilly Global External R&D, Eli Lilly and Company

Andrew Mackie joined Lilly in 2010 to develop partnership opportunities and to work with institutions to develop creative ways in which to collaborate and fund drug discovery and development. Based at Erl Wood (UK), Andrew seeks to identify opportunities from European Academic Institutions, Biotech companies and other Pharmaceutical partners.

Previously Andrew has focused on early company growth and financing, pre-clinical research, clinical development and business development gained from pharmaceutical (Novartis, Sanofi), biotech (Antisoma) and investment (IP Group) companies.

Andrew joined the UK biotech sector with Antisoma prior to its IPO, initially to establish the clinical department. Later he managed Antisoma’s strategic alliance with F Hoffman-La Roche and in-licensed new drug leads through partnerships and acquisitions. Immediately prior to joining Eli Lilly, he was Head of Life Sciences at IP Group, developing early stage healthcare companies. Andrew holds a BSc in biochemistry from Queen’s Canada, an LLB from the University of London and an MBA from the London Business School.

Anita Riyat, Corporate Strategy, AbbVie Inc.

Anita Riyat is currently a Director of Corporate Strategic Planning at AbbVie in Chicago, where she leads strategic initiatives to evaluate growth opportunities for the company. Prior to this role, she was a member of the Global Business Development group, leading commercial assessments and strategic discussions for potential opportunities.

Prior to joining AbbVie, Anita was at L.E.K. Consulting advising leading companies and financial investors in the pharmaceutical, biotech and health care sectors. Strategic projects included new market entry, portfolio optimization, and M&A assessments across all major therapeutic areas.

Anita received her B.S. in Biomedical Engineering from Northwestern University.

Anthony Rosenberg, Head of M&A and Licensing, Novartis Pharma AG

Tony Rosenberg joined Sandoz in 1980 in the UK where he held various leadership positions in sales and marketing, business development and strategic planning. In 1994 he moved to Basle, initially in international product management (Clozaril), and undertook roles of increasing responsibility in Global Marketing, ultimately as Head Global Marketing Primary Care. In 2000 he became Global Head of the Transplant and Immunology Business Unit. In 2005 he was appointed Global Head Business Development & Licensing (Pharma) and has managed major in-licensing transactions in the cardiovascular, CNS, respiratory, infectious disease and oncology areas, as well as divestment and M&A deals. In 2010 he was given additional responsibility for leadership of the Molecular Diagnostics group. In 2013 he was appointed as Head M&A and Licensing (Corporate).

Tony Rosenberg has a BSc (Biological Sciences) University of Leicester, and an M.Sc (Physiology) University of London.



Speakers


WELCOM

ESPEAKERS

t back :: next u

Avi Spier, Director, Strategic Alliances, Novartis Institute for BioMedical Research, Inc.

Dr. Spier was educated in Biological Sciences at Oxford University, received his Ph.D. in molecular neuroscience from Cambridge University at the MRC-Laboratory of Molecular Biology and trained as a postdoc at The Scripps Research Institute (TSRI), La Jolla, CA, in the laboratory of Dr. Gregor Sutcliffe. In 2001, Dr. Spier co-founded Allon Therapeutics, Inc. and led the peptide therapeutic neurodegenerative disease focused company as its President and CEO through two financing rounds and up to its entry onto the Toronto Stock Exchange. In 2004, Dr. Spier joined the Genomics Institute of the Novartis Research Foundation (GNF), a ~600 person biomedical research institute within the Novartis Institutes for Biomedical Research (NIBR), as its Director of Business Development. Most recently, in 2012 Dr. Spier was appointed Director of Strategic Alliances in NIBR, with responsibility for search and evaluation activities for the Cardiovascular, Metabolism and Diabetes (CVM), Global Discovery Chemistry (GDC), Center for Proteomic Chemistry (CPC) and GNF organizations.

Barbara Dalton, VP Venture Capital, Pfizer Inc.

Dr. Dalton is responsible for Pfizer’s Venture Investments (www.pfizerventureinvestments.com), managing the current private equity portfolio and advising on equity transactions. She began her pharmaceutical career as a research scientist at SmithKline before moving to their venture capital subsidiary, S.R. One, Limited. Dr Dalton was also a founding member of EuclidSR Partners, a private venture capital firm. Barbara has managed diverse fund and company investments throughout the world that focus on life sciences and healthcare. She is an advisor to the Dean of the Penn State Eberly College of Science, where she received her undergraduate degree, and a member of The Penn State Research Foundation Board of Directors. She leads the Healthcare Investing Group of the New York City Investment Fund and is a former member of the Board of Directors of the Alzheimer’s Disease Research Foundation, NY Biotech Association and the National Venture Capital Association. Dr Dalton received her PhD in Immunology and Microbiology from The Medical College of Pennsylvania (now Drexel University College of Medicine).

Bernard Coulie, CEO, ActoGeniX NV

Bernard Coulie joined ActoGeniX as Vice President Research and Development in September 2006. In 2009, he was appointed Chief Medical Officer, and in 2010 he was appointed Chief Executive Officer.

Prior to his appointment to ActoGeniX, Bernard was Therapeutic Area Leader Internal Medicine at Johnson & Johnson (J&J) Pharmaceutical Research and Development Europe. Bernard joined J&J in 2000, and held various positions with increasing responsibilities in drug discovery and early clinical development. Between 1997 and 2000, he was staff Gastroenterologist at the Division of Gastroenterology and Hepatology of the Mayo Clinic (USA). Bernard holds an MD and a PhD from the University of Leuven.

He is a Board-certified Internist and Gastroenterologist and received his MBA from the Vlerick Management School.

Bernard Sixt, CEO, ImmunID

Dr Sixt has over 25 years of pharmaceutical industry experience in the development and commercialization of laboratory services, in vivo and in vitro diagnostics, and pharmaceuticals for industry leaders such as Amersham (now part of GE Healthcare), and Nycomed (now part of Takeda). He is a co-founder of Agendia and has served as the company’s CEO from 2003 until 2011. Dr Sixt holds a Master of Science degree in Biochemistry and Chemistry from Ludwig Maximilians University, and a PhD from the Technical University, both in Munich, Germany.



Speakers


WELCOM

ESPEAKERS

t back :: next u

Beth Jacobs, Managing Partner, Excellentia Global Partners

Beth Jacobs currently serves as Managing Partner of Excellentia Global Partners, a global life sciences investment bank, founded in 2008. Most recently, Beth was a General Partner at Bio-IB, a life science-focused investment bank in New York.

Beth has served in senior executive roles in her twenty five years of experience in both investment banking and in the corporate sector. Prior to 2003, Beth was Managing Director and Co-Head of Global Capital Markets at ING Barings, shortly after their acquisition of Furman Selz LLC, where she founded and led its international institutional equity group. She began her career at Prudential Securities where she founded the international institutional equity business, and later headed the same product execution group at both Morgan Stanley and Lehman Brothers.

In the corporate sector, Beth was most recently Senior Vice President for Laureate Education Inc. (NASDAQ: LAUR), a $3 billion market cap company in the education sector. She worked across all business units in a corporate development role with a distinct focus on identifying and executing on opportunities in China.

She currently serves as a Board Governor of the New York Academy of Sciences, where she sits on the Executive Committee, as a Director of EF Foundation, a global educational services company based in Stockholm and Cambridge, Mass, founding Global Ambassador for Susan G. Komen for the Cure, Board member for both the Harvard Kennedy School of Government Women’s Leadership Board. Ms. Jacobs also serves as a special advisor to the Chairman of the Board for both Positive Exposure and the Susan Love Foundation.

Beth received an MBA in international business from American University in Washington, DC in conjunction with the School of Foreign Service, and a BA, cum laude, from Boston College. She also studied at Centre d’Etudes Internationale in Geneva, Switzerland.

Björn Odlander, Founding Partner, HealthCap

Dr. Björn Odlander is the Managing Partner of HealthCap which he co-founded in 1996. He has been associated with 100 venture investments, 30 IPOs and a strong industrial foot-print. At present, he is a Director of inter alia Bonesupport AB, Nordic Nanovector AS, Nordic Vision Clinics and OxThera AB. Through the years, Dr. Odlander as a director supported the success of companies such as Affibody AB, Biotage AB, Jerini AG, NeuroNova AB, NicOx S.A. and Q-Med AB.

Prior to founding HealthCap, Björn Odlander led the healthcare equity research team at ABB Aros Securities from 1992-1996. He was voted best pharmaceutical analyst consecutively from 1993 to 1996 according to the Swedish business journal Affärsvärlden.

Dr. Odlander has an MD degree from Karolinska Institutet and a PhD in physiological chemistry from the Nobel Laureate and HealthCap advisor Prof. Bengt Samuelsson’s lab at Karolinska Institutet.

Bernd Goergen, Senior Investment Manager, High-Tech Gründerfonds Management

Since 2008, Bernd Goergen, Ph.D. works for the High-Tech Gruenderfonds (HTGF) as Senior Investment Manager. The biologist and DVFA-certified Biotech analyst combines 5 years of research experience in virology-immunology and in-depth expertise from 7 years (1994-2000) international diagnostics marketing for global market leaders in Germany and the US. Between 2000 and 2007 he joined the investment banking department of a major German bank, where he organised M&A activities and capital market transactions like IPOs and capital increases for life science companies. Bernd currently manages a portfolio of 14 companies for HTGF with a 50-50-split between medical devices and pharma/biotech. He also serves as a board member in 4 of the funds life science firms.



Speakers


WELCOM

ESPEAKERS

t back :: next u

Carlos de Sousa, Chief Business Officer, To-BBB Technologies BV

Dr. Carlos de Sousa is a Medical Doctor and Research Fellow from the University of Lisbon and holds an EMBA from the NYU Stern School of Business. He started his pharmaceutical industry career in medical positions at Duphar and Pfizer. Carlos obtained his international Business Development experience at Pfizer, Novartis, Schwartz Pharma, Newron Pharmaceuticals and Takeda/Nycomed. In his last position he was involved in the acquisition of Nycomed by Takeda and drove the plan for the new integrated Global Licensing and Business Development structure as member of the Integration Team. He joined to-BBB as CBO in 2013.

Carole Nuechterlein, Head of Roche Venture Fund Basel, Roche Venture Fund

Carole Nuechterlein has headed the Roche Venture Fund since 2001. Prior to her current position, she worked in the pharmaceutical/biotech industry as an attorney for ten years. She joined Roche from SangStat in Fremont California where she was General Counsel.

Carole began her career working at Skadden Arps Slate Meagher & Flom in the M&A group. From there, she worked at Syntex/Roche in Palo Alto, California focusing on M&A, research collaborations and licensing deals. Due to her background in M&A, Carole led the negotiation team for the Roche acquisitions of GlycArt and Therapeutic Human Polyclonals.

She currently serves as a director on Lysosomal Therapeutics, Inc and as a board observer at Alios & Ambrx. She also led the investments on Ambit, BioFire Diagnostics, Conatus, Envoy, Nereus & Pharmasset and served as a board observer for all of these except Pharmasset.

She has a BA from Valparaiso University and a JD from University of Michigan.

More information on the Roche Venture Fund can be found at www.venturefund.roche.com.

Casi DeYoung, Chief Business Officer, Mirna Therapeutics

Casi DeYoung joined Mirna Therapeutics in March 2014 as Chief Business Officer. Prior to Mirna, Ms. DeYoung served as Vice President of Business Development at Reata Pharmaceuticals, where she was responsible for negotiating three large international partnerships. Previously, Ms. DeYoung also served as the Vice President of Business Development for ODC Therapy, Inc., an immunotherapy company. Ms. DeYoung held various roles including Director of Global Oncology Operations for EMD Pharmaceuticals, Inc., the U.S. affiliate of Merk KGaA, a global healthcare company. She began her career in the healthcare practice of management consulting firm Accenture. Ms. DeYoung received a B.S. in Chemistry from Southwestern University, and an M.B.A. from the University of Texas at Austin.

Carlos Buesa, CEO, Oryzon SA

Carlos is a specialist in the Biotech Industry. Dr Buesa got his PhD in Biochemistry and Molecular Biology from the University of Barcelona, Spain in 1993. He was post-doctoral fellow in the Faculty of Medicine at the University of Ghent in Belgium and later Senior Investigator at the Flemish Institute of Biotechnology (VIB).

Back in Spain, in 2000, he founded Oryzon. Since inception he has served as Chief Executive Officer and Chairman of the Board of Directors. Under his leadership the company has got +14M euros in several funding rounds and the company has evolved from a genomics based company to a clinical company with its first program in Epigenetics in Oncology in Phase I/IIA.

He has taken the executive education programme (PADE) at the IESE Business School in Barcelona and several additional educational programs in finances, negotiation skills, international commerce and advanced business development

He is now board member of the Spanish Association of BioIndustry (ASEBIO), VicePresident of the Association of Catalan Biotechnology Companies (CataloniaBio), and he was also member of the Executive Committee of BioRegió de Catalunya, a regional biocluster body that has been set up with the aim of improving of the biotechnology sector in Catalonia.

In addition, he sits on the board of other biotech companies like GEADIC Biotech, PaloBiofarma, Neurosciences technologies, NINFAS Biotech and Oncnosis Pharma.

He is also board member in the VC-seed firms Inveready seed and Inveready Biotech.



Speakers


WELCOM

ESPEAKERS

t back :: next u

Chip Clark, CEO, Genocea Biosciences, Inc.

Prior to joining Genocea, Chip co-founded and served as Chief Business Officer of Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA). Before that, Chip was a Principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies, after serving in a variety of commercial roles at SmithKline Beecham (now GlaxoSmithKline). Chip holds a B.A. from Harvard University and an M.B.A. from The Wharton School at the University of Pennsylvania.

Chris Britten, Head, Business Development, Sanofi Pasteur MSD

Chris is currently Head of Business Development at Sanofi Pasteur-MSD with responsibility for all business and corporate development activities. He is also a Non-executive Director at Phico Therapeutics Ltd.

Sanofi Pasteur-MSD is a Joint Venture between Sanofi Pasteur and Merck & Co. and is focused on the development and commercialisation of vaccines in Europe. Chris is also the Managing Director of Vantage Life Sciences, offering strategic and transaction advisory services to the life science sector, and a Non-Executive Director at Phico Therapeutics Ltd.

Chris joined Sanofi Pasteur-MSD in 2013 following positions at Astellas (Europe) in Business and Commercial Development and several years at Deloitte Corporate Finance where he headed up the Life Science Advisory practice assisting clients across the life science sector in a wide range of transactional activities (M&A, divestments, partnering, valuation, fund-raising). Prior to Deloitte, Chris was at GlaxoSmithKline where he held roles of increasing responsibility in Business Development, Corporate Ventures and R&D.

Chris holds a PhD in Biochemistry and an MBA in Finance.

Chris Maggos, Consultant

Chris has over 20 years of experience in the life sciences industry covering business development, investor relations, communications, investing and molecular neurobiology. Recently Chris co-founded the Alpine Institute for Drug Discovery, a non-profit social enterprise whose mission is to serve academic researchers and technology transfer offices, especially in the Alpine region, by commercializing academic discoveries with therapeutic potential. Previously, at Addex Therapeutics, Chris was a member of the executive management board and held the positions of head of investor relations & communication (2007-2010) and director of business development (2010-2013). Before that, he worked as a journalist for the leading biotechnology trade publication BioCentury (2001-2007); an investor at Casdin Life Science Partners (later Cooper Hill), a NYC-based biotechnology hedge-fund (1997-2000); and a molecular neurobiologist studying drug dependence at The Rockefeller University (1993-1997), where he co-authored 12 peer-reviewed publications. Chris holds a BA in English Literature from Yale University, where he also completed pre-medical studies.

Chandra P. Leo, Investment Advisor, Private Equity Team, HBM Partners AG

Dr. Chandra P. Leo is a Partner at HBM Partners. He has gained over ten years of experience in healthcare venture capital at HBM Partners and Wellington Partners. Dr. Leo currently serves as a director or observer on the boards of CardiacAssist, Delenex Therapeutics, Gynesonics, i-Optics and Symbiomix. He was previously a board director or observer at Anthera Pharmaceuticals, ChemoCentryx, ESBATech and Panomics. Dr. Leo also worked as a postdoctoral scientist at Stanford University and as a physician at the University Hospital of Leipzig, Germany. He received his doctoral degree in medicine from the Freie Universitaet Berlin / Charité in Germany and earned his M.B.A. at INSEAD in France.



Speakers


WELCOM

ESPEAKERS

t back :: next u

Christiane Smerling, Head of Nuclear Medicine & Imaging, 3B Pharmaceuticals GmbH

Christiane Smerling has served as Head of Nuclear Medicine & Imaging at 3B Pharmaceuticals since January 2010. She has established 3BP’s Nuclear Medicine Division and is responsible for 3BP’s theranostic tracer development programs. Under her direction, 3BP’s lead development program is currently being prepared to enter clinical trials in pancreatic adenocarcinoma.

Prior to joining 3B Pharmaceuticals, Dr. Smerling has worked a scientist at Jerini AG, where she managed a discovery program identifying modulators of hypoxic signaling. Dr. Smerling received her degree in biochemistry from the Freie Universität Berlin and her PhD from the University of Cambridge.

Christiane Smerling has served as Head of Nuclear Medicine & Imaging at 3B Pharmaceuticals since January 2010. She has established 3BP’s Nuclear Medicine Division and is responsible for 3BP’s theranostic tracer development programs. Under her direction, 3BP’s lead development program is currently being prepared to enter clinical trials in pancreatic adenocarcinoma.

Prior to joining 3B Pharmaceuticals, Dr. Smerling has worked a scientist at Jerini AG, where she managed a discovery program identifying modulators of hypoxic signaling. Dr. Smerling received her degree in biochemistry from the Freie Universität Berlin and her PhD from the University of Cambridge.

Christoph Pittius, VP, Head of Transactions, Business Development, Global Product and Portfolio Strategy, AstraZeneca

Christoph Pittius, Ph.D., is Vice President and Head of Transactions for AstraZeneca’s Business Development located in Mölndal, Sweden, focusing on in-licensing of clinical-stage opportunities primarily in metabolic and cardiovascular indications, one of AZ’s three focus areas. Prior to joining AstraZeneca in 2011, Christoph was Executive Director Business Development and Licensing at Novartis Oncology in Florham Park, NJ., USA, focusing on late-clinical-stage oncology compound licensing, and before that VP of Global Business Development at Jubilant Biosys, an India-based provider of preclinical drug discovery services and partner in risk-sharing alliances. From 2002 to 2008, at Boehringer Ingelheim, he first licensed respiratory technologies, products and devices out of their German headquarters, and then headed Global Discovery Alliances for all therapeutic areas in Ridgefield, CT, USA, a part of BI’s global R&D organization. From 2000-2002, he was Director at Ferghana Partners, a healthcare boutique investment bank in New York City, which provides biotech clients with strategic and negotiation expertise executing M&A, venture financing and corporate partnerships. From 1990-2000, Christoph was at Hoechst, renamed to Hoechst Marion Roussel and later Aventis, initially as a bench scientist in molecular biology, and since 1994 as Director New Technologies Licensing, first in Frankfurt, Germany, and then in Bridgewater, NJ, USA. Christoph’s original training was as a biochemist and molecular biologist. He received his Ph.D. at the University of Hannover in Germany in conjunction with the Max-Planck-Institute of Psychiatry in Munich, followed by a post-doc at the National Institutes of Health and a visiting Scientist at the American Red Cross Holland Lab.

Christina Takke, Partner, Forbian Capital Partners

Christina holds a PhD in Developmental Biology, which she obtained under the supervision of Prof. Dr. Campos-Ortega at the Institute of Development Biology of the University of Cologne. As an undergraduate Christina studied Molecular Biology / Biochemistry at the Technical University of Darmstadt, Université de Bordeaux and at the Institut National de la Recherche Agronomique (INRA) Montpellier. After her studies, she gained experience in working with biotech startup companies at Bio-Gen-Tec-NRW in Cologne, Germany, a regional development organization for the biotechnology industry. She evaluated business proposals and assisted the young biotech companies in the fundraising process. Christina joined the ABN AMRO Capital Life Sciences team as an analyst in 2000. Following this assignment she became Principal before being promoted to Partner. At Forbion Christina is responsible for scouting and analysis of new investment opportunities as well as general deal execution. Christina currently serves on the supervisory boards of Forbion’s portfolio companies Amakem NV, arGEN-X BV, and Pieris AG. In recent years she served on the board of Bioceros, and she was closely involved with GlycArt AG as a Board Observer (sold to Roche in 2005).



Speakers


WELCOM

ESPEAKERS

t back :: next u

Corrine Savill, Head Business Development & Licensing, Novartis Pharma AG

Corinne has over 15 years of broad experience in both the pharmaceutical and biotech arena. In her current position, she has responsibility for all Business development and partnering deals within Novartis.

After a Ph.D. in Immunology and a number of academic and pharmaceutical research positions, Corinne joined Imutran Ltd a UK based Biotech as Director of Research. In 1996 Imutran was acquired by Novartis and Corinne made the COO. She moved to Basel in 2001 as the CEO of the Novartis Bio Venture Fund, managing a CHF 100 million investment fund. In 2005 Corinne moved to head up Global Search and Evaluation with Novartis Business development where she was responsible for the identification and evaluation of potential license-in or M&A opportunities, growing the Novartis development pipeline and supporting the business goals of Novartis. In 2010 Corinne became Novartis’s Global Head of Pricing and Market Access responsible for the pricing and market access strategies for the portfolio of Novartis Pharma’s development and in Market products world-wide.

In June 2013 Corinne was appointed Head Business Development and Licensing Novartis Pharma AG.

Daniel Elger, Chief Financial & Corporate Development Officer, Genkyotex SA

Daniel joined Genkyotex as Chief Financial and Corporate Development Officer in June 2014. He was previously Chief Financial Officer of LSE AIM-listed biotech e-Therapeutics plc. Before that he was Vice President, Marketing and Communications, at London-listed oncology company Antisoma plc. Earlier in his career Daniel worked in marketing and communications agencies serving major pharma companies. He holds a BA in Physiological Sciences (Medicine) and a PhD in cancer cell biology, both from Oxford University

Christopher Earl, Senior Advisor, Merck Research Laboratories Ventures

Christopher D. Earl, PhD is an entrepreneur, investor and non-profit leader with broad experience in science, venture capital, and the management of biotechnology companies and not-for-profit organizations. He currently serves as Senior Advisor to the two corporate venture funds of Merck & Co. (MSD): Merck Research Laboratories Ventures (MRLV) and the Merck Global Health Innovation Fund (GHIF).

Previously, Dr. Earl was the first President and CEO of BIO Ventures for Global Health (BVGH), a not-for-profit organization devoted to harnessing biotech R&D to develop cures for neglected tropical diseases. Supported by industry and the Bill & Melinda Gates Foundation, BVGH promoted financial incentives for tropical disease R&D and forged collaborations between leading companies and research institutions.

Dr. Earl joined Perseus Capital in 1997 to build its investment portfolio in biotechnology, which led to the founding in 2000 of the Perseus-Soros BioPharmaceutical Fund, now known as Aisling Capital. There, he led investments in companies developing therapeutics for oncology and infectious diseases and served as a director on portfolio company boards. Several of these companies achieved FDA approval for innovative drugs that today sell over $1 billion. Earlier in his career, Dr. Earl was President and CEO of Avitech Diagnostics, Inc., and a General Partner of Plant Resources Venture Funds.

Dr. Earl serves on the Board of Directors of AdvanDx Biosciences, Asuragen, Inc., Daktari Diagnostics, Inc., and GenomeDx Biosciences, Inc. Dr. Earl received a BA in Biology from the University of Pennsylvania, and a PhD in Cellular and Developmental Biology from Harvard University.



Speakers


WELCOM

ESPEAKERS

t back :: next u

David Alderson, EU Practice Lead, Global Market Access Consulting, Evidera

David Alderson, MBA MCIM, MEng, is EU Practice Lead for Payer Strategy at Evidera. Prior to Evidera he was VP at GfK Bridgehead, where for over 4 years he led the consultancy team and a number of market access projects. David has over 17 years within the pharmaceutical and biotech industry, covering a range of commercial, strategic, marketing and operational roles. Over 10 years of that was spent at Glaxo, where he was involved in both the Welcome and SmithKline Beecham mergers in manufacturing strategy roles and commercial strategy and analysis. He also worked at Novartis,(Basel) within Global Marketing as Respiratory and Dermatology Franchise Manager. Following Novartis he moved into the Biotech sector joining Cambridge Antibody Technology (AZ/Medimmune) in 2004, responsible for strategic marketing and commercial. In 2008 he joined Napp, where he was responsible for marketing of the transdermal pain products.

David Colpman, Former Head of Global Business Development, Shire

Dan J. Gelvin, Managing Director, Life Sciences, Aurum Holdings MKI Ltd.

Dr. Dan Gelvan is a seasoned life-science executive who before joining Aurum Ventures managed GammaCan International, Inc., a development-stage pharmaceutical company. Previously, Dr. Gelvan founded and managed Zetiq Technologies, a drug discovery company specializing in cell-based high-throughput screening for novel anti-cancer drugs. Dr. Gelvan founded Zetiq after leaving a senior position in Clal (Israel) Ltd., one of Israel’s largest holding conglomerates. Dr. Gelvan holds a PhD in Business Economics from RUC in Denmark, and a BA and MA in Economics from the Hebrew University in Jerusalem. Dan is an experienced lecturer of corporate finance and entrepreneurship. Dr. Gelvan was a member of Israel’s National Committee for Biotechnology for an extended period of time. Dr. Gelvan is currently on the boards of: LifeBond, VBL Pharmaceuticals, CorAssist, Nephera, Beta-O2, Noblegen, Vecta and I2O Pharma.

Daniel Teper, CEO, Immune Pharmaceuticals, Inc.

Dr. Daniel Teper is the founder and CEO of IMMUNE Pharmaceuticals. Dr. Teper was the Managing Director for North America at Bionest Partners, a global Strategy Consulting firm advising pharmaceutical and public biotechnology companies and previously a New York based Partner at ISO Healthcare Consulting (now part of Monitor Group). Daniel started his career at Sandoz (now Novartis) Global Headquarters in Basel and then in the United States where he had growing responsibilities in sales, marketing and new product development. He held senior executive positions in Europe, first at GSK as Head of Commercial Operations for Glaxo France and then as President and Chief Operating Officer of Laboratoires Delagrange through the acquisition by Synthelabo (now part of Sanofi). He then became President at Global EURO RSCG Healthcare Worldwide, a leading marketing and communication group, where he help launch multiple industry blockbusters. Daniel was a cofounder of Novagali (NYSE Euronext: NOVA), which was recently acquired by Japan’s Santen. Dr. Teper holds a Doctor of Pharmacy degree (PharmD) from Paris XI University and an MBA from INSEAD.



Speakers


WELCOM

ESPEAKERS

t back :: next u

David Urech, Co-CEO & CSO, Numab AG

David Urech is the CSO and co-CEO, as well as a founder of Numab. He holds an MSc in Molecular Biology and Neurosciences from the University of Zurich and a PhD in Biochemistry from the Biocenter in Basel. Before his engagement with Numab, David was Head of Research & Preclinical Development at Esbatech, where he was a member of the Senior Management. David conceived Esbatech’s antibody discovery platform and his seeding scientific work on the pharmacokinetic properties of antibody fragments enabled the development of ESBA105, a TNF-inhibitory scFv that became the first antibody fragment to be applied topically by eye drops. The technologies and compounds developed by David and his team turned out to be a value driving factor for Esbatech’s acquisition by ALCON in September 2009. David is an inventor on numerous patent applications and his scientific work has been published in peer-reviewed journals.

Deborah Harland, General Partner, SR One

Deborah joined SR One in 2005 to establish the firm’s European investment office. She brings to SR One extensive operational, drug development and licensing experience gained through numerous roles held in clinical development, medical affairs and business development during her more than 20 year tenure in the pharmaceutical industry. Deborah is currently a member of the Board of Directors of Mission Therapeutics, Bicycle Therapeutics, Atopix Therapeutics , AtoxBio, f-star and VH Squared. She was previously a member of the Board of Directors of Addex Pharmaceuticals (IPO, SIX Swiss Exchange, 2007), Pharmakodex Limited (sold to Orexo) and Syntaxin Limited (sold to Ipsen) and an observer on the Boards of Ablynx (IPO, Euronext Brussels 2007) and 7TM Pharma. Deborah received her BSc. (Hons.) in Pharmacology from the University of Bath, her PhD in Pharmacology from the University of London, and her MBA from Henley Management College.

Dirk Beher, CEO, ASCENEURON SA

Dirk Beher is a founder, the Chief Executive Officer and a member of the Board of Directors of Asceneuron SA. He led the successful spin-off proposal for Merck Serono’s Alzheimer’s disease portfolio and raised EUR 5 million in seed funding, both of which led to the incorporation of the company in October 2012.

Dirk has over 22 years of experience in the field of Alzheimer’s disease & neurodegeneration and spent over 16 years in CNS drug discovery. Prior to Asceneuron he has held various positions with increasing responsibilities at major pharmaceutical and biopharmaceutical companies such as Merck & Co. (Merck Sharp & Dohme), Amgen and Merck Serono in locations around the globe.

Dirk holds a Ph.D. and a M.S. in Biology from the Ruprecht-Karls University Heidelberg, Germany. He is an inventor of seven submitted patents and currently authors 49 peer-reviewed publications and reviews.

David Phillips, Partner, SR One

David joined SR One in 2008 to pioneer a new function to incubate and spin-out technologies from GSK and subsequently joined the team focusing on European investments. David brings a range of experience to SR One, including senior management roles in sales and marketing, commercial strategy and business development at Glaxo Wellcome, Cephalon, Medical Venture Management, The Automation Partnership and Galapagos. David has significant deal making experience in the pharmaceutical and biotech sectors and has run a number of successful businesses deriving healthy exits for investors.

David has a BSc (Hons) in Pharmacology from the University of London and is a member of the Charted Institute of Marketing. David is based in London.

David E. Anderson Ph.D., Co-Founder & SVP, Research, VBI Vaccines

Dr. Anderson is a co-founder of VBI Vaccines and serves as Senior Vice President, Research. He is actively involved in management of preclinical research efforts and for building and protecting VBI’s intellectual property.

Prior to joining VBI, Dr. Anderson developed a multi-disciplinary research program focused on elucidating mechanisms by which inflammation is regulated, particularly in the context of autoimmunity and tumor immunology, while an Assistant Professor at Harvard Medical School.



Speakers


WELCOM

ESPEAKERS

t back :: next u

Ed Saltzman, President, Defined Health

Ed is President of Defined Health, a leading business development strategy consultancy to the life sciences. Ed advises senior industry executives on business development and disease area strategy.

Prior to founding Defined Health, Ed held positions at the Ayerst Laboratories unit of American Home Products and at FIND/SVP.

Ed is a well regarded and in demand speaker on industry issues. He has addressed hundreds of industry audiences over the past 20 years. In addition, Ed regularly presents targeted strategy briefings and conducts discussions privately with scores of boards of directors, executive management committees and licensing and business development groups at large pharma, specialty pharma and biotech companies.

Ed is a member of the Licensing Executives Society and the New York Pharma Forum and is a graduate of New York University.

Prof. Edwin Constable, Head of Research, University of Basel

Professor Edwin (Ed) Constable was born in Scotland in 1955 but moved to the south of England shortly afterwards. He studied chemistry at St. Catherine’s College, Oxford, and doctoral studies were also in Oxford, where he worked with Professor Ken Seddon on the design of metal complexes for solar cells. He then moved to Cambridge where he held sequentially an 1851 Research Fellowship, a University Demonstratorship and Lectureship and was a Fellow of Darwin and Robinson Colleges. In 1993 he accepted a call to the Chair of Inorganic Chemistry in Basel where he remained until 2000 when he returned to the United Kingdom to a Chair of Chemistry in Birmingham.In 2002 he returned to Basel where he currently holds a Chair of Chemistry. He was Research Dean of the Faculty Sciences and is currently Vice-Rector for Research of the University.

His scientific interests and expertise lie in metallosupramolecular and materials chemistry, especially in the use of metal ions for the assembly of novel architectures incorporating specific electronic or photophysical properties. He is a highly cited researcher and has published over 500 research papers and many books. and is actively involved in industrial collaborations, national and EU funded programs relating to interfacial and heterogeneous chemistry and their application to nanoscale electronic, catalytic and electrocatalytic devices. Interest centres upon the development sustainable materials chemistry for dye-sensitized nano crystalline solar cell and OLEDs and related lighting technologies. He received an ERC Advanced Grant (2011-2016) for his project LiLo (Light-In, Light-Out) relating to sustainable materials chemistry and is actively involved in the Swiss Nanoscience Institute. He runs the research group jointly with his wife, Professor Catherine Housecroft.

He has been involved in the assessment and development of educational programmes in many European and middle Eastern countries and is a frequent speaker at public and scientific meetings for the public awareness of science as well as presentations on sustainable next generation technologies.

Doug Doerfler, President & CEO, MaxCyte, Inc.

Douglas Doerfler has over 35 years experience in the discovery, development and international financing and commercialization of biotechnology products and companies. He joined MaxCyte as its founding President and CEO in June 1999.

Prior to joining MaxCyte, he held senior corporate development and operating responsibilities for PFRM, Inc., a privately owned biotechnology holding company. He was President, Chief Executive Officer and a Director of Immunicon Corporation, a cell-based therapy and diagnostics company. Doug also held various executive positions with Life Technologies that included leading global businesses, mergers and acquisitions and its IPO.

Doug plays an active role as an advocate for the life sciences industry. He is Chairman of the Tech Council of Maryland and serves on the Board of Directors and Executive Committees of the Alliance for Regenerative Medicine and the Biotechnology Industry Organization and Co-Chairs BIO’s Capital Formation Committee.

Doug received his B.S. in Finance from the University of Baltimore School of Business and holds a certificate in Industrial Relations.



Speakers


WELCOM

ESPEAKERS

t back :: next u

Erik van den Berg, CEO, AM-Pharma B.V.

Erik has over seventeen years experience in the pharmaceutical and biotechnology industries. He joined AM-Pharma in September 2007 as Chief Business Officer and became the company’s CEO in 2011.

Previously, as a Senior Executive at Organon (NL) he was responsible for leading the Company’s global biotechnology business development. At Organon, he also held European Business Development as well as Marketing and Sales roles relating to the Company’s biotechnology services.

Prior to joining Organon, Erik worked in business and corporate development at the biotechnology company IsoTis, and as a Management Consultant at Arthur D. Little. Erik has been involved in the execution of over 20 transactions and partnerships and raised more than €130M in equity and debt financing for biotechnology companies. He is also the founder and board member of two high-tech start-up companies.

Erik has a MSc in Chemistry from the University of Utrecht (NL) and an MBA from Manchester Business School (UK).

Eric Falcand, Head of Alliance Management and US licenses, SERVIER

Esteban Pombo Villar, COO, Oxford BioTherapeutics

Esteban is Chief Operations Officer for Oxford Biotherapeutics. Prior to joining OBT, Dr Pombo-Villar was at Novartis for over 20 years, the last 12 years of which he focused on all aspects of creating and managing alliances. Most recently he was Head of Alliance Management at the Novartis Institute for Biomedical Research (NIBR), responsible for alliances up to proof-of-concept in man. He has a PhD in organic chemistry and completed postdoctoral studies at the ETH in Zurich before joining Sandoz Neuroscience Research in Basel in 1988. At Sandoz he worked on drug discovery projects as well as leading collaborative projects investigating the potential of emerging technologies. Dr Pombo-Villar is a Fellow of the Royal Society of Chemistry.

Elena Startseva, Head of Business Development, OCT

As a Head of Business Development, Elena is responsible for new business opportunities assessment and management; she supervises OCT’s marketing activities and strategic partnerships.

Elena has started working in the Pharmaceutical/CRO industry in 2005 as a CRA with Quintiles and has a deep knowledge and expertise in the field of clinical research.

After several years of experience in project management positions at Quintiles and then OCT, Elena was appointed to lead the Business Development team.

Elena holds Doctor of Medicine degree from the St. Petersburg Peadiatric Medical Academy, she completed residencies in forensic and general pathology, and an MBA degree in International Business from Stockholm’s University.



Speakers


WELCOM

ESPEAKERS

t back :: next u

François Thomas, Managing Director, Thomas Conseil SPRL

Medical Oncologist, MBA (MIT)

Former VP drug development Ipsen, VP business development Genset, Partner Atlas Venture, Head of healthcare banking Bryan Garnier, CEO Cytheris, board member of 12 biotech companies

Presently, Managing Director of Thomas Conseil

Florent Gros, Managing Director in Basel, Novartis Venture Fund

For nearly 20 years, Florent has held various positions in the intellectual property and venture areas at Nestlé, Pasteur Merieux Connaught and Novartis. Florent is a Kaufmann Fellow (class 12), holds a Biotechnology Engineering Degree in France, and did his diploma thesis on vaccines at GSK in Belgium. He also holds European and French patent lawyer degrees, and a Masters in Private Law. His prior investments into Okairos, Evolva, Cellerix and Neovacs resulted in successful exits. Florent serves on the boards of Myopowers, Opsona, Immune Targeting Systems, Atlas Genetics, Merus, Gensight, Anokion and Applied Immune Therapeutics.

Florian Schödel, Owner, Philiimmune LLC

Florian Schödel is the founder of Philimmune LLC, a consulting firm which provides strategic advice in the development of biologics, vaccines and pharmaceuticals.

Florian has > 20 years of successful experience in leading teams in the development of vaccines and biologics in the pharmaceutical and biotech industry and in academia.

His passion is preventative medicine and the use of modern science and technology for the improvement of public health – especially in the development of preventative and therapeutic vaccines and biologics.

Florian has a track record in running scientific and operational organizations, in business and strategic planning, for forming international strategic partnerships and alliances, in target identification and in all steps of clinical and pre-clinical development.

He has directed the design and execution of clinical studies for licensure and routinely interacted with international and national regulatory agencies.

A physician and microbiologist by training, Florian was a VP in Vaccines Clinical Research of Merck Research Laboratories and has led the clinical teams responsible for several successful vaccine filings before he founded Philimmune.

Florian graduated in medicine at the Technical University, Munich, and earned doctorates in Transplantation Immunology and Medical Microbiology (Dr. med. Dr. med. habil.) from the University of Munich (LMU). He holds adjunct faculty appointments at the LMU and at the Biodesign Center of the ASU. Florian’s research at the Max-Planck Institute for Biochemistry, at Scripps, WRAIR and INSERM focused on hepatitis B and on novel recombinant vaccines against diseases such as hepB, malaria and typhoid.

Dr Fintan Walton, Founder and CEO, PharmaVentures

In 1992 Dr Fintan Walton co-founded CONNECT Pharma, a predecessor company to PharmaVentures focused on assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making. In 1997 this company became PharmaVentures.

Since its inception, PharmaVentures has worked with blue chip clients on a global basis, delivering more than 600 assignments for companies in 38 countries. Clients have included major pharmaceutical and biotechnology companies as well as diversified chemical corporations, medical device, generic and OTC companies. Its clients have included major banks, investment/merchant banks, and private equity and venture capital groups.

In 1996 he also founded PharmaDeals, the leading database and publishing business related to dealmaking. Thousands of customers from around the world have either bought or subscribed to these PharmaDeals publications. PharmaDeals was sold to IMS Health in Aug 2012.

Educated at Trinity College (Dublin, Ireland), Fintan subsequently gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).



Speakers


WELCOM

ESPEAKERS

t back :: next u

Gary Frost, Professor of Nutrition and Dietetics, Imperial College London

Gary qualified as a dietitian in 1982 and have always maintained a clinical input throughout my career. Was appointed to Professor of Nutrition and Dietetics at Imperial College Jan 2008. Prior to this, for 18 years Gary had work at Hammersmith Hospital. Over his time at Hammersmith he gained his PhD in Nutrition and was appointed Honorary Reader in Nutrition at Imperial College, then joined the University of Surrey as Professor of Nutrition and Dietetics in 2005.

Genghis Lloyd-Harris, Partner, Abingworth LLP

Genghis Lloyd-Harris joined Abingworth in 2004 from Credit Suisse First Boston (CSFB) where he was a Managing Director in the European Equity Research Group based in London. Genghis was responsible for coverage of the European biotechnology industry and was ranked first for Pan-European Biotechnology in the Institutional Investor surveys each year from 2001 to 2003. Before

joining Equity Research at CSFB, he worked for CSFB’s Health Care Group in the Investment Banking Division in New York. Genghis was previously a paediatrician in Melbourne, Australia. His current and past directorships have included HBI, Novexel, Solexa, Synosia and Syntaxin. Genghis holds a Medical Degree from the University of Liverpool in the UK, a PhD in Clinical Pharmacology from the University of Melbourne, Australia, and an MBA from Harvard Business School. He focuses on exits of Abingworth’s venture investments via mergers and acquisitions and IPOs as well as venture investment in the UK and Continental Europe.

Frank Kalkbrenner, Vice President, Head of the Boehringer Ingelheim Venture Fund, Boehringer Ingelheim GmbH

Dr. Frank Kalkbrenner is Managing Director of the Boehringer Ingelheim Corporate Venture Fund. Over the last three years, he has been involved in several investments of the fund. He serves as board member of STAT Diagnostica in Barcelona, Eyevensys in Paris and as interims CEO and board member of Acousia Therapeutics in Tübingen. In addition, he is member of the supervisory and the advisory board of Inserm Transfer Initiative a French Seed Investment Fund based in Paris.

Dr. Kalkbrenner studied medicine and holds a degree in Pharmacology and Toxicology. He spent more than 10 years in academic research in the Max-Planck-Institute for Molecular Genetics in Berlin and in the Institute of Pharmacology of the Freie Universität, Berlin. His academic research focused on gene regulation and signal transduction mediated by ion channels and G proteins.

In 1997 he began his industrial career by joining Schering AG as senior scientist in Experimental Dermatology. Dr. Kalkbrenner joined Boehringer Ingelheim in 1999 and held several positions in the department of Pulmonary Research. In 2005 he took over the responsibility for the Licensing Department. In this function, he was responsible for the licensing activities of the German Boehringer Ingelheim organization as well as for competitive assessment and scientific information systems. In addition, he built up the NBE Research unit at the German Research site in Biberach.

Dr. Kalkbrenner joined the BI Venture fund shortly after its start in 2010.

Dr Frank Grams, VP, Head R&D Alliance Management & Contracting, Sanofi

Frank is the Global Head of R&D Alliance Management & Transactions at Sanofi and a board member of ASAP. He is currently based in Paris, France.

Prior to joining Sanofi he was working in different Partnering functions for Roche in China and Switzerland. Before switching to Partnering, he served in various Research positions for Roche in Switzerland and for Boehringer Mannheim in Germany. He holds a PhD in Chemistry from TU Munich (MPI Biochemistry, Martinsried, lab of Nobel laureate Robert Huber).



Speakers


WELCOM

ESPEAKERS

t back :: next u

Guillaume Plane, Global Product Manager, BioDevelopment Services Process Solutions, Merck Millipore, LLC

Guillaume Plane is in charge of Development and Marketing of new BioDevelopment Services at Merck Millipore, a leading company on the field of biomanufacturing. He joined the company in 2012 after a one year experience as a consultant in strategy for biotech companies and after having created and developed a biotech company during more than seven years. He graduated in biochemistry and in Business administration from the University of Bordeaux, from UC Berkeley, and from the Business school of Paris (ESCP Europe).

Guy Goldberg, CBO, RedHill Biopharma Ltd.

Prior to joining RedHill, Guy served as Senior Vice President of Business Operations at Eagle Pharmaceuticals, a specialty injectable drug development company, based in New Jersey. Previously, Guy was a member of the investment team at ProQuest Investments, a healthcare focused venture capital firm. Prior to that, he was a consultant at McKinsey & Company. Guy holds a B.A. in Economics and Philosophy from Yale University and a J.D. from Harvard Law School.

Guillaume Vignon, Director Business Development Oncology - Global Business Development and Licensing, EMD Serono

Guillaume Vignon is Director of Business Development Oncology at Merck/EMD Serono, responsible for leading business development initiatives, designing deal structures, and negotiating terms of strategic partnerships in the field of Oncology. Guillaume hold several positions within Global Business Development and Licensing with increasing responsibilities in all aspects of deal making. During his career at Merck/EMD Serono, Guillaume closed successfully several complex transactions and forged key partnerships in the fields of Oncology, Companion Diagnostic, and Antibody Discovery, strengthening Merck/EMD Serono’s portfolio of innovative products and enhancing R&D capabilities in the field of Biologics.

Recently, Guillaume was the business development lead of the collaboration between Merck and BeiGene, which has received the 2013 BayHelix Elsevier Alliance of the Year Award recognizing a ground breaking pharmaceutical collaboration agreement involving a Chinese entity.

Guillaume holds an MBA from Hult International Business School, Cambridge, USA, and a Ph.D. in Biochemistry and Molecular Biology from the University of Paris 6/ Pasteur Institute, Paris, France.

Guy Greiveldinger, Director BD&L and M&A, Novartis Pharma AG



Speakers


WELCOM

ESPEAKERS

t back :: next u

Hakan Goker, Investment Director, MS Ventures

Hakan Goker (Ph.D.) is a director at MS Ventures, the corporate venture capital fund of Merck Serono. Previously, Hakan was a partner at Aescap Venture which he joined in 2010 investing in European private biotechnology and medical technology companies. Prior to Aescap, he was at Atlas Venture in London until their cessation of European operations. He was instrumental in the creation, financing, business and R&D strategy of various companies including Orphazyme (DK), F Star (NL), Actogenix (BE), Bicycle Therapeutics (UK), Nimbus Discovery (US), Lumavita (CH), Nitec now Horizon Pharma (CH/US), Protaffin (AU/UK), and Egalet (DK). Hakan received his PhD in oncology from the Institute of Cancer Research/ University of London, UK and continued his scientific career with post-doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his BSc Honours, from University College London. Hakan is a board member of Synaffix BV and is acting CBO of Asceneuron SA.

Hartmut J. Ehrlich, CEO, ABIVAX

Prof. Ehrlich is a physician and global executive with almost 30 years of experience in the bio-pharmaceutical industry. Since 2013, he is Chief Executive Officer of ABIVAX, a privately held, Paris based, clinical stage Biotec company dedicated to the development and commercialization of innovative therapeutic vaccines and antivirals. Prior to that, he spent 18 years at Baxter BioScience (1995-2013), most recently as VP and Head of Global R&D and Medical Affairs (2006-2013) . During this time, he grew BioScience’s global R&D organization from about 600 to more than 1200 team members, and it’s annual R&D budget from S 200 million to more than $ 500 million.

He authored and co-authored more than 120 peer-reviewed scientific research articles and book chapters, and is named as inventor/co-inventor on >15 patent families, largely in the areas of Hemophilia, Immunology and Vaccines. Prof. Ehrlich served as Baxter’s principal investigator on a grant from the US Department of Health and Human Services, which paid $ 242 Mio (2006-2013) for the development of cell-culture derived seasonal and pandemic influenza vaccines.

Most importantly, he drove the licensure of a number of biologics in the areas of Haemophilia, Thrombosis, Immunology, Neurology, Oncology as well as BioSurgery (all addressing key unmet medical needs of patients with severe diseases in these areas), as well as several state-of the art vaccines.

Ian Nicholson, CEO, F2G Ltd.

Ian joined F2G Ltd in March 2013. He has over 25 years of international experience in management and transactions within the life sciences sector. In addition to his role at F2G, he is currently an Operating Partner of London-based Advent Life Sciences LLP. Ian previously spent eight years as CEO of the privately held oncology R&D company, Chroma Therapeutics Limited. Prior to that he was Senior Vice President, Business Development at UK biotechnology company Celltech Group plc. Ian has worked extensively in licensing, M&A and market development in the UK, Europe and the US and holds a BSc (Hons.) from University College London and an MBA from Boston University. He holds Board positions at Consort Medical plc, Clinigen Group plc and Bioventix plc.



Speakers


WELCOM

ESPEAKERS

t back :: next u

Ignacio Faus, CEO, Genmedica Therapeutics

Native of Barcelona. PhD from Indiana University (Indiana, USA).

His early years of scientific research focused on the regulation of gene expression at the transcriptional level. He was an EMBO (European Molecular Biology Organization) fellow at the CNRS-Bristol Myers Squibb Research Center in Strasbourg (France), and later set up his own research group at the Howard Hughes Medical Institute at the University of Chicago (Illinois, USA).

After a career in academic research he transitioned to industry, where he held positions in several pharmaceutical companies and complemented his scientific training with an MBA from the J.L.Kellogg Graduate School of Management at Northwestern University (Illinois, USA).

In 2006 Ignacio was one of the founders of Palau Pharma, a Barcelona-based biotech company focused on developing new drugs for the treatment of autoimmune and inflammation-based pathologies, and was designated company CEO. He raised 46 M € in several venture-backed financing rounds and executed several licensing agreements with global pharmaceutical companies. He successfully divested the company in 2013, selling its assets to some of the largest global pharmaceutical companies in the world. The laboratories and personnel of Palau Pharma were integrated in the structure of the LEITAT Technology Park as a new Drug Discovery & Development company, Draconis Pharma.

He is currently the CEO of Genmedica Therapeutics, a small Barcelona-based clinical-stage biopharmaceutical company in the field of diabetes. In the past two years he has also held consulting engagements with a different range of organizations.

Iris Welten, CEO, Basel Area

Iris Welten has been CEO of BaselArea since December 2011. She has 20 years experience in various international companies in the US, Europe and Asia. In her previous position she was a member of the extended executive committee of a pharmaceutical wholesaler, where she was responsible for Business Development, Communications and Quality Control. She has held senior positions in listed companies such as Deutsche Telekom, Clariant and Swiss Life.

Since 2005 she has also been a lecturer for the Master’s degree in Corporate Finance at the University of Applied Sciences and Arts of Northwestern Switzerland (FHNW). And since 2012 she has been a member of the Life Sciences Commission of the Chamber of Commerce of Basel-Stadt and Baselland.

Iris Welten was born and brought up in Munich, where she studied Communication Sciences, Business Administration and Market Psychology. She has dual German-Swiss citizenship and has lived in the Basel region with her Swiss husband for 12 years.

Jan-Anders Karlsson, CEO, Verona Pharma plc

Dr Karlsson has been the CEO and Director of the Board of Verona Pharma plc, an AIM listed company, since June 2012. Verona Pharma’s lead compound RPL554 is in Phase 2 development for respiratory diseases. In March 2014, a £14m fund raising was completed to further the development of RPL554. He has over 30 years of experience in the pharmaceutical industry, with many successes in the drug discovery and development areas in both large pharmaceutical and biotech companies where he built entrepreneurial drug discovery and development cultures. Before joining Verona Pharma Dr Karlsson was the CEO and a Director of S*BIO Pte Ltd in Singapore from 2005, which discovered 6 novel drug candidates and brought the lead JAK2 inhibitor pacritinib to phase 3 and the HDAC inhibitor pracinostat into multiple phase 2 studies, raised venture funding and established multiple international drug-development and commercial partnerships. Prior to joining S*BIO, Dr Karlsson was the Executive Vice President, Global Research of Bayer Pharma, where he was a member of the Executive Management Committee and responsible for the company’s global drug discovery organization. He worked with Bayer from 1996 and before this he held management positions with increasing responsibility in Rhone-Poulenc Rorer from 1990 to 1996 and Astra AB from 1979 to 1990.



Speakers


WELCOM

ESPEAKERS

t back :: next u

Janis Naeve, Executive Director (Corporate Development), Amgen Ventures

Dr. Naeve joined Amgen in 2005 and is the Managing Director of Amgen Ventures which invests in early-stage biotechnology companies focused on discovering and developing human therapeutics. From 2002 to 2005, Dr. Naeve was director of Corporate Development at X-Ceptor Therapeutics which was acquired by Exelixis. Prior to this she was director of Business Development at Aurora Biosciences where she led transactions for the ion channel technology business unit and managed the collaborations with Pfizer, Merck, Lilly and Bristol Myers-Squibb. Dr. Naeve holds a Ph.D. in Pathology from University of Southern California and completed a post-doctoral fellowship at the California Institute of Technology.

Jason Coloma, Global Head Venture & Innovation at Roche Partnering, F.Hoffmann La Roche AG

Jason Coloma is the Head of Venture and Innovation in Roche Partnering responsible for (1) external innovation with academia and venture capitalists (2) new modalities or technology platforms that can potentially be applied across therapeutic areas (3) opportunities in adjacent sectors that may translate into innovative solutions for patient care, including healthcare IT

Jason was previously Head of the Diagnostics Program Office responsible for supporting the Diagnostics Chief Operating Officer in various strategic initiatives and partnering activities. Jason led a number of partnering activities including commercial and academic agreements, mergers and acquisitions as well as strategic investments. He also oversaw Divisional Portfolio Management as well as Market and Competitive Intelligence.

Prior to his time at Roche, Jason worked in the biopharmaceutical industry both as a strategy consultant and working in operational roles. As a strategy consultant, he primarily worked with biotechnology start-up companies venture capital and private equity firms working on a range of issues including partnering deal support, evaluating the business opportunity of innovative discoveries and implementing external innovation models. Jason also held research and business positions at Amgen, the University of California, San Francisco as well as biotechnology startups.

Jason completed his graduate studies in Immunology at the University of California, Berkeley as well as his MBA from the Tuck School of Business at Dartmouth.

Johan Verbeeck, Senior Director of Partnership Management, Johnson & Johnson Innovation Center, Janssen Pharmaceutical Companies of Johnson & Johnson

Johan graduated as Doctor in Veterinary Medicine at the University of Gent, Belgium in 1994 and joined Janssen Pharmaceutica in Belgium in 1996 in the Department of Animal Health. In 1998 Johan began working in Toxicology as Study Director for a multitude of small molecule development projects. In 2003, he graduated cum laude as Master of Science in Applied Toxicology at the University of Surrey, UK.

In 2005, Johan joined Tibotec and as Director of Toxicology, he was Lead Toxicologist for the development of Prezista and Intelence, Tibotec’s first two approved anti-HIV drugs. At the same time he was Preclinical Development Leader for Bedaquiline, the first new drug in development for tuberculosis in over 40 years. Based on his previous expertise with the compound, Johan was an active contributor to the successful Advisory Committee meeting on Bedaquiline and its subsequent FDA approval. In 2013 Johan was a recipient of the Johnson Medal – the most prestigious award given for research and development within Johnson & Johnson – for his role on the team that developed SIRTURO™ (bedaquiline, TMC207).

In 2007, after the approval of Intelence, Johan transferred to North America to become Head of Toxicology Sciences for Janssen at the Raritan, New Jersey site. In 2011, he became Alliance Manager in the External Alliances and Business Models group. In January 2013, Johan relocated back to Europe to work in his current role with Johnson & Johnson Innovation, London.

Jesse Schulman, CEO, Canbex Therapeutics Limited

Jesse has been the CEO of UCL spin-out Canbex Therapeutics since 2012, and has worked with the firm as a consultant since 2009. In April 2013, he helped Canbex close a $3.2m fundraising round that was led by new investor Merck Serono Ventures, along with existing investors UCL Business and the Wellcome Trust. The Series A will allow Canbex to complete its current Phase I trial of the firm’s lead compound, VSN16R, which is aimed at the treatment of spasticity in people with multiple sclerosis, and prepare for Phase II. Jesse Schulman was trained as a Neuroscientist at UC San Diego and the Salk Institute, and has worked extensively in corporate finance for the biotech sector, helping firms execute fundraising, licensing and M&A transactions.



Speakers


WELCOM

ESPEAKERS

t back :: next u

Johannes F. Zanzinger, Global Head, CardioMetabolic Business Development and Licensing, Boehringer Ingelheim Pharma GmbH & Co. KG

Johannes leads Global Business Development and Licensing for Cardiometabolic Diseases within the Therapeutic Alliances & Strategic Partnerships (TASP) function at Boehringer Ingelheim. In addition, he acts as an adjunct Professor of Physiology at the University of Ulm, Germany.

Johannes gained science and R&D management experience across multiple disease areas in academia and industry, at Pfizer (UK) and Boehringer Ingelheim before taking on his role in Business Development & Licensing in the same company in 2006.

Johannes Zanzinger was trained in Animal Sciences and Biology at the University of Hohenheim in Germany, and held academic positions at the Medical Faculties of the Universities of Freiburg and Heidelberg until 1998.

John A.T. Young, Global Head Discovery, Infectious Diseases, Roche Pharma Research & Early Development, Roche Innovation Center Basel

John Young is responsible for leading the infectious diseases discovery programs at Hoffmann-La Roche Ltd. Prior to joining Roche, he was Professor and Director of the Nomis Center for Immunobiology and Microbial Pathogenesis at the Salk Institute for Biological Studies in La Jolla, California, USA. His laboratory studies viral- and bacterial-host interactions and he was the Director of the HIV Immune Networks Team (HINT), a large NIAID-funded program aimed at characterizing the early immune response to HIV-1 infection. He was the Founding Editor-in-Chief of PLoS Pathogens and was a scientific co-founder of Pharmathene, Inc. He is a recipient of the Eli Lilly and Company Research Award in Microbiology and Immunology and is a Fellow of the American Academy of Microbiology.

John Gustofson, Senior Director, Venture and Early Stage Colaboration, AbbVie

John Gustofson is Senior Director of Venture Investments & Early Stage Collaborations. John is primarily responsible for identifying and transacting both Venture and early stage opportunities across therapy areas including immunology, oncology, virology, renal disease and neuroscience.

Prior to joining AbbVie, John worked at AstraZeneca as a Director of Strategic Partnering and Business Development focused on oncology licensing. John has 19+ years professional experience as a bench scientist and in various roles of market and business development. In addition John has worked in numerous biotechnology companies including Altus Pharmaceuticals and Therion Biologics and spent approximately 4 years in strategy consulting to the life sciences industry.

He holds a bachelor’s degree in Microbiology from Western Illinois University, a Master Degree in Molecular Biology from the Miami University and an MBA from the Boston University

John Haurum, CEO, F-star Biotechnology Ltd.

John Haurum joined F-star as the CEO in May 2012. Previously he was VP Research at ImClone Systems, New York (2010-2012). Before then he was the Chief Scientific Officer and a cofounder of Symphogen A/S, Denmark (2000-2009).

After graduating in Medicine in Aarhus Denmark 1992, Dr. Haurum received a D.Phil. in Immunology from the Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, England. Subsequently, he took up a position as Associate Professor at the Danish Cancer Society and completed his medical training.



Speakers


WELCOM

ESPEAKERS

t back :: next u

Kai Brüning, Senior Portfolio Manager, apo Asset Management GmbH

Kai Brüning is a Senior Portfolio Manager at apo Asset Management, which is a majority owned subsidiary of Deutsche Apotheker & Ärztebank. He manages global healthcare funds for institutional and private clients.

Mr. Brüning works in the healthcare investment area for 15 years. Before joining apo Asset he worked with ADIG/ Cominvest and Deka Investment.

Mr. Brüning holds a Diplom-Kaufmann degree from the University of Cologne and is a DFVA/CEFA degree holder. He was awarded by Thomson Extel surveys in the past and is a board member of the DVFA Life Science Commission.

Katya Smirnyagina, Partner, Capricorn Venture Partners

Dr Ekaterina (Katya) Smirnyagina is a Partner of Capricorn Venture Partners (Belgium) since 2012. Prior to this, she worked for ten years at Alta Partners, a healthcare focused venture capital fund in San Francisco, USA.

She has a PhD in Cellular & Molecular Biology (University of Wisconsin-Madison, USA) and BS in Biochemistry (Lomonosov Moscow State University, Russia). Katya completed her scientific training at the Stanford University School of Medicine, then worked in management consulting and biotech business development.

Dr Smirnyagina currently represents the Health Tech Fund of Capricorn Venture Partners at the boards of iSTAR Medical and Nexstim and is an independent Board Member of Adocia S.A.

Keith Blundy, CEO, Cancer Research Technology

Keith Blundy, Chief Executive Officer Keith joined CRT in 1998, became COO in 2004 and was appointed CEO in 2007. Since then he has overseen the launch of a £50m Cancer Research Technology Pioneer Fund in partnership with the European Investment Fund (EIF) to bridge the UK funding gap between cancer drug discovery and early treatment development. He has initiated risk sharing discovery alliances with AstraZeneca and Teva (formerly Cephalon), the establishment of CRT Inc in Boston (USA) as a business development arm of CRT and the further globalisation of CRT’s cancer IP development and commercialisation through becoming a partner of Cancer Therapeutics Pty in Melbourne, Australia. After completing a PhD at the John Innes Institute and a post doctoral Fulbright scholarship in the US on the regulation of plant gene expression, he spent 10 years managing and commercialising agricultural biotechnology programmes before transitioning to healthcare through business development. Keith has a BSc and PhD in genetics and an MBA from the London Business School. He was formerly a director of KuDOS Pharmaceuticals Ltd and Mission Therapeutics and currently is on the board of Cytosystems Ltd and Cancer Therapeutics Pty. He is a member of Cancer Research UK’s Scientific Executive Board.

Jonathan Garen, Assistant Vice President Business Development, Actavis

Jonathan is an Assistant Vice President of Business Development at Forest Laboratories, Inc., where he has worked since 2003. His responsibilities include the identification, evaluation, and negotiation of transactions for new business opportunities in a wide range of therapeutic areas and stages of development, including licensing and acquisitions in the fields of neurology, inflammation, oncology and metabolic diseases. Prior to Forest, Jonathan was a Director in the Global Licensing department at Pharmacia Corporation. Jonathan was a founder and Vice President of TechEx, an online licensing exchange for early stage opportunities, and was a Licensing Associate at the technology licensing office of Yale University. Jonathan earned his Master of Environmental Sciences from Yale University and his Bachelor of Science in Physics from the Massachusetts Institute of Technology.



Speakers


WELCOM

ESPEAKERS

t back :: next u

Laurenz Kellenberger, CSO, Basilea

Laurenz Kellenberger holds a PhD in organic chemistry from the Swiss Federal Institute of Technology Zurich (ETH Zurich). Since 2009 he has been Chief Scientific Officer of Basilea Pharmaceutica International Ltd.

Laxminarayan Bhat, President & CEO, Reviva Pharmaceuticals, Inc.

Laxminarayan Bhat, PhD, is Founder and Chief Executive Officer of Reviva Pharmaceuticals, Inc. Reviva has advanced extremely rapidly under his leadership, with a portfolio of propriety compounds at different stages in a pipeline encompassing chronic diseases in large therapeutic areas such as CNS, metabolic, cardiovascular and pain. Dr. Bhat he has developed and implemented innovative financing and business models with strategies that have greatly accelerated the drug discovery and development process, resulting in significant savings of time and costs but without sacrificing quality. Dr. Bhat has over 18 years’ experience in drug discovery and development and prior to founding Reviva, he held research positions at XenoPort, ARYx Therapeutics and Higuchi Biosciences Center in the United States. Dr. Bhat has received a global post-doctoral training at the University of Kansas, USA, the Georg-August-Universität, Göttingen, Germany and the Université du Maine, France. In 1995, he was selected for the Alexander von Humboldt fellowship, an internationally recognized award for young scientists to pursue advanced research in Germany. Dr. Bhat received his Ph.D. in synthetic organic chemistry from the Central University NEHU, India and has authored over 15 research papers published in peer-reviewed scientific journals. He is an inventor on more than 100 filed patents and over 35 granted patents.

Laurent Choppe, Managing Partner, Cukierman & Co. Life Sciences

Laurent is leading Cukierman & Co. Life Sciences since 2008 and was involved in all Israeli and international medical device and biotech transactions for the Cukierman group. He brings an extensive international life science experience in managing multifunctional teams and setting up new businesses in pharmaceuticals, biotechnology, nutraceuticals, animal health and direct-to-consumer markets. After a veterinary practice and a new venture management experience, he joined Schering-Plough in 1994 by leading the marketing of major drugs in dermatology, allergy, respiratory and animal health in France, became General Manager in Israel and moved up to Vice President, Virology, Oncology and Cardiology in Canada. He then served as the General Manager of the international headquarters of BELLUS Health (ex-Neurochem NASDAQ & TSE), a global pharmaceutical and nutraceutical company addressing unmet needs in Alzheimer’s disease, AA amyloidosis, diabetes, memory and cognition.

Dr. Choppe is a Doctor of Veterinary Medicine of the University Paris XII, laureate of the École Nationale Vétérinaire d’Alfort, CES of Veterinary Ophthalmology and earned a MBA from INSEAD in Fontainebleau (France). He is married, father of 3 and lives in Lausanne (Switzerland).

Lorenza Castellón, Business Development Consultant, Suda Ltd.

Lorenza is a health & biotech equity analyst at Equity Development Ltd. covering private & publicly listed SMEs companies in Europe and Australia. Prior to joining Equity Development in January 2005 she held similar roles at leading international investment organisations. Equity Development brings together investors and companies by means of writing and distributing detailed research. We provide the markets with both facts and opinions along with fair valuations based upon diverse and appropriate metrics. Over the last decade our brand has become synonymous with quality objective research and we have built close links with institutions across the UK and Europe; like them we are fully regulated. Our team of analysts are FSA approved and boast a cumulative 400 years of experience. Please visit www.equitydevelopment.co.uk for more details and examples of our work or contact me. I am the health & biotech analyst and I have many years of experience in the sector having worked for leading international investment organisations.



Speakers


WELCOM

ESPEAKERS

t back :: next u

Lubor Gaal, Head of Europe, Strategic Transactions Group, BMS

Lubor is the Head of Europe, Search and Evaluation, for Bristol-Myers Squibb, based at the UK headquarters in Uxbridge (London). He is responsible for the identification, acquisition and licensing of drug programs or companies in support of the company’s BioPharma strategy. He is also responsible for all Fibrosis transactions worldwide for business development.

Lubor has extensive experience in evaluating and negotiating transactions with small and large companies, having worked in the U.S. and in Europe. Prior to joining Bristol-Myers Squibb, Lubor was Head of Business Development for Neuro3d in France and CBO of Vectron Therapeutics AG in Germany. In the US, Lubor worked for Berlex Laboratories, where he was responsible for worldwide licensing for Cardiovascular and Neuroscience for Schering AG. Before joining Berlex, he worked for Burrill and Company in San Francisco, where he advised biotechnology and pharmaceutical companies on business development strategies and execution. Lubor received his Ph.D. from the University of California at Berkeley and studied biology at the Universities of Mainz and Tuebingen, Germany.

Luca Bolliger, VP and Group Licensing Director, RECORDATI S.A.

Luca Bolliger studied biochemistry at the ETH in Zürich and completed his undergraduate studies with a Master in Immunology. He graduated at the Biocenter in Basel in biochemistry, and then became Member of the Basel institute for immunology. He then joined the pharmaceutical industry as a Global discovery portfolio manager in the Pharma Strategy Unit at Hoffmann-La Roche Ltd. He then pursued his career in the financial industry as a Fundamental analyst at BT&T asset management, and as a freelance consultant. He established Biopolo Ticino where he also participated in the creation of the Swiss marketing platforms Swiss Biotech and Swiss Medtech before becoming Director Business Development at Actelion. Luca Bolliger joined Recordati from Novimmune where he was director Business Development.

Madhusudan V. Peshwa, Executive Vice President, Cellular Therapeutics, MaxCyte, Inc.

Madhusudan Peshwa, Ph.D., currently serves as Executive Vice President, Cellular Therapies at MaxCyte, Inc. Most recently, he was Executive Vice President for Research and Development at NewNeural LLC, a start-up stem cell therapy company. Earlier he served as Vice President of Manufacturing and as Vice President of Process Sciences at Dendreon Corporation (NASDAQ: DNDN), where we was responsible for development, characterization and manufacture of an autologous dendritic cell vaccine product from concept to late Phase III pivotal studies. His expertise is in the areas of design, characterization, scale-up and implementation of processes, and cGMP systems in the development of engineered cell and tissue products and for biopharmaceuticals’ production.

Dr. Peshwa obtained his Ph.D. in Chemical Engineering from the University of Minnesota and his B.Tech. in Chemical Engineering from the Indian Institute of Technology, Kanpur, India. He is a co-author on over 35 scientific publications and is a co-inventor on five, issued or under review, patent applications.

Lothar Steidler, Vice President Technology, ActoGeniX

Dr Lothar Steidler is the main inventor of the TopAct™ technology.

Lothar started his research career at the University of Ghent (Belgium) during the early 1990s and became principal investigator at the VIB in 2001. In 2003 he relocated to the prestigious Alimentary Pharmabiotic Centre at University College Cork (Ireland), headed by Professor Fergus Shanahan.

In September 2006, Lothar returned to Belgium to take up the position of Director of Technology Development at ActoGeniX. Lothar’s research has shown that Lactococcus lactis, and food-grade microorganisms and commensal bacteria in general, can be genetically engineered to secrete biologically-active therapeutic molecules and can be applied as therapeutic products to treat diseases.

In recognition of this scientific breakthrough, Lothar received the 2001 William Grant and Sons Young European Prize for Invention and Discovery. In 2003, he was also awarded a Science Foundation Ireland investigatorship. His work has been published in various high-level scientific journals such as Science, Nature Biotechnology and Gastroenterology.

Lothar holds a PhD in Biotechnology from the University of Ghent and is currently a guest professor at Ghent University, teaching host-bacteria interactions.



Speakers


WELCOM

ESPEAKERS

t back :: next u

Malcolm Weir, Co-Founder and Chief Executive Officer, Heptares Therapeutics

Malcolm has a BSc and PhD in biochemistry and biophysics from Imperial College, London. He was Head of the Biomolecular Structure Department and then the Molecular Sciences Division of GlaxoWellcome with responsibility for 300 people engaged in target validation and lead discovery. During this time he led the application of structural biology and modelling to drug discovery, resulting in the advancement of clinical candidates to a wide range of diseases. He joined the structural bioinformatics and drug discovery company Inpharmatica Ltd as CEO in 2000, growing it from the spin-out stage to a 100-person company. Inpharmatica was sold to Galapagos NV in 2006. He joined MRC Technology in 2006 in order to establish Heptares Therapeutics Ltd in July 2007, as co-founder and CEO. Malcolm was elected Visiting Professor of Biochemistry at Imperial College, London in 1997 and is on the Chemical Biology Advisory Board at the same university. He served on the Council of the UK Biotechnology and Biological Sciences Research Council from 2004-2011.

Marco Superina, Head M&A Switzerland, Head of Healthcare M&A Europe, Credit Suisse AG

Managing Director, Head Healthcare Investment Banking Switzerland

Joined Investment Banking: 1997 Joined Credit Suisse: 1997

Languages: English, German, French & Italian

Marco Superina is a Managing Director and the Head of Healthcare Switzerland as well as the Head of M&A Switzerland based in Zurich. Marco Superina joined Credit Suisse directly after receiving his Dr. oec. publ. in banking and finance from the University of Zurich.

Marco Superina has extensive investment banking experience. His M&A experience covers a broad range of industries and he has been involved in notable transactions including Switzerland’s first public takeover battle (Centrepulse, ultimately acquired by Zimmer), the first public LBO of a Swiss listed company (Rank Group Holding’s acquisition of SIG Holding) and defence assignments for Ciba (against activist investors), Leica Geosystems (against Hexagon) or Converium (against Scor).

Selected transaction experience includes:

M&A: • Sale of Synthes to Johnson & Johnson for $21.3bn • Sale of Ciba to BASF (CHF6.1bn) • Acquisition of Valeant’s dermatology assets by Galderma ($1.4bn) • Sale of Preglem to Gedeon Richter for CHF445m • Sale of Nutrition & Santé by Novartis for Eur220m • Novartis acquisition of Alcon ($51bn) • Advisor to the Special Committee of Serono on the sale of Merck KG ($12.9bn) • Zimmer acquisition of Centerpulse ($3.2bn) • Advising Actelion against Elliott Associates • Synthes-Stratec acquisition of Mathys (CHF 1.5bn) • Synthes acquisition of intellectual property rights (CHF 1bn) • Acquisition of Groupe OGF by Vestar Capital Partners Europe (EUR 300m) • Galderma acquisition of Spirig Pharma (undisclosed) • IPO of Ypsomed SelfCare Solutions

Maina Bhaman, Director, Healthcare Ventures, Imperial Innovations

Maina Bhaman is Director of Healthcare Investments at Imperial Innovations. Maina has led a number of investments in Imperial Innovations’ healthcare portfolio including recent investments into Psioxus Therapeutics and Cellmedica . Maina currently serves on the board of Autifony Therapeutics, Cell Medica, Ixico ,Psioxus Therapeutics and Topivert Pharma. Maina was also served on the board of Acrobot and Molecular Vision Ltd. Maina joined Innovations in 2006 and prior to that worked in the research and development team at Celltech (previously Oxford Glyco Sciences). Maina’s experience includes Chimeric Therapies, a cell therapy start-up based in Philadelphia and GeneMedicine, a gene therapy company based in Houston, Tx. Maina has a BSc from the University of Texas at Austin and an MBA from the Imperial Business School.



Speakers


WELCOM

ESPEAKERS

t back :: next u

Michael Kranda, CEO, BEAT Biotherapeutics Corp.

Mr. Kranda, M.B.A., has over 25 years of biotech operating, finance and corporate development experience and is now CEO and a director of BEATBio Therapeutics. Most recently Mr. Kranda was CEO and a director of Vaccinogen, a cancer vaccine company. Mr. Kranda served as Managing Director of Vulcan Capital for several years, where he led all aspects of their Life Sciences investment efforts and continues to serve as a consultant. Mr. Kranda was also the CEO of Oxford GlycoSciences, a pioneer in proteomic based drug and diagnostic product development. Prior to joining Oxford GlycoSciences, Mr. Kranda was President, COO and director at Immunex Corporation (now Amgen) and is currently a Director for PTC Therapeutics, Inc. (NASDAQ: PTCT).

Markus Ewert, EVP Business Development, GE Healthcare

Markus is the Executive Vice President, Business Development, for GE Healthcare. He is responsible for developing the GE Healthcare growth strategy, and identifying and executing merger and acquisitions, investments, licenses, and alliances in support of the strategic growth initiatives of the business.

Prior to joining GE in September 2011, Markus was Head of Strategy, BD&L, and M&A for Novartis Molecular Diagnostics, and served as member of the leadership team. In mid-2005, Markus joined Novartis in Basel, Switzerland as a member of the Cardiovascular & Metabolism Franchise Board for Novartis Pharma AG and the Global Business Development & Licensing group where he was responsible for acquiring and licensing projects for the Franchise.

From 1998 to 2005, Markus was President & CEO of two biotech start-ups, initially Axxima Pharmaceuticals AG (focusing on infectious diseases) and subsequently Xerion Pharmaceuticals AG (focusing on mAb technologies and research for cancer therapeutics), both based in Munich, Germany.

Between 1995 and 1998, Markus was the head of International Product Management at Schwarz Pharma where he was later named Director of Business and Corporate Development. At Schwarz, he launched two international core brands and orchestrated several key business transactions.

In 1993, Markus joined The Boston Consulting Group in Munich as consultant to pharmaceutical and chemical companies.

Markus holds a PhD in molecular biology from the University of Heidelberg and an MBA from the University of Chicago.

Markus Hosang, General Partner, BioMedPartners AG

Markus is a General Partner at BioMedPartners AG in Basel, Switzerland. He has strong experience and broad knowledge in strategic and operational aspects of the venture capital business, as well as in pharmaceutical research and in many product development and marketing areas, with special expertise in the areas of biotechnologies, strategic alliances, and theranostics/diagnostics. Before joining BioMedPartners in 2004, Dr. Hosang was a Venture Partner at MPM Capital, where he was co-responsible for their European deal flow, and served on the boards of several European portfolio companies. Previously, he was at Roche in Basel, where, for nearly 20 years, he held several senior management positions in the Pharma R&D organization, including Vice President and Director of Global Pharma Research Strategic Unit and Chief of Staff to the President of Pharma R&D, membership of the Global Board of R&D Directors, Head of Development Projects in Basel and Member of the Roche Portfolio Board, and most recently, as a Deputy Head and Chief Scientific Officer of Genetics and Integrated Medicine, and a member of the Roche Genetics Executive Committee.

He obtained his Ph.D. in Biochemistry from the ETH in Zurich and pursued his postgraduate training at Stanford University Medical School in neurobiology and subsequently at the University of Washington in Seattle in vascular dieseases. Dr. Hosang served on the Board of Directors and the Board of Trustees of the Swiss Foundation for Stipends in Medicine and Biology (SSMBS) as its Treasurer from 1994-2002. He currently is a member of the boards of Okairos AG, Suppremol GmbH and Anergis SA (as interim Chairman of the Board). Earlier he was on the boards of Omrix, Kourion (until its merger with ViaCell), IDEA, Atugen, Avontec and Neuraxo. He has published more than 30 articles in peer reviewed journals, and is coinventor on several patents.



Speakers


WELCOM

ESPEAKERS

t back :: next u

Mohammed Homman, CEO, Vironova AB

Michael Shalmi, Senior Partner, Novo A/S

Michael has been a Senior Partner since 2009 in Novo A/S, and is currently involved with Novo Large Investment.

Previous appointments: 15 years at Novo Nordisk A/S in multiple roles including V.P. International Marketing, V.P. of Haematology Business Unit Europe, V.P. BioPharm Business Unit US, Corporate VP Haemostasis Global Development and Chief Medical Officer BioPharm, Corporate V.P. Clinical Operations Management

Mike Bastian, Business Development Manager, Birken AG

At Birken AG, Mike is responsible for out-licensing of the first-in-class pharmaceutical Oleogel-S10, which has just successfully completed its phase-III trial program for accelerated wound healing of partial-thickness wounds.

In his former position as International Product Manager, he was responsible for global marketing of a plasma-derived pharmaceutical.

Before Mike started his career in the pharmaceutical industry 6 years ago, he graduated with a Master of Science in Molecular Biology from Umeå University in Sweden and received his Ph.D. in Microbiology from Tübingen University in Germany.

Miro Venturi, Global Head – Diagnostics Biomaker, F.Hoffmann-La Roche, Diagnostics Division

After receiving his PhD from the Max-Planck Institute of Biophysics in Frankfurt, Miro specialized in molecular medicine, virology and immunology at the National Institutes of Health, Bethesda, USA. In 2002, Miro joined the pharmaceutical industry as a Biomarker Laboratory Head and project team representative at Pharmacia Corp (later Pfizer Inc.) at the Oncology R&D site located in Nerviano, Italy. In this role, he initially established the biomarker laboratories and actively contributed to the development of numerous oncology programs focusing on small molecular weight kinase inhibitors, including the early development of sunitinib (Sutent) as well as research and exploratory biomarker strategies for several preclinical programs, from lead optimization until PoC clinical studies. In 2005, Miro was invited to join the faculty of the University “Vita Salute San Raffaele” in Milan as Adjunct Professor of preclinical and early clinical development of biopharmaceuticals. In 2007 Miro moved to Novartis as Divisional Head in Biomarker Development, supervising a team of scientists developing assays and supporting project teams in the realization of personalized medicine strategies across the portfolio, with a focus on biologics and oncology programs. His team has contributed to the development of nilotinib (Tasigna) and early programs in both solid tumors and hematological malignancies. Since 2009, Miro joined Roche Oncology where he has contributed the biomarker and personalized medicine strategies and directed the execution for global drug development programs with companion diagnostics, including the development and approval of Perjeta in breast cancer. Miro has recently been appointed Global Head of Diagnostics Biomarkers at Hoffmann-la Roche and is based at the Company´s headquarters in Basel.



Speakers


WELCOM

ESPEAKERS

t back :: next u

Nicholas Benedict, Co-Founder & CEO, Allecra Therapeutics

CEO & Co-founder of Allecra Therapeutics. BA (Hons) King‘s College London University, MBA Univ. Manchester, UK

Nicholas has over 20 years experience in the pharma industry, starting in finance in F. Hoffmann-La Roche before moving to marketing and sales. Roles included Global Head of Anti-infectives Business Unit at Novartis AG in Switzerland, COO of Novartis UK, Chief Commercial Officer at Basilea Pharmaceutica where he successfully co-led the company’s follow-on offering raising over CHF320 million and CEO of Swiss start-up Lumavita AG.

Nicholas Franco, Executive Vice President & Chief Business Development Officer, Actelion Pharmaceuticals, Ltd

Nicholas Franco has over 20 years of pharmaceutical leadership and experience in research, marketing, sales and business development across several therapeutic areas and geographies.

Prior to joining Actelion as Executive Vice President and Chief Business Development Officer, he was Senior Vice President, International Commercial Operations at Axcan Pharma based near Paris, France where he was responsible for ex-North American operations (including Marketing, Operations and Partnering).

Prior to that, he was Head of Market Access Region Europe for Novartis Pharma AG in Basel, Switzerland, where he has held various management positions since 1991, including President of Novartis Ophthalmics, Global Head, Business Development and Licensing Negotiations, Global Head, Neuroscience Franchise and Global Brand Director for gastrointestinal products.

Education: BsC in Biochemistry and MA in Business Administration, Strategic Planning and Marketing from McGill University (Canada).

O. Prem Das, Chief Research Business Development Officer and Heads DFCI’s Office of Research and Technology Ventures (ORTV), Dana-Farber Cancer Institute (DFCI)

O. Prem Das, PhD, is Chief Research Business Development Officer at Dana-Farber Cancer Institute (DFCI) and heads DFCI’s Office of Research and Technology Ventures (ORTV). ORTV is responsible for patenting and licensing discoveries made by DFCI researchers to outside company to create income. ORTV also works with DFCI faculty and Integrative Research Centers to enhance relationships with the corporate sector, generating sponsored research agreements and collaboration opportunities in both clinical and preclinical research.

Prem’s background includes around eight years of experience in managing academic technology transfer offices, twelve years in biotechnology business development, and fifteen years in basic research. Prior to joining DFCI in 2012, Prem was involved in starting up companies and consulting for biotechnology companies and the NCI. From 2006 to 2007, he served as Senior Vice President for Technology Alliances at Praecis Pharmaceuticals, where his business development efforts led to the acquisition of the company by Glaxo SmithKline. Prem directed the Office of Technology Licensing at Harvard Medical School from 2003 to 20006 and the Office of Industrial Affairs at Memorial Sloan-Kettering Cancer Center from 2000 to 2003. He co-founded Heartland BioTechnologies and was Director of Business Development at Cadus Pharmaceuticals in the ‘90’s.

During his academic research career, Prem has published in diverse areas of biology and chemistry. He received his MSc in chemistry from IIT/Kanpur in India and his PhD in biological chemistry from MIT.



Speakers


WELCOM

ESPEAKERS

t back :: next u

Ora Dar, Head of Life Sciences, Office of the Cheif Scientist, Ministry of Economy, Isreal

Ora Dar is the Head of the Life Sciences Sector at the Office of the Chief Scientist at the Israeli Ministry of economy.

Being the head of the sector, Dr. Dar leads a team of experts, and is in charge of the evaluations of all projects in the field of Life Sciences that are submitted to the Chief Scientist’s various grant programs.

Dr. Dar is also responsible for defining and implementing tools and new programs required for supporting R&D in Life Sciences companies, and for enhancing the technology transfer between the Academia and the Industry. This has lead to the initiation and maturation of several viable programs such as, funding academic applied research, dedicated scheme for biotechnology incubator(s), tracks enabling collaboration with global Life Sciences companies, tools for upgrading infrastructures, National Tissue Bank and a special government backed Bio VC Fund.

Previously she spent 16 years in academic research (mostly at the Weizmann Institute of Science), has industry experience, and served 10 years as a consultant to venture capital and investment firms as well as foreign funds.

Dr. Dar is a medical sciences graduate of the Hebrew University of Jerusalem and holds a Ph.D. from the University of London, UK (St. Mary’s Hospital Medical School, Imperial College of Science, Technology and Medicine).

Paola Casarosa, Corp. Vice President of Therapeutic Alliances and Strategic Partnerships, Boehringer Ingelheim GmbH

Paola Casarosa joined BI in 2007. Currently she is the Corporate Vice President for Therapeutic Alliances & Strategic Partnerships. In her career at BI she occupied different positions within the R&D part of the organization, as well as PM Strategy and Portfolio Management.

Before joining BI, Paola was employed at Organon NV/Shering Plough in R&D. Paola received a Ph. D. in molecular pharmacology at Vrije Universiteit in Amserdam and had a Post-Doc experience at Bichat Hospital in Paris.

Peter Sandor, Vice President, Global Marketing Oncology TA, Amgen

Peter Sandor is the Vice President, Global Marketing Oncology at Amgen. He is responsible for the successful realization of the commercial potential for Amgen’s oncology assets.

Peter has 19 years of progressive marketing experience. Prior Amgen, he has held different positions at Bayer Healthcare, including Head of Strategy and Portfolio Management Specialty Medicine, Commercial Development and Life Cycle Management Global Oncology. He also worked for Berlex Laboratories as the lead of the global launch team for a key oncology compound, and held multiple marketing roles with Schering AG in Germany and Hungary.

Peter started his career in bench research as a scientific advisor of the Hungarian Academy. He received his MDS Marketing and MBA from Middlesex University, London and Faculty of Business and Economy, University of Pécs, Hungary, and his MD from University of Pécs, Hungary.

Peter B. DiLaura, President & CEO, Second Genome, Inc.

Peter DiLaura is President and CEO of Second Genome. Second Genome is a biotechnology company in South San Francisco, California that aims to transform lives with medicines developed through innovative microbiome science. The company is developing a pipeline of programs in inflammation and metabolic disease.

Prior to Second Genome, Peter was the Senior Vice President of Products and Marketing at Ingenuity Systems, a systems biology company (acquired by Qiagen). Peter joined Ingenuity in 2001, and during his time at Ingenuity held a variety of roles on the senior management team including business development, global sales and marketing, and corporate strategy.

Prior to Ingenuity, Peter held roles at Chemdex/Ventro and IBM’s Health Care division. Peter began his career in life sciences as a strategy consultant to the pharmaceutical and biotechnology industries in the New York office of The Wilkerson Group.

Peter received a BS in Economics from the Wharton School at the University of Pennsylvania.



Speakers


WELCOM

ESPEAKERS

t back :: next u

Philip A. Serlin, Chief Financial and Operating Officer, BioLineRx, Ltd.

Mr. Serlin assumed his position as Chief Financial & Operating Officer in May 2009. Prior to joining BioLineRx, Mr. Serlin was Chief Financial Officer and Chief Operating Officer of Kayote Networks Ltd. Mr. Serlin also served as Chief Financial Officer of Tescom Software Systems Testing Ltd. (TASE:TSCM), an IT services company publicly traded in both Tel Aviv and London. His background also includes senior positions at Chiaro Networks Ltd. and at Deloitte, where he was head of the SEC and U.S. accounting department at the National Office in Tel Aviv, as well as seven years at the SEC at its Washington, D.C., headquarters.

Mr. Serlin is a CPA and holds a Master’s degree in Economics and Public Policy from The George Washington University.

Philippe Calais, CEO, Isarna Therapeutics GmbH

Dr. Philippe P. Calais joined Isarna Therapeutics as Chief Executive Officer on March 1, 2012. He has over 25 years of biopharmaceutical and pharmaceutical industry experience in both North America and Europe. Formerly he was the President and CEO of Univalor, one of the largest technology transfer organizations in North America, located in Montreal, Canada. He has managed biopharmaceutical companies in Canada and served as a consultant to life science companies, focusing on corporate strategic positioning, company deployment and sales optimization strategies. His management expertise, combined with extensive experience with large pharma companies such as ICI Pharmaceuticals and Roche, covers the full scope of the drug chain – from discovery to clinical development, commercialization as well as partnership and franchise strategic marketing for several therapeutic areas. He has a degree and doctorate in pharmacy from the U. F. Rabelais, Tours, France.

Philippe Lopes-Fernandes, Senior Vice-President, Head of Global Licensing & Business Development, MERCK KGaA / EMD

Philippe Lopes-Fernandes is the Senior Vice-President, Head of Global Licensing & Business Development for EMD Serono. He is responsible for developing search strategies, conducting the search and evaluation of partnering, licensing and M&A opportunities and managing the established alliances. His team provides end-to-end transactions support to ensure execution of high-quality global deals for all Merck Serono business units and all stages of development, from early technology to clinical stage and marketed products.

Philippe is a results driven, innovative and committed executive with more than 20 years of experience in the pharmaceutical industry (in Prescription, Generic and OTC fields). He brings strong expertise in licensing and M&A, project management, marketing and sales, having directly negotiated key deals for Merck KGaA, including the in-licensing of Erbitux, the acquisition of Serono, and the sale of Merck’s generic business to Mylan. He has lived and worked in France, Portugal, Germany, Switzerland and the U.S.

Philippe holds a graduate degree in Business Administration from Institut Superieur de Gestion in Paris, France.



Speakers


WELCOM

ESPEAKERS

t back :: next u

Philippe Mauberna, CFO, Nanobiotix

Philippe has joined Nanobiotix as CFO in June 2013 to conduct the company’s international growth within the Executive Board.

Before joining Nanobiotix, Philippe has been heavily involved in financial projects with an international exposure during start-up launch or innovative SME development. Dedicated to the Life Sciences industry for more than 10 years, he has hold Financial and Operations senior positions to reinforce EMAE commercial effectiveness for Astellas Pharma. As consultant, he has provided change management support for European pharmaceutical companies during their commercial development phase.

Philippe holds a degree in Finances from Paris Assas University, followed by a Management course at INSEAD.

Pierre Vandepapeliere, CMO, Neovacs

Pierre Vandepapelière is MD, PhD and Vice-President, Chief Medical Officer of Neovacs SA, a Biotech company based in Paris, France. With over 25 years’ experience in the vaccine industry, he has led clinical development of numerous complex programs from preclinical to phase III and registration. He has developed a specific scientific, clinical and business expertise in infectious diseases, chronic inflammatory and auto immune diseases, vaccines, adjuvants.

Before joining Neovacs, PV has worked for 18 years at GlaxoSmithKline Vaccines in Belgium where he has led the worldwide clinical development of numerous prophylactic vaccines and therapeutic vaccines for chronic infectious diseases. As Head of Early Clinical Research he was responsible for the clinical assessment of new vaccines, business and in-licensing opportunities, vaccine strategies. The topic of his PhD thesis was: “Therapeutic vaccines for chronic infectious diseases”. (University of Ghent, Belgium. 2008). He also owns a postgraduate diploma in Tropical Medicine. (Institute for Tropical Medicine, Antwerp, Belgium). He has authored numerous publications on vaccines, adjuvants and therapeutic vaccines. PV has therefore a global experience in vaccine development with a specific expertise in therapeutic vaccination.

At Neovacs PV led the development of anti-cytokine therapeutic immunization in Crohn’s disease, rheumatoid arthritis and lupus from pre-clinical to phase II and is highly involved in business development activities. He is also chief medical officer of Abivax, another French Biotech company dedicated to the development of vaccines against infectious diseases.

Rainer Henning, CEO, Biomay AG

Rainer Henning is CEO of Biomay AG, a Vienna based biopharmaceutical company dedicated to immunotherapy products for allergies. He combines extensive experience in both the pharmaceutical and biotech industry with professional background as investment manager. Prior to joining Biomay he successfully served as CEO of Fibrex Medical Inc. At Hoechst AG (now part of Sanofi Aventis) he held several positions including Deputy Head of Cardiovascular Research and was Managing Director of Nippon Hoechst Marion Roussel. He co-invented the blockbuster antihypertensives Tritace® and Odrik® and authored well over 80 granted patents. At Future Capital and Brilleon Capital he served as investment manager and partner.

Rainer Metzger, VP Global Business Development Pharma, QIAGEN GmbH



Speakers


WELCOM

ESPEAKERS

t back :: next u

Rainer Strohmenger, General Partner, Wellington Partners

With over 20 investments in start-up companies, Dr. Rainer Strohmenger is one of Europe’s most experienced venture capitalists in life sciences. Joining Wellington Partners (www.wellington-partners.com) in 1997, he became a Partner in December 2000. His seventeen years of investment activity have involved financing of some of the most successful European biotech, medtech, and diagnostics companies as well as 6 IPOs and 6 successful trade sales.

In the late 1990s Dr. Strohmenger co-managed Wellington’s investment in Swiss biotech player Actelion (SWX: ATLN; www.actelion.com), today a listed company with a market capitalization of more than € 10 billion. He also was responsible for the investments in Grandis (acquired by Novartis), NoemaLife (Borsa Italiana: NOE; www.noemalife.com), Wavelight (acquired by Alcon), 20/10 Perfect Vision (acquired by Bausch & Lomb), immatics (www.immatics.com), mtm laboratories (acquired by Roche) as well as Oxford Immunotec (NASDAQ: OXFD; www.oxfordimmunotec.com), and represents Wellington on the boards of the portfolio companies Definiens (www.definiens.com), Genticel (NYSE Euronext: GTCL; www.genticel.com), Implanet (NYSE Euronext: IMPL; www.implanet.com), invendo medical (www.invendo-medical.com), NEUWAY Pharma (www.neuway-pharma.com) and Quanta Fluid Solutions (www.quantafs.com).

Prior to joining Wellington Partners, Dr. Strohmenger was involved in medical research with a primary focus on cardiovascular physiology and in research on health economics at the Ludwig-Maximilians-University in Munich, Germany.

Dr. Strohmenger holds a Ph.D. in medicine as well as a M.Sc. in economics, both from Ludwig-Maximilians-University in Munich, Germany, and was trained at the Entrepreneurship Center of the MIT, Boston, USA.

Reinhard J. Ambros, Global Head, Novartis Venture Fund

Reinhard Ambros is Global Head of Novartis Venture Funds. Previously, he held the position of Head of Group Strategic Planning for Novartis. He was responsible for post merger integrations at Novartis Corporate M&A and was Global Head BD&L cardiovascular and metabolic diseases at Novartis Pharma. Earlier in his career he held global leadership positions in key drug development projects at Novartis and Roche. He trained as a pharmacist, has a PhD in medicinal chemistry and pharmacology and focused his postdoctoral training in clinical pharmacology. He serves on the Boards of Aileron, Forma, Genedata, Symetis and Tokai.

Richard Goodfellow, Joint CEO, Scancell Holdings Plc.

Richard has had many yearsin the pharmaceutical industry, in both Big Pharma and with Biotech companies. During his time at Astra, he oversaw the launch of Losec and other key products internationally. Thereafter, he held the post of Director of Licensing and New Business Development at Scotia Pharmaceuticals, where he was involved with the company’s flotation on the London Stock Exchange and successfully negotiated numerous deals. Dr Goodfellow is also a founder of Paradigm Therapeutics, a Cambridge based functional genomics company and is a former Director of Enact Pharma plc. He is currently co-founder and Joint CEO of Scancell Holdings plc. He qualified as a Pharmacist from Liverpool University and received his M.B.A. from Bath University.



Speakers


WELCOM

ESPEAKERS

t back :: next u

Robert Pierce, Chief Medical Officer, OncoSec Medical Inc.

Dr. Robert H. Pierce joins OncoSec from Merck Research Labs where he was the Executive Director/Member of the Global Anti-PD-1 Development Team. Dr. Pierce is well regarded for his career-long research into mechanisms of immune tolerance. He is the co-author of over fifty peer-reviewed journal articles and book chapters.

Dr. Pierce received his post-doctoral training at the University of Washington, Seattle, WA, his graduate education and training at Brown University School of Medicine in Providence, RI, and received his undergraduate education at Yale University in New Haven, CT. As a Fulbright Award recipient, Dr. Pierce studied Philosophy at the Albert-Ludwigs-University in Freiburg, Germany.

Roa Movva, Novartis Institutes for Biomedical Research

Rao was born in India and pursued his studies leading to M.Sc degree from Nagpur university in India. He completed my Graduate studies with a Ph.D degree in Molecular Biology at SUNY at StonyBrook, New York in 1980. Subsequently,he joined Biogen S.A , then , a novel start-up biotech company in Geneva, Switzerland as a research scientist in 1980 and worked there until 1987 in various capacities as Project leader, Program executive and Senior research scientist focusing on cloning of novel genes and the expression of recombinant protein

He moved to Sandoz AG in Basel, Switzerland in 1987 and have been with the organization since in several research environments and in various capacities.

As a group leader in the Biotechnology (1987-92), he had developed methods for successful production of various recombinant proteins, including lymphokines IL-3, IL-6 and LIF from E.coli.

From 1992-1996, as the head of Signal transduction Biology group, he contributed to elucidate the of Mechanism of action of action of immunesuppressive drugs, including , notably the identification of TOR protein as the target of Rapamycin, the active component of Novartis transplant (Certican) and cancer(Affinitor) drug.

As the Head of Molecular biology and Gene therapy unit in the (1996-2004), he led very early efforts to evaluate the gene therapy technologies and developed screening strategies for small molecules to identify tool and lead compounds for drug development.

In the past 10 years, he focused his efforts in chemical biology to connect the chemicals with their biological targes to accelerate drug discovery.

In addition he is involved in setting up multiple collaborations between Novartis and the various leading academic instituitions of the world by acting as a scout to identify and initiate new drug discovery projects including the Human microbiome efforts in Novartis Institute for Biomedical research (NIBR).

Overall, Rao has more than 30 years of biotech and large pharma research and drug discovery experience and has authored several peer reviewed publications.

Robin Davison, Director, Healthcare, Edison Investment Research

Robin Davison is director of Healthcare at Edison Investment Research. He has recently taken on a new role focused on business development for the healthcare group, having managed healthcare research at Edison from its inception ten years ago. In this period, he built one of the largest dedicated biotech research teams worldwide with ten analysts and coverage of 95 companies. Robin has over 20 years’ experience in the biotech sector; he has covered biotech and pharmaceuticals companies as an investment analyst and as a journalist on specialist industry and financial publications. He was formerly biotech analyst for Durlacher Corporation, a contributor to Financier Worldwide, a co-founder and editor of Biopoly, a biotech investor newsletter, and editor of Scrip World Pharmaceutical News.



Speakers


WELCOM

ESPEAKERS

t back :: next u

Rodrigo Yelin, General Manager, Otic Pharma Ltd.

Seasoned pharmaceutical and biotechnology drug development executive with Teva (NYSE:TEVA), Proneuron and Pharmos (NASDAQ:PARS)

Roman Schenk, CEO, RECARDIO GmbH

Dr. Roman Schenk is CEO and founder of RECARDIO an Austrian based life science company developing regenerative therapies for cardiovascular diseases.

Prior to founding RECARDIO he was founder and CEO of several life science/health care companies.

He is also board member of various life science/health care companies and international organisations.

Prior to this he held various European management positions in research, marketing and business development in the pharmaceutical industry.

Dr. Roman Schenk is a medical doctor.

Sara Nunez-Garcia, Associate, Sofinnova Partners

Sara Núñez García joined the Life Sciences team as an Associate in 2013; Sara focuses on investments in the biopharmaceutical sector. Prior to Sofinnova Partners, Sara worked in the Licensing and M&A team at Onyx Pharmaceuticals in California, where she proposed option-based and structured deals for various potential acquisitions in the oncology space. Previously, Sara spent six years in the pharmaceutical industry with Solvay and Abbott Laboratories in The Netherlands as a Medicinal Chemist. During her time in drug discovery, Sara worked on preclinical programmes for central nervous system indications, contributing to the submission of several IND packages of novel chemical entities. In addition, Sara led transfer-of-knowledge projects with several universities in Amsterdam. Sara was a postdoctoral fellow in the Biochemistry and Biophysics departments at the Albert Einstein College of Medicine in New York where she developed inhibitors for oncology targets. She has a PhD in Chemistry from the University of Manchester; her doctoral research used a combination of experimental and computational techniques to design and synthesize transition state inhibitors. Sara has published eighteen peer-reviewed articles and patents. Sara also holds an MBA from INSEAD.

Rodolphe Clerval, Chief Business Officer & Co-Founder, Enterome

VP Corporate and Business Development of TcLand Expression

Business Development Manager at Genzyme

Financial analyst for Natixis Bleichroeder

Research Scientist at Aventis Animal Nutrition



Speakers


WELCOM

ESPEAKERS

t back :: next u

Scott Parkinson, Head of Gastrointestinal Health & Microbiome, Néstlé Institute of Health Sciences SA

Scott Parkinson is the leader of the Gastrointestinal Health and Microbiome group at the Nestle Institute of Health Sciences in Lausanne, Switzerland. A native of Canada, Scott completed his undergraduate degree at McMaster University near his hometown of Grimsby, Ontario before beginning his PhD in Molecular Pharmacology at Thomas Jefferson University in Philadelphia, USA.

It was during his PhD that his journey into gastrointestinal diseases began. He studied the epithelial signal transduction in response to E.coli heat-stable enterotoxin, one of the leading causes of pediatric mortality worldwide. Following successful completion of his degree, he remained in Philadelphia to play a part in the development of Targeted Diagnostics and Therapeutics – a successful biotech company that evolved from his PhD group. This environment initiated his passion for applying scientific discovery to the unmet medical need of patients.

Returning to academia, Scott completed a post-doc at the Lincoln’s Inn Laboratories of Cancer Research UK in London where he studied the molecular mechanisms underlying epithelial cell polarity. A second post-doc studying intestinal epithelial stem cell fate decisions in mouse development followed at the Dana-Farber Cancer Institute in Boston, USA.

Scott was then recruited as a laboratory head at the Gastrointestinal Disease Area of the Novartis Institutes for Biomedical Research in Horsham, UK to lead a drug discovery team identifying new targets for Crohn’s disease and ulcerative colitis. He was quickly promoted to lead the Mucosal Biology group and applied his training to initiate new avenues towards treating mucositis and other gastrointestinal diseases. It was during this time when he renewed his interest in the gut microbiota and initiated efforts to understand the principles that underlie their association with complex genetic diseases.

These efforts continued following his transfer to Novartis headquarters in Basel where he led an exploratory group with the challenge of applying the new science of the microbiota to the pharmaceutical industry. Part of this effort led to an appreciation of how the diet is perhaps the critical factor influencing microbial ecology and his natural progression into the mission of the Nestle Institute of Health Sciences where he was recruited to lead microbiome efforts in 2014.

Søren Møller, Managing Investment Director, Novo Seeds

Søren joined Novo A/S in October 2011 as Managing Investment Director of Novo Seeds.

Søren obtained his MSc degree from the Technical University of Denmark in 1993 and his PhD degree in molecular biology in 1997 from the Technical University of Denmark. In addition, Søren has academic training as postdoctoral fellow at Stanford University School of Medicine.

Prior to joining Novo Seeds, Søren served as global manager of Bioinformatics and Genomics at Novozymes. Before Novozymes, Søren was CSO and Vice President of R&D at Exiqon A/S where he was responsible for development of microRNA based products for life science research, pharma services and diagnostics. Previously, Søren worked in cancer drug development as head of Lead Identification at BioImage and as research scientist at Novo Nordisk.

Sascha Alliovic, Vice President Corporate Finance & Corporate Development, MorphoSys AG

Career:

2007-today MorphoSys AG, Vice President Corporate Finance & Corporate Development

2003-2007 Siemens AG, M&A / Investment Management, Head of Major Deal Team

2000-2003 SynCap Management, Director Corporate Finance/M&A

1999-2000 Value Management & Research - Venture Capital & Private Equity

Education:

1993 – 1998 European Business School - MBA

1995 – 1995 James Madison University, Virginia, USA - Computer Science, Bachelor of Science



Speakers


WELCOM

ESPEAKERS

t back :: next u

Stephen B. Helliwell, Senior Investigator, Novartis Institutes for Biomedical Research, Novartis

Stephen Helliwell received his BSc Honours in Biochemistry from the University of Kent at Canterbury in 1992. During his PhD in Biochemistry, awarded in 1996 from the Biozentrum, University of Basel, he identified one of the targets (Tor1p) of the immunosuppressant / anticancer drug, rapamycin (Afinitor), as well as downstream components of Tor signal transduction pathways in yeast. Following a short Post-Doctoral stay at the University of Bern to study links between protein synthesis and cell cycle control, he moved to the Department of Biology at MIT as a Post-Doctoral Fellow to study how extracellular signals regulate the sorting of amino acid permeases in the late secretory pathway. He discovered novel ubiquitination factors controlling Golgi-to-endosome sorting of membrane proteins. Stephen returned to the Biozentrum, University of Basel as an Independent Investigator in 2002 to continue this research. He joined the Chemical Modulators of Biology Unit at its inception in 2005 within the Developmental and Molecular Pathways Department at the Novartis Institutes of BioMedical Research. After 6 years focusing on small molecule target identification using chemogenomic profiling, he is now leading a group interested in disorders caused by defective mitochondria. He continues to lecture at the Biozentrum, University of Basel.

Stephen Sands, Commercial Lead, Oncology/Immunology, F.Hoffmann La Roche AG

Stephen has over 25 years commercial experience in the pharma industry in multiple disease areas, now specializing in oncology. In his current role Stephen is the Oncology Commercial Lead for Roche Partnering, leading the acquisition process for key assets, such as the recently announced partnership between Roche and Oryzon around the epigenetic compound ORY-1001. Prior to this Stephen was the Commercial Director for Roche Oncology and prior to that the Commercial Director for Avastin. In these roles he developed and supported the commercial and marketing strategies for some of the largest brands in the field of oncology.

Sten Verland, Partner, Sunstone Capital A/S

Sten Verland is a partner in the Life Science group and one of the three co-founders. Sten focuses on therapeutics investments.

During his career, Sten has been active as a serial entrepreneur and business angel and has co-founded ten start-ups, primarily in the biotech and CRO fields. While at Sunstone, Sten has played a key role in executing two exits (Action Pharma and Zymenex). Both deals made it to the global Top Ten list of published upfront cash deals in 2007-2012.

Sten holds a Master’s degree in Biology and Mathematics and a PhD in Immunology – both from the University of Copenhagen. Sten serves as a board member of the Danish Venture Capital Association. In his spare time, Sten is both a keen yachtsman and a big admirer of classical music.

Stephanie Léouzon, Principal and Head of Torreya Partners Europe, Torreya Partners

Stephanie Léouzon is Partner and Head of Europe for Torreya Partners, a life sciences boutique advisory firm which she joined in 2012. She also serves on the Board of Directors of Immunovaccine Inc. Previously she worked in Health Care Investment Banking in the US and Europe from 1989-2010, most recently at Credit Suisse as a Managing Director and Senior Advisor. She has advised life sciences clients on more than 20 strategic transactions, valued at over $65billion, and been involved in over 45financing transactions to provide over $10 billion to health care clients.

Stephanie earned an M.B.A. degree from the Darden Graduate School of Business at the University of Virginia in 1989 and a B.A. degree, cum laude, from Mount Holyoke College in 1985.



Speakers


WELCOM

ESPEAKERS

t back :: next u

Thomas Stockman, Director, Healthcare Investment Banking, Citi Group

Tim Herpin, Vice President, Head of Transactions (UK), Business Development, AstraZeneca

Timothy Herpin heads a group of business development professionals involved in all aspects of transactions negotiation and execution at AstraZeneca. Tim joined AstraZeneca in 2011 as Vice-President, Strategic Partnering and Business Development, initially for CNS& Pain and more recently for Oncology & STL. Prior to AstraZeneca, Tim spent eight years in the business development organization at Bristol-Myers Squibb covering both search and evaluation as well as transaction in multiple disease areas. Before his business development career, Tim worked in R&D at Bristol-Myers Squibb, Aventis and Pharmacopeia. Tim grew up in Paris and is a graduate of Ecole Polytechnique in France. He also holds a Ph.D. in organic chemistry from University College London and an MBA in Finance from NYU Stern.

Tim Knotnerus, Director Business Development, Am-Pharma

Tim joined the AM-Pharma team in 2012, and has since been responsible for Business Development of the company. Previously, Tim was a senior associate at Aescap Venture which he joined in 2008. He was instrumental in the financing and support of various portfolio companies including Avantium-the Netherlands, Biocartis-Switzerland, i-Optics-the Netherlands, Ethical Oncology Sciences (now Clovis)-Italy, and to-BBB-the Netherlands. Tim gained both a Science and Innovation Masters and a Drug Innovation Masters with honors from Utrecht University.

Tim Mitchell, CEO, Sareum Ltd.

Dr Tim Mitchell is CEO of Sareum, a drug discovery and development company focusing on cancer and autoimmune disease. Tim co-founded Sareum in 2003 and floated it on the AIM market of the London Stock Exchange in 2004. Previous roles include Director of Structure-Based Discovery at Millennium Pharmaceuticals, Director of Computational Chemistry at Cambridge Discovery Chemistry, and Team Leader at SmithKline Beecham Pharmaceuticals. Tim has a PhD in Computational Chemistry and a BSc in Chemistry.

Stewart Kay, Director Transactions, Worldwide Business Development, GSK

Stewart started his career at Amersham International (now part of GE) and held various sales, marketing and business development positions in the Life Science and Technology Platforms division. He joined Evotec in 2002 as SVP Business Development for Europe and was part of the operational management team. In 2005 he joined Pharmagene as VP Commercial Development and as a member of the Executive Management team took the company into a merger with Asterand. Stewart joined GSK in 2008 and is currently Director Transactions in Worldwide Business Development, Pharma R&D. Stewart hold s Bsc in Biochemistry and a MBA from Warwick Business School.



Speakers


WELCOM

ESPEAKERS

t back :: next u

Tom Johnston, CEO, Mucosis B.V.

Mr. Thomas Johnston is Chief Executive Officer. Mr. Johnston joined Mucosis in May 2011 from Novavax where as Vice President of Strategy he developed and executed a regional partnership strategy with deals in India, Mexico, and South Korea. Prior to Novavax, Mr. Johnston served as an executive-level strategic consultant in a number of industries including biotech, and held various senior-level positions with a number of world-class organizations such as Comcast, Microsoft, and Schlumberger. Mr. Johnston holds an M.B.A. from The Wharton Business School and a Bachelor of Science degree in Computer Science from Arcadia University.

Tom Kronbach, CEO, BioCrea

Tom Kronbach is CEO of BioCrea, which he established as a Management buy-out of assets from Biotie Therapies Corp. in 2010. A new Management Team and new scientific and business ideas were combined with a productive CNS-discovery group. The first success was the acquisition of BioCrea’s Cognition Program by Boehringer Ingelheim in 2012. Since then new projects for Epilepsy, Autism, Depression and Huntington’s disease were established.

Tom has initiated and fostered partnerships with Boehringer Ingelheim, Wyeth/Pfizer and GlaxoSmithKline. Previously, Tom was the CSO of Biotie Therapies Corp. and CSO and co-founder of elbion AG.

Tom holds a Ph.D. in Chemistry from the University of Tubingen, Germany. He was a Post Doctoral Fellow with Urs A. Meyer in Pharmacology at the University of Basle, Switzerland and was Research Associate in Molecular and Experimental Medicine with Eric F. Johnson in at The Scripps Clinic and Research Foundation in La Jolla, CA. Tom then joined Goedecke-Parke Davis in Freiburg, Germany and then Asta Medica -AWD, a Degussa company in Radebeul, Germany, where he had increasing responsibilities up to being Head of R&D.

Tomas Landh, Director, Strategy and Innovation Sourcing, Novo Nordisk

Tomas Landh is since 2008 Director (Strategy and Sourcing) at Novo Nordisk, Diabetes Research Unit, where he is responsible for the scouting and evaluation of in particular, protein therapeutics and related technologies including new drug delivery systems for the treatment of diabetes, its microvascular complications and obesity.

Two years after joining Novo Nordisk in 2003, Tomas was recruited to the Diabetes Research Unit with scouting and evaluation of external technology opportunities for oral delivery of proteins as his main responsibility.

Prior to joining Novo Nordisk, Tomas was R&D Director and Chief Scientist at Camurus AB (1997-2002), a lipid drug delivery company and CEO for Lipid Research Foundation (2001-2003), a foundation sponsoring applied lipid research. Preceding his entrepreneurial career, he was Professor at State University New York at Buffalo doing basic research on cubic cell membrane morphologies and drug delivery. He received his PhD in Biophysical Engineering from Lund’s Institute of Technology.

Tomas has + 20 years of experience of all stages of drug development and delivery, ranging from academia, small businesses, foundations and big pharma/biotech. He has authored a number of scientific papers and book chapters on cell membrane morphologies, pharmaceutical formulations, and holds a number of patents. He is currently an international advisor to LARTA/NIH- and NSF-CAP programs and member of the Science Advisory Board of QChip.



Speakers


WELCOM

ESPEAKERS

t back :: next u

Ulf Grawunder, CEO, NBE-Therapeutics Ltd

Ulf Grawunder is founder and CEO of NBE-Therapeutics, a new Swiss Biotech company that was created in April 2012, and which focuses on the development of “next-generation” antibody-drug conjugates for cancer therapy.

Prior to that, Ulf Grawunder had co-founded 4-Antibody Ltd in 2004, a Swiss therapeutic antibody engineering company, where he initially served as CEO and since 2006 as CSO. Ulf Grawunder obtained his PhD from University of Basel for work performed at the Basel Institute for Immunology. After his PhD he did several years of post-doctoral research at Washington University School of Medicine, St. Louis, and the University of Southern California, Los Angeles in the U.S. After this he returned to Europe and held positions as principal investigator at the Basel Institute for Immunology, the University of Ulm, Germany, and the University of Basel, Switzerland, before starting his first biotech company.

Ulf Grawunder is member of a number of national and international boards of for profit and non-profit organizations, including the scientific advisory board of the Bavarian Immunotherapies Network, BayImmuNet, Germany (www.bayimmunet.de), and the Board of the Swiss Biotech Association (SBA, www.swissbiotech.org).

Vikas Sharma, Director, Business Development, Rexahn Pharmaceuticals, Inc.

An Immunologist by training, Vikas Sharma has been involved in pharmaceutical and biotech business development for over 9 years. Currently, he is responsible for all business development activities at Rexahn Pharmaceuticals and has held business development positions at MedImmune (Astrazeneca), Bradley Pharmaceuticals (NJ), CHOP, and Advanced Bioadjuvants. He has a broad business development experience working with Biologics, small molecule and technologies in multiple therapeutic areas. Besides his expertise in business development, he has also been involved in developing and executing multiple corporate strategic initiatives.

Vincent Charlon, CEO, Anergis SA

Vincent Charlon joined Anergis in January 2009 as Chief Executive Officer (CEO). Dr Charlon brings over 20 years of global clinical development and management experience. From 1990 to 1998, at Hoffmann La Roche Basel as Clinical Research Scientist and then at Hoffmann La Roche Inc. Nutley,USA, as Director of Clinical Research, Dr Charlon held clinical development responsibilities for several international projects. He was the first author of an approved global new drug application for an anti-antihypertensive and anti-anginal new chemical entity and was involved in numerous meetings with the US FDA and European regulatory authorities. From 1998 to 2006, Vincent Charlon was CEO of Hesperion Ltd., the contract research organization (CRO) who designed and conducted all initial clinical trials for Actelion’s [SWX, ATLN] products. In this capacity, Vincent Charlon designed the first clinical trials of Tracleer® in pulmonary hypertension, today Actelion’s biggest product with sales well over CHF 1 billion/year. Vincent Charlon developed Hesperion as a profitable CRO from 3 to 200 employees located in eight country offices, serving over a hundred clients. Two third of Hesperion clients were small biotech companies from North America and Europe. During that time, Dr Charlon also realized two company acquisitions and integrations into Hesperion, as well as the sale of Hesperion to Cerep SA. In 2007-2008, Vincent Charlon was CEO of the drug repositioning start-up company LS Pharma International SA before joining Anergis.

Vladimir Cmiljanovic, CEO, PIQUR Therapeutics AG

Dr. Vladimir Cmiljanovic, Chief Executive Officer and Vice-President of the Board of Directors, has hands-on experience in the range of chemistry disciplines (organic, medicinal, analytical & biochemistry) essential to the discovery of PI3K-Akt-mTOR pathway products. Vladimir built up the team of well-known and recognized experts from the field and is leader of the team creating PIQUR’s industry leading next generation PI3K agents. For his scientific contribution in PI3K-AKT-mTOR research field he was awarded in 2009 with the Camille and Henry Dreyfus Award of the University of Basel and in 2011 with the Novartis and University of Basel Excellence Scholarship for Life Sciences. In 2010 Vladimir was the winner of the Swiss Venture Kick for the development of the PIQUR business idea. In January 2014 PIQUR launched the clinical Phase I study with the active ingredient PQR309; the first results of the study are anticipated in the fourth quarter of 2014.



Speakers


WELCOM

ESPEAKERS

t back :: next u

William Shell, CEO & CSO, Board Member, Targeted Medical Pharma, Inc.

Dr. William Shell is Chairman of the Board, CEO, and Chief Scientific Officer of Targeted Medical Pharma, Inc. Dr. Shell is a board certified cardiologist and inventor possessing multiple United States patents. Dr. Shell attended the University of Michigan Medical School and graduated in June 1967. Dr. Shell was one of the first students chosen by the Michigan Heart Association to train in the cardiovascular division of University Hospital of University of Michigan. He published the first American paper on the syndrome now known as Mitral Valve Prolapse, which demonstrated the genetic nature of this malady. Following his residency at the University of Michigan, Dr. Shell began a National Institutes of Health (NIH) Special Fellowship to study cardiology under Dr. Eugene Braunwald at the University of California San Diego. During his fellowship, Dr. Shell was a member of the team credited with discovering the cardio specific enzyme CK-MB. A diagnostic test for the presence of the CK-MB enzyme is now the clinical foundation for the detection and treatment of heart attacks. Dr. Shell and his colleagues published a total of 44 papers in medical journals on this body of work between 1969 and 1974. Dr. Shell joined the United States Air Force following his fellowship. The first months of his military service were spent in the American Soviet Exchange Program as the first American physician representing the National Institutes of Health and the American government in Moscow. Several publications emanated from Dr. Shell’s work in the Soviet Union, including early biochemical work that defined the relationship between heart cell growth and creatine. In addition, he and his Soviet colleagues performed clinical trials which led to the discontinuation of digitalis as a treatment of heart attacks. These studies lead to the early examination of reperfusion as part of the treatment of heart attacks. Upon his return to the United States, Dr. Shell served as the director of the coronary care unit at Keesler Air Force Base in Mississippi, where he supervised the construction of the first modern coronary care unit for the United States Air Force, which became the model for future units. Dr. Shell was awarded a Presidential Citation by President Richard Nixon for his work in the American Soviet Exchange Program and his administrative work creating the coronary care unit at Keesler. Following his discharge from the Air Force, Dr. Shell returned to Los Angeles and joined the cardiology staff at Cedars of Lebanon Hospital and Mount Sinai Hospital. During his tenure, he planned, directed and implemented the merger of the coronary care unit at Cedars of Lebanon and Mount Sinai Hospital to what is now known as Cedars-Sinai Medical Center in Los Angeles, California. Dr. Shell was also Director of the Cardiac Catheterization Laboratory and Director of Cardiac Rehabilitation. In addition, he participated in the planning, funding and administration of NIH grants and managed a biochemistry research laboratory at Cedars-Sinai Medical Center. Dr. Shell also was given teaching responsibilities at both Cedars-Sinai and the University of California at Los Angeles, where he obtained the title of Associate Professor of Medicine in Residence. In 1989, Dr. Shell, along with Ms. Elizabeth Charuvastra, founded Beverly Glen Medical Systems, a cardiac diagnostic service company. Dr. Shell served as the chief scientific officer and chief medical officer. The technology that was developed at this company resulted in two patents that allow for the measurement of autonomic nervous system activity and measurements of the QT interval on 24-hour electrocardiograms. The technology has been used by the pharmaceutical industry in establishing safety standards for new drugs, by the Veterans Administration to establish that the Gulf War Syndrome is a form of nervous system dysfunction, and by the Environmental Protection Agency and other environmental groups to examine the effects of environmental toxins on the brain and other parts of the autonomic nervous system. In 1991, Dr. Shell founded and served as chairman and chief executive officer of SeeShell Biotechnology, which merged with a company called Interactive Principals, which in turn merged into Interactive Medical Technologies, Inc. (IMT), whose stock was quoted on the Over the Counter Bulletin Board. Dr. Shell relinquished the daily CEO role and retained the title of Chairman of the Board of Directors until 1995. Dr. Shell is the author of more than 150 scientific articles published in peer reviewed journals.

Wilder Fulford, Principal, Torreya Partners (Europe) LLC

Wilder is the founding partner of Torreya Partners Europe, the London branch of Torreya Partners, an international advisory firm assisting Life Science companies with M&A, licensing, alliances, financings and other transactions. Dr. Fulford has had a long career advising healthcare companies of all kinds around the globe. After completing his PhD in molecular biology at the Rockefeller University in 1986, he worked for a few years as a venture capitalist, before embarking on a career as an M&A advisor. He has run healthcare M&A or coverage groups in New York and London at Salomon Brothers, Merrill Lynch, Bank of America and (most recently) Deutsche Bank. He has participated in close to 100 financing and M&A transactions with an aggregate value in excess of $100 billion. Torreya Partners has a full team in London, and about a dozen mandates in execution, and has closed five transactions so far in 2013 in biotechnology, specialty pharma, vaccines, medical devices, and OTC. Globally, Torreya Partners has completed over 100 Life Sciences assignments in the 6 years since inception.

SUPPORTING ORGANISATIONSEXHIBITORS

ORGANISERSW

ELCOME

SPEAKERSPRESENTING COM

PANIES

t back :: next u

3B Pharmaceuticals GmbH www.3b-pharma.com

CONTACTDr. Christiane Smerling Head of Nuclear Medicine & Imaging

ADDRESS Magnusstr. 11 Berlin 12489 Germany

TELEPHONE +49 30 63924317

EMAIL Christiane.Smerling @3b-pharma.com

YEAR FOUNDED2008

COMPANY PROFILE

3B Pharmaceuticals GmbH (3BP) is a German biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for oncology indications with a high unmet medical need. As a leader in peptide discovery and optimization, 3BP has built a technology platform extending from hit identification to early clinical development. Technologies are applied to both in-house and collaborative R&D.

3BP’s targeted radiopharmaceuticals provide a focused and personalized approach to the treatment of cancer.

Peptides and peptidomimetics constitute excellent tumor-specific targeting moieties and can be coupled to therapeutic and diagnostic radioisotopes via a linker and a chelator. Radiolabeled peptidomimetics specifically bind target-expressing tumor cells and kill these as well as neighboring tumor cells by direct radiation-induced cell damage and via the bystander and cross-fire effect. Using 3BP’s theranostic approach, you can see where your drug is going and monitor the efficacy of the treatment. This allows the identification of responders leading to faster and cost-efficient clinical trials and increased chances of successful treatment. It also allows personalized dosing based on individual imaging data, thus achieving maximal therapeutic effect with minimal unwanted side effects.

PRODUCT PIPELINE

3B Pharmaceuticals discovers and develops targeted radiotherapeutics with a focus on oncology. Having established in vivo proof of concept and with first patient data available in our NTR1 program, 3BP is on the verge of transforming into a clinical stage company.

3BP-227 is a highly effective targeted radiopharmaceutical for the treatment of pancreatic adenocarcinoma that comes with a chemically identical companion diagnostic, making the target NTR1 its inherent biomarker predicting response to treatment. The stratification of patients in responders and non-responders ensures efficient development, small and economical clinical trials, and maximal patient benefit. Importantly, anecdotal patient data show an extraordinary uptake and retention in tumor and metastases. Exceptionally high radiation doses are delivered to the neoplastic lesions while sparing normal tissues and organs, indicating a high probability of response to therapy.

3BP is currently seeking a strategic partner or an investment for development of 3BP-227 through clinical trials.

OPPORTUNITIES

NTR1-Program / 3BP-227, pre-IND

Integrin-Program, lead optimization

MANAGEMENT

Dr. Ulrich Reineke, Managing DirectorDr. Christiane Smerling, Head of Nuclear Medicine & ImagingDr. Jan Michel, Director of Finance, Operations, and Corporate DevelopmentDr. Frank Osterkamp, Director of Chemistry and AnalyticsDr. Matthias Paschke, Director of Biology & Assay Technologies


ORGANISERSW

ELCOME


PANIES

t back :: next u

ABIVAX www.abivax.com

CONTACTProf Hartmut Ehrlich CEO

Daniel Kenny Chief Commercial Officer

ADDRESS 5, rue de la Baume Paris 75008 France

TELEPHONE +33 1 75 66 2024

FAX +33 1 75 66 20 39

EMAIL [email protected]

YEAR FOUNDED2013

COMPANY PROFILE

ABIVAX is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialisation of novel anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases.

PRODUCT PIPELINE

ABX 203, A Therapeutic Vaccine against HBV. ABX 203 is a therapeutic vaccine intended for patients with chronic hepatitis B disease. It is composed of both the Hbs and Hbc antigens and thus a mix of 2 VLP structures. ABX 203 has successfully been tested in a Phase 1 clinical trial in healthy volunteers as well as in Phase 1 study and two Phase 2 studies in patients with chronic hepatitis B disease. The candidate vaccine is scheduled to enter into a pivotal Phase 2/3 clinical trial in Asia in late 2014.

ABX 464, A Novel Small Molecule Inhibiting HIV Replication. ABX 464 is a product based on proprietary chemical library targeting RNA splicing. This small molecule has a novel and unique mode of action and is able to induce a long-lasting HIV viral load reduction in vitro. In vivo, ABX 464 does not induce any resistance when tested up to 24 weeks. A phase 1 study in healthy volunteers was completed in Q2 2014 and clinical trials in HIV patients are scheduled to start in Q3, 2014.

ABX 196, An Adjuvant for Therapeutic Vaccines. ABX 196 is a novel adjuvant candidate for vaccination based on NKT cell agonists. This platform is based on technology and exclusive patent rights from Scripps Research Institute, the University of Chicago, and the Brigham Young University.

A Phase 1 clinical trial with a prophylactic Hepatitis B vaccine has recently been completed. The addition of ABX 196 to immunogenic HBs antigen resulted in protective anti-HBs antibody responses in a majority of patients.

Study results indicate that in those receiving ABX 196with HBs antigen, a single injection appears sufficient to provide protection. A publication outlining the adjuvanticity of ABX 196 in humans against Hepatitis B is in submission. A new delivery system and formulation for ABX 196 will be tested in a clinical trial scheduled to start in Q4 2014.

ABX 318, A Therapeutic Vaccine against HPV. ABX 318 is a human papilloma virus vaccine candidate obtained from the British Columbia Cancer Agency (BCCA), containing a new antigen that is based on the fusion of the E7 antigens from HPV 16,18,31,45 and 52. Following encouraging results in preventing TC-1 tumour growth in mice, the vaccine is currently going through formal preclinical development to move into Phase 1 in 2015.

MANAGEMENT

Prof Hartmut Ehrlich MD, CEOAlain Chevalier, CFODaniel Kenny, Chief Commercial Officer


ORGANISERSW

ELCOME


PANIES

t back :: next u

Abzena www.abenza.com

CONTACTElaine Phillips Executive PA

ADDRESS Babraham Research Campus Cambridge CB22 3AT United Kingdom

TELEPHONE +44 1223 903498


FINANCIAL SUMMARY

FY2014 aggregate group revenues of £5.8m, derived from immunogenicity assessment, protein engineering, bioconjugation and cell line development services.

£20m IPO completed July 2014 (LON: ABZA)

COMPANY PROFILE

Abzena provides proprietary technologies and value-added services to enable the development of better biopharmaceuticals.

Abzena comprises two wholly owned subsidiary businesses – PolyTherics and Antitope – which have established a broad suite of complementary technologies that are designed to improve the chances of successful development of antibodies and proteins with enhanced therapeutic benefits.

Antitope provides immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture

PolyTherics specializes in proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimization of the therapeutic properties of biopharmaceuticals.

PRODUCT PIPELINE

EpiScreen (immunogenicity assessment)

Composite Human Antibodies & Composite Proteins (protein engineering)

Composite CHO (cell-line development)

ThioBridge (ADC conjugation technology)

TheraPEG, HiPEG, CyPEG & PolyPEG (PK optimisation technologies)

MANAGEMENT

John Burt, CEOJulian Smith, CFOMatthew Baker, CSOSally Waterman, Senior VP, Corporate DevelopmentNeil Butt, VP, Business DevelopmentDonna Hackett,VP, IP, Commercial & Legal Affairs


ORGANISERSW

ELCOME


PANIES

t back :: next u

Acousia Therapeutics www.acousia.com

CONTACTDr. Michael Bös CEO

ADDRESS Sindelfingerstrasse 3 Tübingen 72070 Germany


YEAR FOUNDED2012

FINANCIAL SUMMARY

Company is closing financial round A and is seeking additional investors.

COMPANY PROFILE

Acousia will develop drugs for local application, which will restore hearing in patients who have lost their hearing ability due to various reasons, e.g. noise trauma, treatment with ototoxic drugs or sudden deafness. In addition, this therapy will have the potential to treat the age-related decrease in hearing capacity.

MANAGEMENT

Dr. Michael Bös, CEO


ORGANISERSW

ELCOME


PANIES

t back :: next u

Actavis plc www.actavis.com

ADDRESS U.S. Administrative Headquarters Morris Corporate Center III 400 Interpace Parkway Parsippany, NJ 07054

Actavis plc 1 Grand Canal Square Docklands Dublin 2 Ireland

TELEPHONE Investor Relations+1 (862) 261-7488

U.S. Administrative Headquarters +1 (862) 261-7000

COMPANY PROFILE

Actavis plc (NYSE: ACT) is a unique specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world.

The Company has global headquarters in Dublin, Ireland and U.S. Administrative Headquarters in Parsippany, New Jersey, USA.

Highlights

• Actavis markets a broad portfolio of branded and generic pharmaceuticals and develops innovative medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women’s health, urology, cardiovascular, respiratory and anti-infective therapeutic categories.

• Actavis markets approximately 1000 generic, branded generic, established brands and Over-the-Counter (OTC) pharmaceutical products globally through operations in more than 60 countries.

The Company is an industry leader in product research and development, with one of the broadest brand development pipelines in the pharmaceutical industry, and a leading position in the submission of generic product applications. Actavis has commercial operations in more than 60 countries and operates more than 30 manufacturing and distribution facilities around the world.


ORGANISERSW

ELCOME


PANIES

t back :: next u

Actinium Pharmaceuticals www.actiniumpharma.com

CONTACTSandesh Seth Chairman

ADDRESS 546 Fifth Avenue New York New York 10036 United States

TELEPHONE +1 64 684 05442


YEAR FOUNDED2000

COMPANY PROFILE

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium’s targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company’s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

PRODUCT PIPELINE

Iomab™-B - in development for preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission.

Actimab-A, Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multi-center trial.

OPPORTUNITIES

Out licencing

Iomab-B x-US

Actimab-A

MANAGEMENT

Sandesh Seth, CEOKaushik Dave, PhD., CEODragan Cicic, CMO


ORGANISERSW

ELCOME


PANIES

t back :: next u

ActoGeniX NV www.actogenix.com

CONTACTDr Bernard Coulie CEO and CMO

ADDRESS Technologiepark 4 Zwijnaarde 9052 Belgium

TELEPHONE +32 9 261 06 00


YEAR FOUNDED2006

FINANCIAL SUMMARY

Shortly after its inception, the Company raised Euro €20 million through a Series A equity round. In 2009, an additional EUR €15.5 million was raised and in 2013, EUR €10.7 million raised in its Series B round. EUR €46 million (US$ 65 million) raised in total from a consortium of life sciences investors including: Gimv, Biotech Fund Flanders, Baekeland Fund, BioVest, LSP, Aescap Venture, Ventech and Saffelberg Investments.

COMPANY PROFILE

ActoGeniX is a biopharmaceutical company focused on the development and commercialization of a new generation of biological drugs called ActoBiotics™. ActoBiotics™ are protein drugs that can be orally administered and have the potential to treat a broad range of severe diseases, including gastrointestinal diseases, metabolic diseases, immune disorders and allergies.

PRODUCT PIPELINE

OPPORTUNITIES

AG013 in oral mucositis

AG014 in IBD

platform applications

Type 1 diabetes platform

microbiome modulation

MANAGEMENT

Bernard Coulie, MD PhD MBA, Chief Executive Officer and Chief Medical OfficerAnjan Aralihalli, MBA, Chief Business OfficerLothar Steidler, PhD, Vice President TechnologyPieter Rottiers, PhD, Vice President R&DSam Corveleyn, PharmD PhD, Director CMC OperationsEmil Pot, LL.M, EPA, General CounselDecebal Bora, PharmD, Director Regulatory Affairs


ORGANISERSW

ELCOME


PANIES

t back :: next u

AFreeze GmbH www.afreeze.com

CONTACTDr. Gertraud Unterrainer CEO

ADDRESS Eduard Bodem Gasse 8 Innsbruck 6020 Austria

TELEPHONE +43 512 20 90 120


YEAR FOUNDED2008

FINANCIAL SUMMARY

AFreeze is a medical device company with a cryo-catheter to treat atrial fibrillation, a USD 1.3 bn market. The device is under regulatory review and marketing will start in Q1, 2015. To date, the company has raised more than € 8 M in equity and public funding and is now seeking a final financing round of € 2 M to finance the market introduction of the system in selected European countries.

COMPANY PROFILE

AFreeze is a medical device company founded in 2008 and based in Innsbruck, Austria. It has developed a complete stand-alone system to treat atrial fibrillation, a cardiac rhythm disease affecting 14 million people worldwide. Atrial fibrillation (AF) leads to a five-fold increased risk of stroke and a three-fold increased mortality in patients. Treatment of AF patients is done by catheter ablation or drugs (with side effects and poor success rates). During catheter ablation, electrical signals in the heart of the patient are being blocked (ablated) by use of a catheter. The catheter emits energy (typically radiofrequency) and induces lesions, which intermit the electrical signal cascade. The CoolLoop® cryoablation catheter uses extreme cold to induce long circular lesions in the patient’s heart and thus provides a unique lesion pattern (WACA) which improves the clinical outcome. The handling of the device is extremely simple (shortening the procedure time) and it has a very good safety profile. The company is led by a highly (financially) committed management team, with combined more than 50 years of experience.

PRODUCT PIPELINE

The CoolLoop® cryoablation system consists of a proprietary console (guiding the whole process), a steerable sheath (to introduce the catheter) and the cryo-catheter, delivering unparalleled cooling capacity for the treatment of atrial fibrillation. Two of the three components are already CE-marked, the catheter is under regulatory review and approval is expected for the end of 2014/early 2015. A first in man clinical study has been successfully completed and a multi-center clinical study to further validate the initial results is ongoing.

OPPORTUNITIES

AFreeze is seeking a € 2 M financing round to finance the company to the exit. The proceeds will be used to market the cryo-ablation system in selected European countries.

MANAGEMENT

Dr. Gertraud Unterrainer, CEODr. Gerald Fischer, Chief Technology OfficerDr. Florian Hintringer, Chief Medical Officer


ORGANISERSW

ELCOME


PANIES

t back :: next u

Amarantus BioScience www.amarantus.com

CONTACTSGerald Commissiong President and Chief Executive Officer

John Commissiong Chief Scientific Officer

Bob Farrell Chief Financial Officer

Marc Faerber Vice President Finance

ADDRESS 655 Montgomery St. San Francisco 94111 United States

TELEPHONE +1 408 701 5005


YEAR FOUNDED2006

FINANCIAL SUMMARY

6/30/14

Cash $1,402

Avg Shares outstanding 734,023,717

2014 Common stock placement $20,000

Stock symbol: AMBS

COMPANY PROFILE

Amarantus BioScience Holdings, Inc. is a development-stage, publicly-traded biotechnology company discovering & developing first-in-class treatments for diseases associated with the dysfunction of a wide range of biological pathways, including protein misfolding, cell cycle dysregulation, neurodegeneration and apoptosis (Programmed Cell Death).

Degenerative disorders such as Parkinson’s, Alzheimer’s, Retinitis Pigmentosa, Diabetes and ALS as well as Cardiovascular Disease such as Myocardial Infarction, Angina, Coronary Artery Disease and Heart Failure are in need of treatments that address the region specific apoptosis associated with each disorder. The Company has a focus on developing certain small molecules, biologics, and biomarkers surrounding the intellectual property and proprietary technologies it owns and to which it has licenses to treat and/or diagnose Parkinson’s disease, Alzheimer’s disease, Retinitis Pigmentosa and other human diseases.

Amarantus has a license to Eltoprazine, owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF”) and has a license to the LymPro Test®.

Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments and diagnostics in development for concussions and TBI. The Company believes that TBI-induced neurodegeneration represents a new frontier of clinical research which may ultimately allow for commonalities between chronic degenerative disorders.

Amarantus BioScience Holdings, Inc. intends to advance its therapies and diagnostics to provide patients with safe and effective treatment options in the care of their illnesses..

MANAGEMENT

Gerald Commissiong, President and Chief Executive OfficerJohn Commissiong, Chief Scientific OfficerBob Farrell, Chief Financial OfficerMarc Faerber, Vice President Finance Amarantus

Bioscience

(OTCQB: AMBS)

Amarantus BioScience Holdings, Inc.is a biotechnology company focused on

the discovery and development of novel diagnostics and therapeutics

related to neurodegeneration and apoptosis.


ORGANISERSW

ELCOME


PANIES

t back :: next u

AM-Pharma B.V. www.am-pharma.com

CONTACTSErik van den Berg CEO

Tim Knotnerus Director Business Development

ADDRESS Rumpsterweg 6 Bunnik 3981 AK The Netherlands

TELEPHONE +31 30 228 9222


YEAR FOUNDED2002

FINANCIAL SUMMARY

AM‐Pharma raised €29.2M in Q4 2011, enabling AM‐Pharma to finalize the GMP production and the development through phase II.

COMPANY PROFILE

AM–Pharma is a biopharmaceutical company developing proprietary recombinant human alkaline phosphatase therapeutics, which have the potential to transform the treatment prospects for patients with chronic or life-threatening inflammatory diseases.

AM-Pharma discovered that alkaline phosphatase can protect organs against inflammation and tissue damage. While this enzyme is found in many cells of the body, it is present at reduced levels in certain diseases including Acute Kidney Injury and Ulcerative Colitis.

The Company’s proprietary therapeutics are disease modifying therapies and have the potential to be “first-in-class” medicines.

PRODUCT PIPELINE

Recombinant Human Alkaline Phosphatase: Intravenous to treat Acute Kidney Injury (Phase II)

Recombinant Human Alkaline Phosphatase: Oral application to treat Inflammatory Bowel Disease (Preclinical stage)

MANAGEMENT

Erik van den Berg, CEOAndrea van Elsas, VP ResearchSteve Connor, VP Pre-clinical DevelopmentJacques Arend, CMOPeter Verwayen, VP FinanceTim Knotnerus, Director Business Development


ORGANISERSW

ELCOME


PANIES

t back :: next u

ANERGIS SA www.anergis.ch

CONTACTSVincent Charlon PhD CEO

Zoltan Czigler MBA Finance Director

ADDRESS BioPole III Route de la Corniche 9B CH-1066 Epalinges Switzerland

TELEPHONE +41 21 651 9220

FAX +41 21 651 9221


YEAR FOUNDED2001

FINANCIAL SUMMARY

Seed funding (2005): CHF 2 M

Round A (2011): CHF 19.5 M

Convertible loan (2014): CHF 8 M

COMPANY PROFILE

Anergis develops disease-modifying allergy vaccines requiring only 2 months of treatment. Final clinical proof-of-concept has been established this year with the clinical evidence of long term efficacy in a 200 patient-field based trial.

Anergis is a Swiss-based biopharmaceutical company specializing in the discovery and development of novel ultra-fast and safe allergy immunotherapy (AIT) products, for the treatment of allergy, the most prevalent and fastest growing chronic condition in the industrialized world with over 500 million people affected. Current AIT remains underused due to its long duration (3-5 years of treatment), low tolerance and safety risks.

Anergis allergy vaccines are based on the proprietary technology of Contiguous Overlapping Peptides (“COPs”) developed in Lausanne, Switzerland by the team of Prof François Spertini. The technology of COPs allows the identification and development of uniquely profiled proprietary products intended for ultra-fast and safe desensitization. To date, Anergis has established the proof-of-concept of its unique approach to AIT with COPs targeting bee venom and birch pollen allergies, both in animals and in humans. . After a successful Phase IIa clinical trial, the birch pollen allergy product completed a 240-patient European Phase IIb trial in Summer 2013 and a second season follow-up trial in 2014. AllerT is planned to enter Phase III in 2015. In addition, Anergis is developing its product portfolio with two other preclinical product candidate vaccines targeting house dust mites and ragweed pollen allergies.

Anergis is open to co-development, partnering and/or licensing on a project by project basis and by geographies.

Anergis is also seeking funding to accelerate the development of the ragweed allergy vaccine and the house dust mite allergy vaccine.

PRODUCT PIPELINE

AllerT: Birch pollen allergy

AllerDM: House Dust mites allergy

AllerR: Ragweed pollen allergy

OPPORTUNITIES

AllerT: Birch pollen allergy

AllerDM: House Dust mites allergy

AllerR: Ragweed pollen allergy

MANAGEMENT

Vincent Charlon, CEOChristophe reymond, CSOZoltan Czigler, CFOGilles Della Corte, Director Clinical DevelopmentVanya Beltrami, Director Product Development


ORGANISERSW

ELCOME


PANIES

t back :: next u

APEPTICO www.apeptico.com

CONTACTDr. Bernhard Fischer CEO

ADDRESS Mariahilferstr. 136, top 1.15 Vienna 1150 Austria

TELEPHONE +43 664 1432919

FAX +43 1 2533037795


YEAR FOUNDED2008

FINANCIAL SUMMARY

APEPTICO is a privately-held biotechnology company based in Austria, developing peptide-based products targeting chronic and life-threatening pulmonary diseases.

So far, APEPTICO has received EUR 10 million by private investors from Switzerland and Germany to develop lead compounds from discovery through phase II proof-of-concept clinical studies..

COMPANY PROFILE

APEPTICO is a privately-held biotechnology company based in Austria, developing peptide-based products targeting chronic and life-threatening pulmonary diseases, including cardiac & non-cardiac pulmonary edema, edematous respiratory failure, acute lung injury, ARDS, Influenza, pneumonia, primary graft dysfunction, ischemia reperfusion injury and high altitude pulmonary edema.

APEPTICO’s family of AP301 peptides are synthetic peptides which corresponds to structural motifs of human proteins. All AP301 peptides activate lung fluid clearance and protect both endothelial and epithelial lung tissue from microbial toxin- and reactive oxygen species-induced hyper-permeability. The peptides are being developed by APEPTICO in various pulmonary indications.

APEPTICO’s AP301-peptide has been validated in two phase IIa clinical studies.

By concentrating on synthetically produced protein structures APEPTICO avoids general risks associated with gene- and cell-technologies.

APEPTICO makes use of its technology platforms PEPBASE(TM) and PEPSCREEN(TM) to significantly reduce cost and to shorten time to market.

PRODUCT PIPELINE

1. AP301 peptide for treatment of pneumonia induced pulmonary oedema.

AP301 peptide is being developed for the prevention and treatment of pulmonary edema / edematous respiratory failure caused by microbial and viral lung infection. Currently, no specific treatment is available to patients with microbial / viral pneumonia to activate alveolar fluid clearance and to treat respiratory failure / lung injury.

AP301 peptide is a fully synthetic short peptide version of a loop region of a human protein.

Oral inhalation of AP301 peptide was safe and well tolerated in a Phase I clinical study completed in 2012.

In January 2014, a mult-cause proof of concept Phase IIa clinical study was completed in patients with pulmonary edema with top line results.

AP301 will be the first drug therapy for prevention and treatment of various forms of life-threatening pulmonary edema, including non-cardiac & cardiac pulmonary edema.

2. AP301 peptide for treatment of Primary Graft Dysfunction.

AP301 peptide has being developed for the prevention and treatment of Primary Graft Dysfunction (PGD) / Ischemia Reperfusion Injury (IRI) following lung transplantation. Currently, no specific treatment is available to prevent and treat PGD / IRI of the lung.

AP301-IRI is a fully synthetic short peptide version of a a loop region of a human protein.


AP301 peptide has been validated in a proof of concept Phase IIa clinical study in patients with pulmonary edema.

In 2013, APEPTICO initiated a Phase IIa clinical study in patients suffering from Primary Graft Dysfunction following lung transplantation.

AP301 will be the first drug therapy for prevention and treatment of primary graft dysfunction following lung transplantation.

continued...


ORGANISERSW

ELCOME


PANIES

t back :: next u

3. AP301 peptide for treatment of High Altitude Pulmonary Edema (HAPE).

AP301 peptide is being developed for the treatment of High Altitude Pulmonary Edema and Mountain sickness.

Currently, no specific treatment of HAPE / Mountain sickness exists.

AP301 peptide is a fully synthetic short peptide.


AP301 has been validated in a proof of concept Phase IIa clinical study in patients with pulmonary edema.

AP301 will be the first drug therapy for treatment of High Altitude Pulmonary Edema (HAPE).

4. AP301 peptide for treatment of pulmonary edema.

AP301 peptide is being developed for the treatment of cardiac and non-cardia pulmonary edema in critically ill patients.Currently, no specific treatment is available to instantyl activate alveolar fluid clearance and to prevent and treat pulmonary hyperpermeability.

AP301 peptide is a fully synthetic short peptide version of a loop region of a human protein.


In January 2014, a mult-cause proof of concept Phase IIa clinical study was completed in patients with pulmonary edema with top line results.

AP301 will be the first drug therapy for instant activation of alveolar fluid clearance and treatment of various forms of life-threatening pulmonary oedema, including non-cardiac and cardiac lung edema.

OPPORTUNITIES

Licensing Out: AP301 for treatment of pulmonary permeability oedema. Stage Phase IIa clinical study “proof-of-concept” completed.

Licensing Out: AP301 for treatment of primary graft dysfunction following lung transplanation. Phase IIa clinical study “proof-of-concept” completed.

Investment Opportunity: Phase IIb clinical studies of AP301 in pulmonary permeability oedema.

Investment Opportunity: Phase IIb clinical studies of AP301 in lung transplantation.

MANAGEMENT

Bernhard Fischer, CEO

APEPTICO www.apeptico.com

CONTACTDr. Bernhard Fischer CEO

ADDRESS Mariahilferstr. 136, top 1.15 Vienna 1150 Austria

TELEPHONE +43 664 1432919

FAX +43 1 2533037795


YEAR FOUNDED2008

...continued


ORGANISERSW

ELCOME


PANIES

t back :: next u

Aptose Biosciences aptose.com

CONTACTAvanish VellankiSenior Vice PresidentChief Business Officer

ADDRESS 2 Meridian Rd Toronto ON, M9W 4Z7 Canada

TELEPHONE +1-416-798-1200


YEAR FOUNDED1986

FINANCIAL SUMMARY

$ in CAD

Cash, Cash Equivalents and Investments (May 31, 2014): $30.4M

Warrant Proceeds (gross) Raised Since May 31, 2014: $6.6M

Debt - Promissory and Convertible Notes (May 31, 2014): $0.6M

Basic Shares Outstanding (pro forma July 15, 2014):139.3M

Fully Diluted Shares Outstanding (pro forma July 15, 2014)1:159.1M

Institutional Ownership:~55%

Notes:1)Comprised of A) 139.3M shares outstanding B) Warrants to purchase 2.6M shares, C) options to purchase 15.2M

shares at a weighted average price of $0.54 per share and D) convertible notes that convert into 2.0MM shares

COMPANY PROFILE

Aptose Biosciences is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer research coupled with companion diagnostics to identify the optimal patient population for our products. The Company’s small molecule cancer therapeutics pipeline includes products designed to provide additive or synergistic efficacy with existing anti-cancer therapies and regimens without overlapping toxicities.

PRODUCT PIPELINE

APT-253 is a clinical-stage, small molecule therapeutic that acts through induction of the innate tumor suppressor Krüppel-like factor 4 (KLF4). Aptose is currently pursuing the Phase I clinical development of APTO-253 is a novel small molecule that has demonstrated potent anti-tumor activity in cancer cells via tumor suppressor induction leading to cell cycle inhibition and programmed cell death. APTO-253 has been shown to induce the tumor suppressor gene Krüppel like factor 4 (KLF4) and expression of p21, resulting in cell cycle arrest and apoptosis. Nonclinical pharmacology studies have demonstrated in vivo anti-tumor activity in solid tumors and hematologic cancers. Aptose has completed a Phase 1 study in patients with advanced or metastatic solid tumors in which promising clinical activity was observed.

A vast majority of patients with acute myeloid leukemia (AML) exhibit down-regulation of KLF4 expression, which is directly associated with leukemogenic events, or the onset of leukemia. In addition to AML, a similar function for KLF4 as a tumor suppressor factor has been reported in adult T-cell leukemia, lymphoma, multiple myeloma and high-risk MDS. Induction of KLF4 expression may therefore be an effective therapeutic option in these patient populations. Aptose is planning to commence a Phase 1b clinical study with escalating doses of APTO-253 followed by two disease-specific expansions planned in adults with hematologic malignancies in 2014.

The APTO-500 program aims to discover and develop potent, first-in-class small molecule inhibitors of maternal embryonic leucine zipper kinase (MELK). MELK plays an important role in cancer cell cycle, signaling pathways, and stem cells. MELK is highly expressed in several cancer types and its expression correlates with poor prognosis in glioma and breast cancer.

IL-17E (also known as IL-25) is a recently identified cytokine that plays an important role in inflammation. Aptose scientists were the first to discover the anticancer properties of IL-17E against a range of solid tumors, including human melanoma, pancreatic, colon, lung, ovarian and breast tumor models with very low toxicity.

OPPORTUNITIES

APTO-253 • APTO-500 • IL-17E

MANAGEMENT

Dr. William G. Rice, PhD, Chairman, Chief Executive Officer and PresidentDr. Daniel D. Von Hoff, MD, Senior Vice President, Medical AffairsAvanish Vellanki, MBA, MBS, BA, Senior Vice President and Chief Business OfficerGregory Chow, CPA (inactive), MBA, BA, Senior Vice President and Chief Financial Officer


ORGANISERSW

ELCOME


PANIES

t back :: next u

Arisgen SA www.arisgen.com

CONTACTSAndrew Parker CEO

Paolo Botti CSO

Duc Tran Snr Dir NCD

ADDRESS 14, Chemin des Aulx Plan-les-Ouates 1228 Switzerland

TELEPHONE +41 (0) 22 880 1010


YEAR FOUNDED2009

COMPANY PROFILE

Arisgen is a drug delivery company with a proprietary formulation technology that enables delivery of therapeutic peptides via oral or buccal/sub-lingual routes. Arisgen’s technology has the potential to transform the injectable peptide market offering oral alternatives for these medications. Arisgen aims to be a world leader in the development of orally available peptide drugs through development of its own products and partnerships that allow the application of the technology to proprietary peptide therapeutics. Arisgen is currently developing a portfolio of novel products focused on the treatment of metabolic diseases and oncology. The lead programme is a novel fast acting oral form of a GLP-1 agonist for the treatment of diabetes which will enter clinical development in 2015. Arisgen is seeking additional investors and partnerships to expand it’s activities and pipeline.

PRODUCT PIPELINE

GLP-1 agonist - rapid acting sub-lingual dosage form of exenatide for the treatment of Type 2 Diabetes. Pre-clinical, progressing through toxicology and will enter the clinic in 2015.

Drug Delivery Platform - ArisCrown is a proprietary drug delivery platform available for partnering. We have data on a range of peptides (octreotide, MIF-1, leuprolide, etc.) in pre-clinical species demonstrating that ArisCrown can confer oral bioavailability from 5-50% on peptide therapeutics.

OPPORTUNITIES

Sub-Lingual GLP-1 Agonist (Exenatide)

ArisCrown Drug Delivery Platform

MANAGEMENT

Andrew Parker, CEOPaolo Botti, CSODuc Tran, Snr Dir NCDChristophe Guichard, CFO


ORGANISERSW

ELCOME


PANIES

t back :: next u

Asceneuron SA www.asceneuron.com

CONTACTDirk Beher CEO

ADDRESS EPFL Innovation Park Bâtiment B Lausanne 1015 Switzerland

TELEPHONE +41 21 693 8242


YEAR FOUNDED2012

FINANCIAL SUMMARY

EUR 5 M Seed, 2012

COMPANY PROFILE

Asceneuron is a neurodegeneration therapeutics company which is run by a team of highly experienced and passionate drug hunters. Built on scientific rigor our pipeline is rapidly progressing toward the next substantial value inflection points. Within one year Asceneuron will undergo a transformation into a clinical stage biotechnology company.

With the current EUR 5M Seed from Merck Serono Ventures and the next Series A round we aim to unlock the full potential of our pipeline. With one asset in the highly attractive orphan drug space and a de-risked program targeting a clinically validated pathway Asceneuron is well positioned to deliver breakthrough medicines.

PRODUCT PIPELINE

ASN-561: O-GlcNAcase inhibitor which prevents the removal of O-linked ‐-N-acetyl-glucosamine carbohydrate moieties from the microtubule-associated tau protein. Thereby the formation of toxic neurofibrillary tangles in the brain can be drastically reduced. The molecule is in IND-enabling studies and is predicted to enter the clinical trials in 2015.

Our M1 muscarinic acetylcholine receptor positive allosteric modulator (M1 PAM) is aimed at improving cognitive function by stimulating cholinergic neurotransmission. This approach is expected to lead to an improved symptomatic drug whilst exploiting a biological pathway that has already yielded acetylcholinesterase inhibitor drugs. Our front running molecules are in late lead optimization.

OPPORTUNITIES

Tau modifier (O-GlcNAcase inhibitor)

Cognition enhancer (M1 PAM)

MANAGEMENT

Dirk Beher, Chief Executive OfficerChristoph Wiessner, Chief Operating Officer


ORGANISERSW

ELCOME


PANIES

t back :: next u

B Cell Design www.b-cell-design.com

CONTACTArmelle Cuvillier CSO

ADDRESS 98, rue Charles Legendre Limoges 87000 France

TELEPHONE +33 55 512 3021

EMAIL armelle.cuvillier @b-cell-design.com

YEAR FOUNDED2007

COMPANY PROFILE

B Cell Design is a French biotechnology company developing targeting immunotherapy drugs (anti-HIV vaccine and Imagning solutions against early colorectal cancer metastasis) and human chimeric antibodies solutions for In vitro Diagnostic.

BCD built an innovative platform based on humanized transgenic mice models to offer a complete panel of isotype determined monoclonal antibodies, as specific IgG1, IgA1, IgM and IgE.

PRODUCT PIPELINE

Anti-HIV vaccine (pre-clinical trial)

15B3-monoclonal IgA anti-colorectal cancer (immunotherapy and Imaging) (pre-clinical trial)

OPPORTUNITIES

anti-HIV vaccine

Imaging of early colorectal cancer metastasis

Monoclonal IgA anti-colorectal cancer

MANAGEMENT

Pierre Gipoulou, CFO, CEO Armelle Cuvillier, PhD, CSOGaël Champier, PhD, CTO


ORGANISERSW

ELCOME


PANIES

t back :: next u

BEATBiotherapeutics beatbiotherapeutics.com

CONTACTSMr. Michael Kranda CEO

Dr. Sam Teichman CMO

ADDRESS 1380 112th Ave NE, Suite 200 Bellevue 98004 United States

TELEPHONE +1 425-647-4236

EMAIL mkranda @beatbiotherapeutics.com

YEAR FOUNDED2013

FINANCIAL SUMMARY

BEATBio is a private biotechnology company. The Founder’s developed the technology with over $50MM of NIH grant funding. BEATBio has raised $4MM in convertible promissory notes to date and is raising a Series A to finance entry into human clinical trials.

COMPANY PROFILE

BEAT BioTherapeutics Corp. (BEATBio) is developing BB-R12, a novel biological therapy with the potential to revolutionize the treatment of heart failure. Heart failure is a large and growing epidemic. The World Health Organization reports that 29% of deaths worldwide are due to cardiovascular disease. Approximately 6 million Americans are living with heart failure today. New therapies to address this epidemic are urgently needed to decrease patient mortality, improve patient functional capacity and quality of life, as well as address the burgeoning cost of care.

BB-R12 therapy is based on our founder’s fundamental and patented discovery that dATP is a superior fuel for cardiac muscle contraction than is ATP, producing more powerful contractions. This corrects the underlying deficit present in the majority of patients with heart failure by allowing the heart to pump more blood. In cardiac muscle cells, dATP is synthesized by a well-characterized enzyme, ribonucleotide reductase. BB-R12 gene therapy delivers a vector that codes for an optimized form of ribonucleotide reductase that increases intracellular dATP only in cardiomyocytes and enhances cardiac performance. BB-R12 transformed cells can deliver dATP to surrounding cells passively by diffusion through gap junctions, resulting in more powerful heart muscle cell contraction, tissue and organ contraction, improved muscle relaxation and significantly improved cardiac performance. BB-R12 is being developed to treat heart failure by increasing cardiac performance. BB-R12 has shown efficacy in multiple animal models, including a swine heart failure model.

BEATBio’s founders, from the University of Washington, are recognized experts in cardiovascular biology, muscle physiology and bioengineering and have received nearly $50MM of NIH funding.

BEATBio holds worldwide rights to this technology and used a recently raised $4MM seed financing to successfully complete the initial stages of pre-clinical development and manufacturing scale-up. We have assembled a strong team of advisers and contractors that allowed us to rapidly achieve significant milestones. The company is now raising a Series A financing to complete IND-enabling studies and commence Phase I human trials.

Accomplishments to Date:• Demonstrated that BB-R12 restores ejection fraction and overall cardiac performance in animal models of

heart failure and improves contraction and relaxation in healthy and depressed heart muscle cells following injury with no safety issues identified to date.

• Developed and manufactured a humanized gene construct and scaled up manufacturing using a system licensed from the NIH.

• Confirmed earlier rodent experiments using our human construct.• Completed a successful proof-of-concept study with the humanized construct in a large-animal (swine)

myocardial infarction / heart failure model demonstrating substantial performance recovery and dose-responsiveness with no observed safety issues.

• Built out a strong management team that now includes Sam L. Teichman, MD, as CMO.• Held a successful Pre IND meeting with the FDA and confirmed our forward development plans and timeline to

enter the clinic in early 2016.

PRODUCT PIPELINE

BB-R1R2 is a novel biologic in pre-clinical development poised to complete IND enabling studies in 2015 with first dose in man targeted for QI 2016.

OPPORTUNITIES

Raising a Series A equity financing.

MANAGEMENT

Michael Kranda, CEODr. Sam Teichman, CMOGreg Mahairas, CSO


ORGANISERSW

ELCOME


PANIES

t back :: next u

BioCrea www.biocrea.com

CONTACTTom Kronbach CEO

ADDRESS Meissner Strasse 191 Radebeul 01445 Germany

TELEPHONE +49 351 40430

FAX +49 351 40433216


YEAR FOUNDED2010

COMPANY PROFILE

At BioCrea we turn concepts into drug candidates, creating first-in-class drugs to treat debilitating central nervous system (CNS) diseases. Through the combination of our unique discovery platforms, the use of patient-derived models and clinical data together with an experienced, visionary team, the company discovers and develops new drug candidates for pharmaceutical and biotechnology partners.

PRODUCT PIPLINE

NR2B NAM program for Depression at candidate selection

LT GABA PAM program for epilepsy and autism spectrum disorders

PDE10 program in Huntington’s disease

OPPORTUNITIES

NR2B NAM for Depression

LT GABA PAM for Epilepsy and autism spectrum disorders

PDE10 inhibitor for Huntington’s disease

MANAGEMENT

Tom Kronbach, CEOChristiane Kronbach, COOMartin Gunthorpe, CSOSimon Ward, EVP Chemistry and Development


ORGANISERSW

ELCOME


PANIES

t back :: next u

BioLineRx Ltd www.biolinerx.com

CONTACTSDr. Kinneret Savitsky Chief Executive Officer

Mr. Philip Serlin Chief Financial and Operating Officer

ADDRESS 19 Hartum Street Jerusalem 91450 Israel

TELEPHONE +972-2-548-9100

FAX +972-2-548-9101


YEAR FOUNDED2003

FINANCIAL SUMMARY

$33 million cash as of 30/6/14

Operational capital through 2016

COMPANY PROFILE

BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx’s current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Bellerophon BCM (f/k/a Ikaria) and is in the midst of a pivotal CE-Mark registration trial; BL-8040 for treating acute myeloid leukemia (AML) and other hematological indications, which is in the midst of a Phase 2 study; and BL-7010 for celiac disease, which is in the final stages of a Phase 1/2 study.

PRODUCT PIPELINE

OPPORTUNITIES

BL-8040 - AML and other hematological indications

BL-7010 - Celiac disease

BL-5010 - Skin lesions

BL-7040 - IBD

MANAGEMENT

Dr. Kinneret Savitsky, Chief Executive OfficerMr. Philip Serlin, Chief Financial and Operating OfficerDr. Leah Klapper, Chief Scientific OfficerDr. Arnon Aharon, VP Medical AffairsMr. David Malek, VP Business Development


ORGANISERSW

ELCOME


PANIES

t back :: next u

BioLingus www.biolingus.com

CONTACTYves Decadt CEO

ADDRESS Grossmatt 6 Hergiswil NW 6052 Switzerland

TELEPHONE 07866 45430


FINANCIAL SUMMARY

Private company – private investors.

COMPANY PROFILE

BioLingus : sublingual delivery of therapeutic biologicals.

BioLingus is a Swiss biotech company spearheading the development of oral (sublingual) delivery of peptides and proteins. It is a cutting-edge and mature solution for oral formulations not only for peptides, but also small molecules, novel protein scaffolds, nucleotides, domain antibodies, vaccines, immunotherapies, enzymes etc. The company focuses the development of its own products on treatment of chronic diseases, such as diabetes and inflammatory diseases. A particular area of interest is also cancer immunotherapy, as sublingual administration allows for targeting the lymphatic system directly.

BioLingus’ main office is in Switzerland, and we have a satellite company in Hong Kong.

PRODUCT PIPELINE

Lead product is oral exenatide. BioLingus is actively looking to develop other oral biologics with partners.

Sublingual dose/efficacy effect of mode of action (MOA) of drug

20

Mode of action may have strong

influence on sublingual dose/

efficacy

Immune-modulatory aspect in

MOA

No

Yes

GLP-1 (exenatide)

Model Drug

Interferon Interleukin

5-10 times SC dose for same

efficacy

Sublingual Dose

Less or far less then SC/

IV dose*

Diabetes Fertility

Cardiovascular Osteoporosis

Application examples

Cancer Immunotherapy

Allergy, RA Vaccines

*Increased efficacy is due to immune cascade in oromucosal area and lymphatic system. This also may lead to less side effects. Exact mechanism is not well understood and is subject to further studies.


ORGANISERSW

ELCOME


PANIES

t back :: next u

BIOMAY AG www.biomay.com

CONTACTRainer Henning CEO

ADDRESS Vienna Competence Center Lazarettgasse 19/1 Vienna 1090 Austria

TELEPHONE +43-1-7966-296-100

FAX +43-1-7966-296-222


YEAR FOUNDED1984

COMPANY PROFILE

Biomay aspires to be a worldwide leader in research, discovery and development of disease modifying allergy therapeutics. Our products will dramatically improve the quality of life of patients by offering long-term cure for their disease.

We discover and develop recombinant allergy vaccines with a superior efficacy and safety profile. These innovative vaccines are based on cutting edge science for immunotherapy and prophylaxis that we generate in close cooperation with our academic partners. Our lead product, the grass pollen vaccine BM32 is nearing completion of a Phase IIb trial.

In addition, we develop an extrcorporeal apheresis device based on a single chain IgE antibody fragment, which is indicated for patients with severe Asthma.

Manufacturing of our own and our clients’ development products complies with the highest quality standards. Additionally, we support our clients by offering highly professional GMP contract manufacturing Services for Proteins and plasmid DNA.

PRODUCT PIPELINE

OPPORTUNITIES

Outlicensing

BM32 (grass pollen allergy vaccine, phase IIb)

BM35 (house dust mite allergy vaccine, preclin.)

BM34 (ragweed pollen allergy, preclin.))

BM31 (birch pollen allergy, preclin.)

MANAGEMENT

Rainer Henning, CEOHans Huber, COOKarl Fister, CFOAngela Neubauer, Head of Product Development


ORGANISERSW

ELCOME


PANIES

t back :: next u

BIOPHYTIS www.biophytis.com

CONTACTStanislas Veillet CEO

ADDRESS 1 av. de l’OPERA PARIS 75001 France

TELEPHONE +33 14 183 6610


YEAR FOUNDED2006

COMPANY PROFILE

BIOPHYTIS develops new therapeutics derived from phytonutrients involved in ageing processes. Its candidates are both drug and nutraceutical products, with a focus on Sarcopenic Obesity and dry AMD.

PRODUCT PIPELINE

BIO103 : sarcopenia : drug candidate : regulatory PC

BIO101 : sarcopenic obesity : nutraceutical candidate : clinical

BIO203 : geographic atrophy : drug candidate : regulatory PC

BIO201 : dry AMD : nutraceutical candidate : clinical

OPPORTUNITIES

15M€ round C investment in 2015

MANAGEMENT

Stanislas Veillet, CEORené Lafont, CSOWaly Dioh, COOJ.C. Montigny, CFO


ORGANISERSW

ELCOME


PANIES

t back :: next u

BioVersys AG www.bioversys.com

CONTACTMarc Gitzinger CEO

ADDRESS Hochbergerstrasse 60c Basel 4057 Switzerland

TELEPHONE +41 61 633 22 500


YEAR FOUNDED2008

COMPANY PROFILE

Bioversys AG is a privately held Swiss biopharmaceutical company located at the Technology Park in Basel that focuses on research and development of small molecules which switch off drug resistance within bacterial pathogens and thereby restore the efficacy of approved antibiotics. Spun out of the ETH-Zurich in 2008, BioVersys has profound technological expertise that is based on solid IP. BioVersys has built up an innovative technology to screen and develop drugs that act more upstream than conventional antibiotics. BioVersys’ compounds will be used in combination with an existing antbiotic, thereby renewing efficacy as well as intellectual property for the established drug.

MANAGEMENT

Dr. Marc Gitzinger, CEODr. Marcel Tigges, CSODr. Peter Sennhenn, VP Medicinal Chemistry


ORGANISERSW

ELCOME


PANIES

t back :: next u

Blueprint Genetics blueprintgenetics.com

CONTACTTommi Lehtonen CEO

ADDRESS Tukholmankatu 8 Helsinki 00290 Finland

TELEPHONE +35 84 477 00411

EMAIL tommi.lehtonen @blueprintgenetics.com

YEAR FOUNDED2012

FINANCIAL SUMMARY

Total funding to date €3.0m, investors include business angels and Inventure, a Helsinki-based venture fund. Revenue 2013 €0.3m, estimate for 2014 is €1.3m.

COMPANY PROFILE

Blueprint Genetics provides non-cancer genetic diagnostics for professional use. Our Next-Generation Sequencing (NGS) based products are targeted for hospitals and the pharma sector.

According to BCC Research, the market for non-cancer inherited diseases will increase from only $41m in 2013 up to $1.8Bn by 2018.

Our Stanford-based technology enables us to cut the prices of so called Mendelian diagnostics by 30-75% compared to competitors while providing the highest quality and most comprehensive panels in the industry.

The high sequencing quality, low error rate and large panels enable us to introduce an unforeseen low level of false negatives to clinical customers.

PRODUCT PIPELINE

A platform for sequencing all clinically relevant genes with a very low production cost and clinical sequencing quality. With the platform we are able to address all genetic diagnostics needs for the following categories:

– Cardiovascular disorders

– Metabolic and immunological disorders

– Neurological disorders

– Opthalmalogic disorders

– Connective tissues

– Non-metabolic liver diseases

– Hearing disorders

– Lung disorders

– Nephrological disorders

– Hematology disorders

– Malformation syndromes

MANAGEMENT

Dr. Tommi Lehtonen, CEODr. Samuel Myllykangas, CTODr. Tero-Pekka Alastalo, Medical DirectorDr. Juha Koskenvuo, Medical Director


ORGANISERSW

ELCOME


PANIES

t back :: next u

Canbex Therapeutics Limted www.canbex.co.uk

CONTACTJesse Schulman CEO

ADDRESS London BioScience Innovation Centre 2 Royal College Street London NW1 0NH UK

TELEPHONE +44 207 554 5872


YEAR FOUNDED 2005

COMPANY PROFILE

Canbex is dedicated to improving the quality of life for people with multiple sclerosis (MS) and potentially other disorders, through better treatment for spasticity.

Spasticity is the sudden and uncontrollable movement of limbs and torso, and is among the most painful, damaging and debilitating symptoms of MS. Current drug treatments for spasticity are effective but are plagued by sedative and other side effects that sharply limit their usefulness.

VNS16R was shown to be safe and well tolerated in a Phase I trial in healthy volunteers. In particular, there was no sedative or other cognitive effect seen. Canbex is now preparing to carry out a Phase II trial of VSN16R’s efficacy as an anti-spastic treatment for MS patients, supported by its leading London-based scientific and clinical team.

Canbex believes that VSN16R has the potential to meet an important medical need, and to address a highly attractive commercial opportunity.

PRODUCT PIPELINE

VSN16R is a small molecule therapy in Phase I for treatment of spasticity in multiple sclerosis.

MANAGEMENT

Dr. Jesse Schulman, CEODr. Keith Powell, ChairmanProf. David Selwood, Chief Scientific OfficerProf. David Baker, Head of Biology


ORGANISERSW

ELCOME


PANIES

t back :: next u

CAP-CMV GmbH www.cap-cmv.de

CONTACTSDr. Albrecht Läufer CEO

Dr. Gudrun Schiedner CSO

ADDRESS Gottfried Hagen Str. 62 Köln 51105 Germany

TELEPHONE +49 221 99 57 26 01


YEAR FOUNDED2013

FINANCIAL SUMMARY

A round 1.7 €

COMPANY PROFILE

CAP-CMV GmbH is a venture capital backed vaccine development company founded in 2013.

PRODUCT PIPELINE

CAP-CMV´s lead compound is a preclinical stage vaccine for prevention of human cytomegalovirus related diseases. The active immunogenic ingredient is Dense Bodies, produced in human CAP cells and carrying the most complete set of antigens: pp65, pentamer complex (gpUL128-131), gB, gH.

OPPORTUNITIES

Investment opportunity to take HCMV candidate through to phase II

MANAGEMENT

Dr. Albrecht Läufer, CEODr. Gudrun Schiedner, CSO


ORGANISERSW

ELCOME


PANIES

t back :: next u

CARLINA Technologies carlinatech.com

CONTACTOlivier Meyer President & CEO

ADDRESS 22 rue Roger Amsler Angers 49100 France

TELEPHONE +33 78 786 2893


YEAR FOUNDED2010

FINANCIAL SUMMARY

2015:Sales and other revenues: 1 618 647 €EBITDA: - 995 119 €Year earning: - 634 205 €

2016:Sales and other revenues: 1 013 473 €EBITDA: - 1 594 753 €Year earning: - 1 287 945 € ‐

2017:Sales and other revenues: 17 800 000 € ‐EBITDA: 13 732 928 € ‐Year earning: 14 684 798 € ‐

COMPANY PROFILE

CARLINA Technologies is a biopharmaceutical company specialized in the development of nanomedicines. Using its patented innovative drug delivery platforms, the company develops controlled release pharmaceutical forms of small chemical and protein-based therapeutics in human endocrinology (diabetes and growth hormone related diseases) and animal oncology (dog cancers). CARLINA Technologies also provides its unique know-how and drug delivery platforms to the pharmaceutical industry in order to improve the efficacy and safety of partners’proprietary compounds.

PRODUCT PIPELINE

1. Peptidots-insulin: Prolonged release formulation of insulin at preclinical stage.

2. Peptidots-somatotropin: Sustained-release formulation of growth hormone at lead optimization stage

3. Soludots-PTX: Tumor-targeted nanoparticles of paclitaxel for the treatment of cancer in companion animals, entering clinical trial in dogs

OPPORTUNITIES

CARLINA is seeking a series A round equity financing in the amount of 4,5 million € that will be completed by non-diluting 1,5M‐€ coming from National French Public Investment source, for the next 3 years divided in 3 disbursements attached to specific mil

Co-development of Peptidots-insulin partnership with out-licensing opportunity

Co-development of Peptidots-somatotropin partnership with out-licensing opportunity

Co-development of Soludots-Paclitaxel partnership with out-licensing opportunity

MANAGEMENT

Olivier Meyer, PhD, President & CEO


ORGANISERSW

ELCOME


PANIES

t back :: next u

Cellphire, Inc. www.cellphire.com

CONTACTNigel J McWilliam V.P. Business Development

ADDRESS 9430 Key West Avenue Rockville Maryland 20850 USA

TELEPHONE +1-240-268-1143


YEAR FOUNDED2007

FINANCIAL SUMMARY

Privately held.

COMPANY PROFILE

Cellphire is set to become a leader in next generation biologics, using proprietary cell stabilization technology. The initial focus is to be a dominant developer, producer and supplier of proprietary stabilized therapeutic platelet derived products for applications in which coagulation factor replacement, cessation of bleeding and growth factor therapies are indicated. The Company has developed a freeze-drying process that enables the prolongation of shelf life of platelet function from merely 5 days to three years or more, at room temperature.

This technology is positioned to transform blood banking practices, particularly the way platelet materials are deployed, stored and utilized in multiple healthcare segments including blood banking, emergency response centers, hospitals, clinics and the military. Moreover, the technology will also enable pathogen inactivation methods for platelet products, thereby reducing bacterial infection risk of platelets, one of the largest causes of death following transfusion. The technology development has also led to a freeze-dried platelet reagent that can be used for platelet function testing and point-of-care diagnostics. In September, 2013, the BioMedical Advanced Research and Development Authority (“BARDA”) awarded Cellphire a contract of up to $56.7 million to further develop Cellphire’s proprietary treated platelets (Thrombosomes®) as a possible treatment for acute radiation syndrome. This contract underwrites the development of Thrombosomes® through Phase II. Assuming success, Thrombosomes® would be stockpiled to address a nuclear event. There are other potential applications as diverse as imaging, drug delivery, veterinary medicine, dental and orthopedic implants among other things. The technology has been applied to the formulation of new stabilized platelet derivative products, containing hemostatic and wound-healing factors, such as the incorporation in wound-dressings and bandages, and in sprays and powders for the direct application to a wound for cessation of bleeding or to augment coagulation factor therapy. All these applications address not just a US demand, but are relevant worldwide.

PRODUCT PIPELINE

Thrombosomes® – freeze dried platelets, entering P1 Sept 2014 in USA for radiation remediation

OPPORTUNITIES

Advanced wound management

Replacement for PRP

Drug (or imaging) Delivery vehicle

Aesthetic/cosmetic surgery

Personalized medicine

MANAGEMENT

Stephen H Willard, CEOG. Michael Fitzpartick, PresidentRichard O Cliff, COONigel J McWilliam, VP Bus Dev


ORGANISERSW

ELCOME


PANIES

t back :: next u

CEVEC www.cevec.com

CONTACTSWolfgang Kintzel CEO

Frank Ubags COO

ADDRESS Gottfried-Hagen Str. 62 Köln 51105 Germany

TELEPHONE +49 221 46020800


YEAR FOUNDED2004

COMPANY PROFILE

CEVEC commercialises a proprietary expression platform for biopharmaceuticals based on human amniocytes. The versatile CAP® and CAP-T® cells exhibit exceptional yields for antibodies and complex proteins and are also an excellent tool for vaccine and virus production.

CEVEC commercialises its platform through:-licensing on a non-exclusive and exclusive to Biotech and Pharmaceutical companies-supplying cGMP clinical materials based on CAP® Technology.

PRODUCT PIPELINE

CAP® Technology for: antibodies complex proteins vaccines virus production lentiviral packaging cell lines

Supply of cGMP clinical materials based on CAP® Technology.

OPPORTUNITIES

€ 4 million investment to reach profitability in 2017

Licenses for Virus Production, exclusive and non exclusive

Licenses for difficult to produce proteins

Licenses for vaccine production

MANAGEMENT

Wolfgang Kintzel, CEOFrank Ubags, COONicole Faust, CSOHartmut Tintrup, CBO


ORGANISERSW

ELCOME


PANIES

t back :: next u

Clanotech AB www.clanotech.se

CONTACTNigel J McWilliam CEO

ADDRESS Fogdevreten 2a Solna 171 65 Sweden

TELEPHONE +46 37 47 179


YEAR FOUNDED2006

FINANCIAL SUMMARY

Clanotech AB is private Company. Main shareholders are Karolinska Development AB and Rosetta Capital.

COMPANY PROFILE

Clanotech is active in Ophthalmology. Clanotech strategy spans from therapeutic areas with high commercial potential as wet Age Reglated Macular Degeneration (wAMD) to ophthalmology niche indications with orphan drug opportunity such as developing adjvant in glaucoma surgery techniques.

Clanotech’s lead candidate is a small molecule inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery stimulates the formation of new blood vessels through pathways that are partly complementary and partly interrelated with the VEGF pathway.

Clanotech lead candidate is in late preclinical development stage ready to enter the clinical phase I.

PRODUCT PIPELINE

CLT-28643

late preclinical development stage

OPPORTUNITIES

Partnering

Investment

MANAGEMENT

Mia Östlund, Clinical Operation ManagerGrit Zahn, Preclinical OperationMario Fsadni, Chief Medical Officer and Safety PhysicianCraig McCarthy, Regulatory Affairs ManagerNinus Caram, CMC Manager Bernhard Huitfeld, Statistician and Data ManagerMarcus Jerling, PharmacokineticsLars Gråbergs, Preclinical safetyHans Schink, QAAnn Sofie Sternås, IPTom Pike, BD


ORGANISERSW

ELCOME


PANIES

t back :: next u

CoDa Therapeutics, Inc www.codatherapeutics.com

CONTACTBrad Duft President & CEO

ADDRESS 12520 High Bluff Drive Suite 350 San Diego, CA 92130 USA

TELEPHONE +1 858 677 0474


YEAR FOUNDED2006

FINANCIAL SUMMARY

Privately funded late clinical development stage company.

COMPANY PROFILE

CoDaTherapeutics is a biopharmaceutical company focused on the development and commercialization of therapeutics for wound care and tissue repair based on a new platform technology known as “Gap Junction Modulation.”

Founded on patented inventions and data generated in the laboratories of Professor Colin Green (University of Auckland) and Professor David Becker (University College London), CoDa is building a portfolio of novel, proprietary compounds that, through control of gap junctions, can reduce cell to cell communication and improve wound healing and tissue repair post-injury.

These first-in-class compounds represent a new paradigm in wound care – improving wound healing while managing inflammation and scarring.

Our patent-protected lead product candidate, Nexagon®, dramatically improves the body’s ability to repair damaged tissue and has broad applications. The technology has been shown to work in a variety of tissue types including, eye, skin, brain, nerve, and spinal cord. Numerous pre-clinical models show improved wound closure and healing rates, as well as reduced lesion spread (cell death), swelling, inflammation, and scarring.

PRODUCT PIPELINE

In addition to Nexagon®, CoDa has secured the rights to Peptagon™, a peptide-based medicine for blocking gap junctions that has proved useful in models of stroke, for example. CoDa has also secured rights to other wound-healing opportunities to broaden its technology platform in this area and secure long-term commercial life-cycle growth, including wound-healing technology from Bristol University based on modulation of another protein, called osteopontin. Leveraging CoDa’s core technologies in gap junction modulation and wound healing could transform multiple billion dollar markets, create substantial benefits for patients and their health care providers, and provide substantial returns for CoDa investors and partners.

MANAGEMENT

Brad Duft, CEODavid Pool, CFODr. Dave Eisenbud, CMOTracey Sunderland, COOGrove Matsuoka, SVPDr. Anthony Phillips, Medical Director


ORGANISERSW

ELCOME


PANIES

t back :: next u

Cortendo www.cortendo.com

ADDRESS Box 47 SE-433 21 Partille Sweden

TELEPHONE +46 (0)31-26 30 10


COMPANY PROFILE

Cortendo AB is a biopharmaceutical company headquartered in Göteborg, Sweden. Its stock is publicly traded on the NOTC-A-list (OTC) in Norway.

Pioneer in the field of cortisol inhibition – late stage effort focused in Cushing’s Syndrome

Cortendo is a pioneer in the field of cortisol inhibition and has completed early clinical trials in patients with Type 2 diabetes. The development of the lead drug candidate NormoCort (COR-003), the 2S, 4R-enantiomer of ketoconazole, was re-directed during 2012 to Cushing’s syndrome, an orphan disease. The company has initiated Phase 3 development.

Commercial mindset with a pipeline focused on orphan drugs and metabolic diseases

The company’s strategy is to primarily focus its resources within orphan drugs and metabolic diseases and to seek opportunities where the path to commercialization or partnership is clear and relatively near-term. Strategically, Cortendo’s business model is to commercialize relevant opportunities in the United States while partnering its assets ex-US. Backed by a highly experienced leadership team Cortendo has plans to continue to implement its pipeline expansion efforts, as well as other near term revenue opportunities.

Cortendo’s History

Cortendo can trace its origin to the early 1980‐s when Dr. Per Marin began his investigations into the pathophysiology of obesity and related metabolic disorders.

The breakthrough came in 1991 when he had a realization, and formed the hypothesis, that normalizing the synthesis of the stress hormone, cortisol, addresses an important underlying biological mechanism in the development of Metabolic Syndrome and a major pathological manifestation of type

Proactiv small reason http://barodasteelsuppliers.com/index.php?what-do-they-test-for-accutane of, up discernible http://bassicity.com/kd/advair-hfa-packaging been shows have friends excellent. Recommended http://www.myenchantedevening.com/index.php?how-does-prednisone-cause-hypokalemia Pale my. Order can strattera cause joint pain still both some colognes remedio wellbutrin xl 300 shaver and it http://astrosumit.com/index.php?viagra-side-effects-pulse stay my last http://montanagrantfishing.com/prednisolone-sol-side-effects eyelids and – all taking lamictal and depakote together big product me a , tramadol hcl apap 37.5 side effects at enough reasonable. Than, nexium mobic interaction believe my stress doesn’t week does lasix work on dialysis patients the consistency hair with. Two barodasteelsuppliers.com doctor shopping tramadol no. Easily Cetaphil hesitant http://astrosumit.com/index.php?probiotics-after-flagyl making. Really tried tube lisinopril doses for hypertension smell they sigma is this ritalin and celexa shower it, Argan shipping because.

2 diabetes. The first patent for the concept of normalizing cortisol synthesis as a treatment for Metabolic Syndrome was filed in 1994. Further research using ketoconazole, a marketed drug provided proof of concept in patients with severe Metabolic Syndrome, and Cortendo was founded in 1996 by Dr. Per Mårin. Clinical trials began in 1999 and culminated with a successful Phase 2a program using an enantiomer of ketoconazole (COR-003, also referenced as NormoCort) in 2005 through a collaboration with DiObex. Significant expansion of the Cortendo patent portfolio continued during this time period.

In 2008, Cortendo re-acquired rights to the program. In 2011, Cortendo hired Dr. H. Joseph Reiser as CEO and Dr. Theodore R. Koziol as COO. In February 2012, Mr. Alexander Lindström joined Cortendo as CFO. During the first quarter of 2012, Cortendo announced that the development of the lead drug candidate NormoCort (COR003), the 2S, 4R-enantiomer of ketoconazole, has been re-directed to Cushing’s syndrome, and announced a modified commercial strategy.

During 2012 both the FDA and EMA granted COR-003 Orphan Drug Designation. Also, Cortendo announced during 2012 it has initiated a New Chemical Entity (NCE) discovery program for next generation compounds that could have application in type 2 diabetes and metabolic syndrome as well as orphan drug diseases. In Jan 2014 Dr John Amatruda joined Cortendo AB as Acting Chief Medical Officer. During the first half of 2014, Cortendo initiated Phase 3 development of NormoCort in Cushing’s Syndrome.

CORTENDO


ORGANISERSW

ELCOME


PANIES

t back :: next u

Critical Pharmaceuticals www.critcalpharmaceuticals.com

CONTACTDr Gareth King CEO

ADDRESS BioCity Pennyfoot Street Nottingham NG1 1GF UK

TELEPHONE +44 (0) 115 882 0100

EMAIL gareth.king @criticalpharmaceuticals.com

YEAR FOUNDED2005

FINANCIAL SUMMARY

Critical Pharmaceuticals has raised £5.8m to date from angel and institutional investors including Catapult Venture Managers, The Lachesis Fund, e-Synergy, The University of Nottingham, The Wellcome Trust and Celtic Pharma Holdings.

Critical Pharmaceuticals is seeking to raise a minimum of £10m GBP / $16m USD equity investment to fund a total of four Phase II clinical trials on CP024 intranasal growth hormone and CP046 intranasal teriparatide. The funds will also be used to further build Critical Pharmaceuticals clinical development capability and US presence to enhance the conduct of the trials and commercialisation of the products.

With positive efficacy and safety results from the Phase II clinical trials, the company should be able to secure a high value exit through trade sale or further funding through an IPO to complete the Phase III registration package.

COMPANY PROFILE

Critical Pharmaceuticals is a privately funded clinical stage biotechnology company focused on developing improved versions of marketed biologic drugs using it’s patented drug delivery platform technologies.

The company’s lead products are an intranasal human growth hormone product, targeted at a $3.1bn market, and CP046 intranasal teriparatide product for the treatment of osteoporosis, a $1.2bn market. The development pathway for both programs is clear and low risk as it involves drugs with well established efficacy and toxicity, and previous exposure to man in a successful Phase I clinical trials.

Critical Pharmaceuticals patented CriticalMix™ and CriticalSorb™ technology platforms are applicable to the large and fast growing market of biological drugs. The technology has been validated in collaboration with other biopharmaceutical companies with two partner programs poised to enter clinical development.

The products and platform technology has extensive IP protection, including granted US patents.

PRODUCT PIPELINE

OPPORTUNITIES

CP024 nasal Growth Hormone to treat growth hormone deficiency in adults and children – Completed two Phase I clinical trials and seek investment to complete Phase II program.

CP046 Nasal Teriparatide to treat osteoporosis – Completed Phase I clinical trial and seek investment to conduct Phase II trial.

MANAGEMENT

David Gough, Chairman a successful entrepreneur founding six biotech companies, including Vectura plc.

Dr Gareth King, CEO a biotech deal-maker with extensive experience in drug discovery and clinical development from Harvard, AstraZeneca & Incyte Pharmaceuticals.

Professor Steve Howdle, Founder and CSO a leading scientist in supercritical fluids and Professor of Chemistry at the University of Nottingham.

Alan Baines, CFO a highly experienced financial director in building and developing early stage companies.


ORGANISERSW

ELCOME


PANIES

t back :: next u

Dana-Farber Cancer Institute www.dana-farber.org

CONTACTSO. Prem Das, PhD Chief Research Business Development Officer Office of Research and Technology Ventures

ADDRESS 450 Brookline Ave Boston MA 02493 USA

TELEPHONE +1 617 632-5893


YEAR FOUNDED1947

COMPANY PROFILE

Comprehensive Cancer Center

OPPORTUNITIES

Start-ups: 14/15 of our most recent startups have exited/secured major funding. There are many more opportunities

Small molecules: We have 6 molecules in the clinic in the last 3 years, and there are more available.

Virology: Unusual for a Cancer Center, we have active small molecule and antibody programs against a broad range of viruses

Preclinical/clinical development: We welcome inquiries on how partners can tap into the collective expertise at Dana-Farber to help develop candidate drugs

Immuno-oncology: Dana-Farber has many active clinical and preclinical programs, and experts in clinical development.


ORGANISERSW

ELCOME


PANIES

t back :: next u

Dipexium Pharmaceuticals, Inc www.dipexiumpharmaceuticals.com

CONTACTDavid Garrett Vice President, Finance & Corporate Development

ADDRESS 61 Broadway Suite 1905 New York 10006 USA

TELEPHONE +1 917-509-0957


YEAR FOUNDED2010

FINANCIAL SUMMARY

Completed $38M IPO in March 2014. Fully funded through at least mid-2016, which is expected to include completion of Ph3 trials, NDA filing, NDA approval, and initial commercial launch.

COMPANY PROFILE

Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) is a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide. Initially, Locilex® is targeted for the treatment of Mild DFI. Based on a compilation of available clinical and microbiology data, Locilex® is also considered a promising product candidate to treat other mild and moderate skin and skin structure infections, including infected decubitus ulcers, infected burns, infected surgical wounds and nasal colonization of methicillin-resistant staphylococcus aureus (MRSA).

PRODUCT PIPELINE

Locilex (pexiganan cream 0.8%) – broad spectrum, topical antibiotic peptide. Two identical US based Phase 3 trials for the treatment of patients with mild infection of diabetic foot ulcers currently enrolling. NDA filing expected 2H15. Locilex IP extends to 2032.

OPPORTUNITIES

Regional Locilex Out-Licensing Opportunities

MANAGEMENT

David Luci, Esq., President & CEORobert DeLuccia, Executive Chairman David Garrett, VP, Finance & Corporate Development Robert Shawah, Chief Accounting Officer


ORGANISERSW

ELCOME


PANIES

t back :: next u

DORPHAN www.dorphan.com

CONTACTSDr Stéphane Demotz Founder and CEO

ADDRESS DORPHAN S.A. EPFL Innovation Park Lausanne 1015 Switzerland

TELEPHONE +41 (0)21 693 8550


YEAR FOUNDED2012

FINANCIAL SUMMARY

DORPHAN S.A. has been until now mainly financed by the Swiss Sanfilippo Foundation, which is its main shareholder. The company is currently looking for additional funds (‐ 5 million) to complete the preclinical development of its two drug candidates up to IND/beginning of phase 1 clinical trials for Sanfilippo disease type B (mucopolysaccharidosis IIIB) and for Morquio disease type B (mucopolysaccharidosis IVB).

COMPANY PROFILE

DORPHAN is a spin-off of the Swiss Sanfilippo Foundation. The company is currently conducting the preclinical development of drug candidates for rare and orphan genetic diseases, with a strong focus on mucopolysaccharidoses. DORPHAN is developing pharmacological chaperone compounds, which are small molecules capable of rescuing the activity of the enzymes deficient in the targeted diseases.

PRODUCT PIPELINE

1. Iminosugar-based pharmacological chaperone compound of the N-acetyl-glucosaminidase: in preclinical development, lead compound identified, for the treatment of Sanfilippo disease type B (mucopolysaccharidosis IIIB), patent in national phases covering the drug candidate in development.

2. Iminosugar-based pharmacological chaperone compound of the beta-galactosidase: in preclinical development, lead compound identified, for the treatment of Morquio disease type B (mucopolysaccharidosis IVB) and GM1-gangliosidosis, patent application filed covering the drug candidate in development.

OPPORTUNITIES

Pharmacological chaperone drug candidate in preclinical development for the treatment of Sanfilippo disease type B (mucopolysaccharidosis IIIB).

Pharmacological chaperone drug candidate in preclinical development for the treatment of Morquio disease type B (mucopolysaccharidosis IVB) and GM1-gangliosidosis.

MANAGEMENT

Dr Stéphane Demotz, Founder and CEODr Julie Charollais-Thoenig, Project Manager and Business Developer


ORGANISERSW

ELCOME


PANIES

t back :: next u

ENTEROME www.enterome.com

CONTACTPierre Belichard CEO

ADDRESS 94 av Ledru Rollin Paris 75011 France

TELEPHONE +33 688 837623


FINANCIAL SUMMARY

Private company

17M euro raised (Serie A + B)

Investors : Seventure, Lundbeckfond, Omnes, Danone, Shire

COMPANY PROFILE

Enterome develops therapeutics and personalized medical tests and companion diagnostics based on profiling of the human gut microbiome, with the goal to improve management of microbiome-related diseases, e.g., metabolic, gastrointestinal, and autoimmune.

PRODUCT PIPELINE

MANAGEMENT

Pierre Belichard, CEOMarie-Laure Bouttier, COODusko Ehrlich, CSOAlessandra Cervino, Head of DiscoveryJames Clark, CTO


ORGANISERSW

ELCOME


PANIES

t back :: next u

eNovalys www.enovalys.com

CONTACTDr Frank Hoonakker President

ADDRESS 1 RUE JEAN SAPIDUS ILLKIRCH 67400 FRANCE

TELEPHONE +33 (0) 388 105 181


YEAR FOUNDED 2009

COMPANY PROFILE

Today the consensus is reached that collective intelligence (open innovation) is the keystone of turning innovation’s ecosystem from work intensive to knowledge driven. For doing that it is required in massively capture, share and exploit the lost scientific raw data.

Reflecting on this issue, more than 5 years ago eNovalys began to invent new search engine able to extract knowledge from these raw data, to deploy crowdsourcing strategy in order to access the data and to build around these assets a new economic model.

Our breakthrough strategy enable for the first time researchers to systematically collect massively share and mine raw scientific data as it has never been possible before. Rapid accesses to this unprecedented scientific knowledge will magnify researcher innovative throughput.

Starting by the field of chemistry, eNovalys has validates the benefits claimed. Since 2012 eNovalys has gather a user community in Canada, France, Germany, Switzerland and the USA. More than 1,200 scientists in 90 laboratories use our products. More than 1,000,000 reactions have been catalogued.

PRODUCT PIPELINE

ePro : Recording, indexing and managing reactions via an electronic laboratory notebook that provides added value services including stock control, MDS management, security, updates, and backups.

eShare : Sharing experiments, like in the ELN, by a «one click» tool with the appropriate standardized metadata.

eSniff : A search engine providing eNovalys’ users with relevant information.

MANAGEMENT

Dr. Frank Hoonakker, CEO & co-founder Designer of eNovalys’ search engine following his PhD in computational chemistry. Dr Hoonakker successfully developed industrial standard products and brought them to the market. He is responsible for company developing and delivering the company strategy.

Dr. Alain Wagner, co-founder – is the seminal force behind eNovalys. Dr Wagner is currently director of the Laboratory of Functional ChemoSystem (LFCS) and author of more than 130 peer reviewed papers and inventor of 15 patents, and serves as scientific and operational advisor to eNovalys.

Dr. Vincent Rietsch – received his Ph.D. in synthetic organic chemistry at Strasbourg University and completed a post-doctoral studies in the USA. Dr Rietsch conceptualized a strategy for capturing and organizing data and leads the user community in compilation of the set of lost chemical information.

Dr. Ning Xia – received his Ph.D. in Organic Chemistry from the National Superior School of Chemistry at Montpellier. A brilliant software developer Dr Xia led the industrialization of eSniff and the development of the first versions of the platform and is now responsible for IT and of the development of novel tools for eNovalys’ users.


ORGANISERSW

ELCOME


PANIES

t back :: next u

Eyevensys www.eyevensys.com

CONTACTRaffy Kazandjian President & CEO

ADDRESS Pépinière - Paris Santé Cochin 29 rue du Faubourg Saint Jacques 75014 Paris France

TELEPHONE +33 (0)1 84 79 10 60


YEAR FOUNDED2008

FINANCIAL SUMMARY

Financing raised since inception: 5 M€

Key Shareholders:– Boehringer Ingelheim Ventures– BPI France Innobio– Cap Decisif– Inserm Transfert Initiative

COMPANY PROFILE

Eyevensys is developing a game changing approach in the treatment of major ophthalmic diseases with the expression and delivery of therapeutic proteins in situ.

EYEVENSYS was founded on the basis of research on electroporation techniques in the ciliary muscle of the eye, by Prof. Francine Behar-Cohen, Professor of Ophthalmology at the Descartes School of Medicine in Paris, and Chief Medical Director of the Gonin Ophthalmic Hospital in Lausanne.

This novel therapeutic approach is based on the use of a proprietary single-use injection and electroporation guide to selectively transfect eye tissues with a plasmid encoding for a therapeutic protein. Transfected cells will produce the protein over a course of several months and deliver the therapeutic agent directly in the vitreous, thus saving traumatic and repeated subretinal injections. The procedure in itself is fast and minimally invasive.

The electroporation technology benefits from several distinctive advantages vs other approaches, in particular vs viral-based strategies.

i) Compared to intravitral delivery of proteins, it yields prolonged effects, up to 6 months of sustained expression and delivery,

ii) Compared to AAV gene transfer, it allows a precision control of transfected tissues, at injection and electroporation sites, allows repeatability, provides an exit strategy, presents marked risk and cost benefits.

PRODUCT PIPELINE

The Company’s lead program is for the treatment of refractory uveitis, via the electrotransfer of a TNF‐ receptor plasmid. The Uveitis indication would enable a fast clinical proof of concept, considering that the most severe forms (PSII) have an orphan disease status.

The second indication pursued by the Company targets wet age-related macula degeneration (wet AMD). AMD would position the technology a long term therapy with a well validated target, as an alternative to Lucentis and other antibodies fragments (e.g. Bayer-Regeneron).

Other targets may include diabetic retinopathies (targets: VEGF and PIGF-1), neurodegenerative diseases such as dry AMD, glaucoma, and retinal dystrophies (orphan diseases), for which targets can be neurotrophic factors GDNF and CNTF, as well as light-induced retinal degeneration.

The Uveitis pre-clinical program has been reviewed by EMA, is well in progress, and first-in-man is planned to start in Fall 2015.

MANAGEMENT

Raffy Kazandjian, CEO Dr. Luc Lebreton, Development DirectorProfessor Francine Behar-Cohen, Founder. Chief Medical Director, Gonin Ophthalmology Hospital (Lausanne - Switzerland)


ORGANISERSW

ELCOME


PANIES

t back :: next u

F2G Ltd www.f2g.com

CONTACTIan Nicholson Chief Executive

ADDRESS F2G Ltd Lankro Way Eccles Manchester M30 0LX UK

TELEPHONE +44 161 7851271


YEAR FOUNDED1998

FINANCIAL SUMMARY

Privately funded. Investors include Advent Life Sciences, Novartis Bioventures, Sunstone Capital, Merifin Capital, K Nominees, Astellas Venture Fund.

COMPANY PROFILE

F2G Ltd, based in Manchester UK, is dedicated to the discovery and development of new and clinically superior drug classes to treat life-threatening systemic fungal infections in at-risk patient populations. The lead clinical candidate, F901318, now in Phase I studies, is a new class of antifungal acting against a new cellular target and is being developed as an IV and oral therapy to treat invasive aspergillosis and other life-threatening fungal infections. The antifungal market is currently estimated at over $6 billion annually and is growing steadily year on year. Market growth is expected to increase with the emergence of new clinical indications in allergies and asthma. The company has impressive internal capabilities, employing a core team of scientists with a unique understanding of the antifungal arena, supported by an experienced management team.

PRODUCT PIPELINE

Product Name: F901318Description: Novel class of antifungal acting against a new cellular targetDevelopment Stage: Phase I

OPPORTUNITIES

Partnering and collaborations in the arena of treatment of serious human fungal infection.

MANAGEMENT

Mr Ian Nicholson, Chief Executive OfficerDr Richard White, ChairmanDr Mike Birch, Chief Operating OfficerDr Tony Kennedy, Chief Scientific and Development OfficerDr John Rex, Senior Advisor and Non-executive Director


ORGANISERSW

ELCOME


PANIES

t back :: next u

F-star Biotechnology Ltd. www.f-star.com

CONTACTSJohn Haurum CEO

Dr. Jane Dancer Chief Business Officer

ADDRESS B280 Moneta Babraham Reserach Campus Cambridge CB22 3AT United Kingdom

TELEPHONE +44-1223497400


YEAR FOUNDED2006

FINANCIAL SUMMARY

To date F-star has raised more than €38 million in venture capital from VC investors: Aescap Venture, Atlas Venture, Novo Ventures, and TVM Capital; as well as from corporate investors: Merck Serono Ventures, MP Healthcare Venture Management, and SR One.

COMPANY PROFILE

F-star is a biopharmaceutical company dedicated to developing novel bispecific antibody products that provide a significant improvement over the current standard of care. Given its strong patent position, it is the only biopharmaceutical company with the ability to create and develop Fcab™ antibody fragments, and bispecific antibodies, by modifying the constant region of an antibody. In particular, F-star’s Modular Antibody Technology™ enables rapid discovery and development of bispecific antibodies by introducing additional binding sites to the constant region of an antibody and offers unprecedented ease in the development and manufacturing of bispecific monoclonal antibodies. Using the Modular Antibody Technology™, F-star generates bispecific antibodies (mAb 2™) that possess the favourable characteristics of traditional monoclonal antibodies, without the production challenges often associated with other antibody formats. F-star is now applying its proprietary technology to the development of a pipeline of product candidates.

MANAGEMENT

John Haurum, CEO Dr. Jane Dancer, Chief Business Officer


ORGANISERSW

ELCOME


PANIES

t back :: next u

G7 Therapeutics www.g7therapeutics.com

CONTACTCarlo Bertozzi CEO

ADDRESS Wagistrasse 21 Schlieren 8952 Switzerland

TELEPHONE +41 44 635 56 01


FINANCIAL SUMMARY

G7 Therapeutics is currently actively looking for an investor providing Series A financing to accomplish the next step in the transformation of its scientific breakthrough GPCR drug discovery platform into reality.

COMPANY PROFILE

G7 Therapeutics’ unique technology allows to create and use biophysically stabilized GPCRs in a tailor-made format for in-vitro high-throughput screening (HTS) and structure-based drug design (SBDD).

Our complementary approach of using established cell-based assays together with the structural information and biochemical assays allows us to create highly specific binders for GPCRs.

G7 Therapeutics is pursuing proprietary programs in the area of cardiology and is going to apply its GPCR stabilizing technology platform on behalf of its partners.

MANAGEMENT

Carlo Bertozzi, PhD, CEOLutz Kummer, PhD, CSO


ORGANISERSW

ELCOME


PANIES

t back :: next u

GamaMabs Pharma www.gamamabs.com

CONTACTStephane Degove CEO

ADDRESS 1 place Pierre Potier BP 50624 cedex 1 Toulouse 31106 France

TELEPHONE +33 1 70 96 00 67


YEAR FOUNDED2013

FINANCIAL SUMMARY

Raised 3.6 M€ in a series-A round in 2013.

COMPANY PROFILE

GamaMabs Pharma is a French Biotechnology company developing innovative monoclonal antibodies in cancer. GamaMabs’ lead project is the monoclonal antibody (mAb) 3C23K, currently in advanced pre-clinical stage, which targets Anti-Mullerian Human Receptor 2 (AMHR2 / MISR2) in ovarian cancer. The company values high-potential technologies in oncology developed initially at LFB Biotechnologies including EMABling® which increases mAbs’ activity through the activation of immune system cells.

PRODUCT PIPELINE

1. 3C23K: mAb targeting AMHRII/MISRII in ovarian cancer, in advanced preclinicals

2. HER3 program: glyco-engineered optimized antibodies in lead stage

3. HER4 program

OPPORTUNITIES

Series-B round financing

co-development or ADC strategy on AMHRII program

HER3 program

MANAGEMENT

Stephane Degove, CEOJean-François Prost, MD, VP R&D and StrategyJean-Marc Barret, Head of PharmacologyCatherine Combot-Pletan, Head of Projects Development


ORGANISERSW

ELCOME


PANIES

t back :: next u

Genkyotex SA www.genkyotex.com

CONTACTSDr Daniel Elger Chief Financial and Corporate Development Officer

Mr Alexandre Grassin Director of Finance and Administration

ADDRESS 16 Chemin des Aulx 1228 Plan-les-Ouates Geneva Switzerland

TELEPHONE +41 228 801025


YEAR FOUNDED2006

FINANCIAL SUMMARY

Raised CHF 51m to date; currently raising new venture round.

COMPANY PROFILE

Genkyotex is pioneering the development of NOX inhibitors, a new class of drugs with application across multiple therapeutic categories. The Company’s lead drug GKT137831 is in a phase II trial in diabetic nephropathy, with data due in mid-2015. A second candidate, GKT901, is expected to enter the clinic in early 2015. The Company has other early-stage NOX inhibitors and its discovery platform continues to generate further candidates.

PRODUCT PIPELINE

GKT137831, NOX1&4 inhibitor in phase II trial for diabetic nephropathy (results expected mid-2015); GKT901; expected to enter phase I in early 2015.

OPPORTUNITIES

Potential out-licensing/collaboration opportunities

GKT137831 – NOX1/4 inhibitor in phase II for diabetic nephropathy; potential for development in NASH/other settings

Platform collaborations – NOX inhibtors

MANAGEMENT

Dr Ursula Ney, CEODr Philippe Wiesel, CMODr Jeanette Wood, CSODr Daniel Elger, Chief Financial and Corporate Development OfficerMr Alexandre Grassin, Director of Finance and Administration


ORGANISERSW

ELCOME


PANIES

t back :: next u

Genmedica Therapeutics www.genmedica.com

CONTACTIgnacio Faus CEO

ADDRESS Parc Científic de Barcelona Edifici Hèlix Baldiri i Reixach, 15 - 21 Barcelona 08028 Spain

TELEPHONE +34934020167


YEAR FOUNDED2005

FINANCIAL SUMMARY

The company has gone through several rounds of financing in order to develop its products for the treatment of diabetes.

COMPANY PROFILE

Genmedica Therapeutics is a clinical stage biopharmaceutical company developing first in class molecules for the treatment of type II diabetes.

PRODUCT PIPELINE

Lead molecule is GMC-252 and is ready for Phase II clinical trials in type II diabetes.

OPPORTUNITIES

GMC-252 for the treatment of type II diabetes. Phase I study completed in the United Kingdom.

MANAGEMENT

Ignacio Faus, CEO


ORGANISERSW

ELCOME


PANIES

t back :: next u

Genocea Biosciences, Inc. www.genocea.com

CONTACTChip Clark President and CEO

ADDRESS 100 Acorn Park Drive Cambridge MA 02140 USA

TELEPHONE +1 617 876-8191


YEAR FOUNDED2007

FINANCIAL SUMMARY

NASDAQ: GNCA

COMPANY PROFILE

Genocea Biosciences is harnessing the power of T cells to create life-changing medicines.

We’ve created a pipeline of novel vaccine and immunotherapy programs that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immune responses against a wide array of diseases. Our pipeline includes programs addressing herpes simplex virus-2 (HSV-2), pneumococcus, chlamydia, HSV-2 prophylaxis, malaria and cancer immunotherapy.

PRODUCT PIPELINE

GEN-003, Phase 2b immunotherapy for genital herpes

GEN-004, Phase 2a vaccine for pneumococcal disease

OPPORTUNITIES

GEN-003 - a Phase 2, first in class immunotherapy to treat genital herpes

GEN-004 - a Phase 2a, first in class vaccine to prevent pneumococcal disease

ATLAS T cell discovery platform with applications in infectious disease and immuno-oncology


ORGANISERSW

ELCOME


PANIES

t back :: next u

Heptares Therapeutics www.heptares.com

CONTACTMalcolm Weir CEO

ADDRESS BioPark Broadwater Road Welwyn Garden City AL7 3AX UK

TELEPHONE +44 (0)1707 358 628


YEAR FOUNDED2007

FINANCIAL SUMMARY

USD60m raised in seed, Series A and Series B venture financing rounds.

COMPANY PROFILE

Heptares creates transformative medicines targeting G protein-coupled receptors (GPCRs), a superfamily of drug receptors linked to a wide range of human diseases. Our proprietary structure-based drug design technology enables us to engineer drugs for highly validated, yet historically undruggable or challenging, GPCRs. Using this approach, we have built an exciting pipeline of new medicines with the potential to transform the treatment of Alzheimer’s disease, ADHD, diabetes, schizophrenia, migraine, and other diseases. Our pharmaceutical partners include Cubist, MorphoSys, Takeda, AstraZeneca and MedImmune, and we are backed by Clarus Ventures, MVM Life Science Partners, Novartis Venture Fund, the Stanley Family Foundation and Takeda Ventures.

PRODUCT PIPELINE

Selective muscarinic M1 receptor agonist (Phase 1)

Alzheimer’s disease, Schizophrenia

First selective muscarinic M1 receptor agonist for treatment of Alzheimer’s disease and other disorders of cognitive impairment.

M4 and Dual M1/M4 receptor agonists (preclinical)

Psychosis in Schizophrenia, Alzheimer’s and other diseases

First-in-class selective M4 agonists for the treatment of psychosis and related behavioural & psychiatric symptoms. Dual M1/M4 agonists for patients with co-morbid psychosis and cognitive impairment.

Adenosine A2A receptor antagonists (late preclinical)

ADHD, ADD, Attention disorders

Novel small molecule antagonists that selectively enhance dopaminergic transmission in key regions of the brain linked to ADHD. Target profile is once daily, fast-acting, effective non-stimulant with superior safety and tolerability vs. current agents.

CGRP antagonists (preclinical)

Migraine Treatment & Prophylaxis

Novel oral/intra-nasal small molecule antagonists of the calcitonin gene-related peptide (CGRP) receptor, a clinically validated mechanism for treating & preventing migraine attacks.

GPR39 agonists (preclinical)

Type 2 Diabetes

First oral small molecule GPR39 agonist, a novel and biologically validated mechanism for improving glycaemic control and preventing disease progression via preservation of islet cell function.

GLP-1 agonists (preclinical)

Type 2 Diabetes

First oral once-daily GLP-1 agonist. GLP-1 is a breakthrough mechanism for controlling glycaemia and reducing weight in patients with type 2 diabetes.

Orexin 1 antagonists (preclinical/discovery)

Binge Eating, Nicotine Addiction

First selective Orexin 1 subtype receptor antagonist for treatment of addiction and compulsive disorders.

mGlu5 receptor modulator (preclinical/discovery)

Autism, Depression, Dyskinesia

Novel mGluR5 receptor negative allosteric modulator with potential best-in-class selectivity, pharmacokinetics and safety.

Continued...


ORGANISERSW

ELCOME


PANIES

t back :: next u

Heptares Therapeutics www.heptares.com

CONTACTMalcolm Weir CEO

ADDRESS BioPark Broadwater Road Welwyn Garden City AL7 3AX UK

TELEPHONE +44 (0)1707 358 628


YEAR FOUNDED2007

...continued

OPPORTUNITIES

Selective muscarinic M1 receptor agonist

M4 and Dual M1/M4 receptor agonists

Adenosine A2A receptor antagonists

CGRP antagonists

GPR39 agonists

MANAGEMENT

Malcolm Weir, CEO and co-founderFiona Marshall, CSO and co-founderDaniel Grau, PresidentTim Tasker, CMO & VP DevelopmentBarry Kenny, CBOMIles Congreve, VP Chemistry


ORGANISERSW

ELCOME


PANIES

t back :: next u

Humabs BioMed SA www.humabs.com

CONTACTSDr Alcide BarberisPresident and CEO

Dr Davide CortiSenior VP and CEO

ADDRESS Via Mirasole 1 Bellinzona 6500 Switzerland

TELEPHONE +41 91 825 63 80


YEAR FOUNDED2004

FINANCIAL SUMMARY

Cash positive thank to licensing and collaboration agreements creating near term revenues as well as longer term milestones and royalties. Currently seeking investments for taking a program into clinical development.

COMPANY PROFILE

• Discovery and development of potent, fully human monoclonal antibodies to a pre-clinical level before licensing to development partners

• Flexibility to share risk/rewards in collaborative partnerships

• Build a sustainable company that will create near term revenues as well as a stream of longer term milestones and royalties

• Option to take a Humabs antibody program into own clinical development

• Continue out-licensing of the anti-infective antibodies followed by a focused expansion in the field of cytokines and other inflammatory targets, as well as in cancer.

PRODUCT PIPELINE

OPPORTUNITIES

RSV+MPV antibody program

HBV antibody program Dengue antibody program

Rabies antibody program

GM-CSF antibody program

MANAGEMENT

Alcide Barberis, PhD, CEODavide Corti, PhD, CSOFilippo Riva, MBA, CFO


ORGANISERSW

ELCOME


PANIES

t back :: next u

Immune Pharmaceutcials immunepharmaceticals.com

COMPANY PROFILE

Immune Pharmaceuticals Inc. applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, Bertilimumab, is in clinical development for moderate to severe ulcerative colitis and Crohn’s Disease as well as bullous pemphigoid, an orphan auto-immune dermatological condition, Immune licensed worldwide rights for systemic indications of Bertilimumab from iCo Therapeutics (TSX: ICO; OTCQX: ICOTF) in June 2011, while iCo retained rights to all ophthalmic indications. iCo originally licensed the exclusive world-wide rights to Bertilimumab in 2006 from MedImmune, the Global Research and Development Arm of AstraZeneca. Immune’s pipeline also includes NanomAbs®, antibody nanoparticle conjugates, for the targeted delivery of chemotherapeutics. and AmiKet™, a Neuropathic Pain drug candidate ready for Phase III. AmiKet has received Fast Track designation for chemotherapy induced neuropathic pain and Orphan Drug Designation for Post Herpetic Neuralgia.


ORGANISERSW

ELCOME


PANIES

t back :: next u

InnoMedica www.innomedica.com

CONTACTSJonas Zeller Finance

Stefan Halbherr Medical Affairs

ADDRESS Gesellschaftsstrasse 16 Bern 3012 Switzerland

TELEPHONE +41 (0)79 451 20 78


YEAR FOUNDED2000

FINANCIAL SUMMARY

Form of organization: Corporation

Ownership: Privately held company

Type of shares: Bearer shares

Shares outstanding: 1.1 million, CHF 1.- per share

ISIN: CH0011082366

Trading: electronically, OTC

Previous capital increases: Spring 2013: 54’100 shares at CHF 11.50

Spring 2014: 45’900 shares at CHF 14.50 (30% oversubscribed)

Planned capital increases for 2014/15: CHF 5.75 mio. to finance clinical trial Phase I

COMPANY PROFILE

InnoMedica is a Swiss biotech startup company based in Bern (management, administration), Marly (production), Zug (headquarters) and Ibaraki (Japan; Yamazaki-DDS Co., Ltd.). In January 2013, InnoMedica initiated the project Targeted Liposomal Doxorubicin (TLD-1, Talidox®) and started operating as an independent pharmaceutical company. Originally established in 2000, InnoMedica was a private equity company focused on investments in the fields of biochemistry and medicine. The vast experience in the Life Science sector combined with broad expertise in capital markets are an optimal foundation for the successful development of the product pipeline.

PRODUCT PIPELINE

Technology and Product:With Talidox® (Targeted liposomal Doxorubicin) InnoMedica introduces an innovative platform technology based on an active targeting mechanism for the site specific delivery of a widely used anticancer drug (Doxorubicin). The liposome-based drug delivery system comprises the encapsulation of the active cytostatic agent Doxorubicin into an unilamellar liposomal particle which is actively directed to the sites of cancer. Talidox’s® concept of active site specific targeting of Doxorubicin after intravenous administration is based on the coating of the liposomal particle with a natural sugar ligand able to recognize specific receptors that are overexpressed both in the cancer and cancer related inflammation.

The pivotal innovation of Talidox’s® drug delivery relies on the nanotherapeutic refinement of current state of the art chemotherapy, intending to promote enhanced local distribution in the tumor tissue as well as to reduce the dose needed to achieve enhanced treatment efficacy. Cancer patients are expected to benefit from better chances of recovery along with reduction of adverse reactions leading to an increased quality of life.

The start of the phase I/II clinical study of Talidox® is scheduled to take place in Q1 2015 in cooperation with the Swiss Group for Clinical Cancer Research.

The picture below graphically illustrates InnoMedica’s drug delivery system.

Continued...


ORGANISERSW

ELCOME


PANIES

t back :: next u


CONTACTSJonas Zeller Finance

Stefan Halbherr Medical Affairs

ADDRESS Gesellschaftsstrasse 16 Bern 3012 Switzerland

TELEPHONE +41 (0)79 451 20 78


YEAR FOUNDED2000

...continued

Research and development:Currently InnoMedica’s research activities are performed in collaboration with the John A. Burns School of Medicine, University of Hawaii, the Theodor Kocher Institute, University of Bern, and the Mario Negri Institute in Milan. Research activities are focused on the functionality and characterization of the new drug delivery system in general and TLD-1 in particular. InnoMedica´s technology serves as a development platform for the treatment of various kinds of cancer, even multi resistant tumors. Later, the product pipeline can be extended applying the same technology to other inflammatory diseases or diseases with inflammation-specific symptoms like arteriosclerosis, multiple sclerosis etc.

OPPORTUNITIES

Participation in the next public financing round for the financing of the phase I clinical trial

As a subcontractor to pharmaceutical companies we can encapsulate active pharmaceutical ingredients into liposomal particles and actively direct it to specific sites of disease.

MANAGEMENT

Dr. Herbert Früh, Chairman of the BoardDr. Peter Halbherr, CEO, Member of the BoardDr. Noboru Yamazaki, CTO, Member of the BoardPascal Halbherr, Project ManagerStefan Halbherr, Medical AffairsJonas Zeller, Finance


ORGANISERSW

ELCOME


PANIES

t back :: next u

Inthera Bioscience AG

CONTACTDr. Ulrich Kessler CEO

ADDRESS Ruetistrasse 14 Schlieren 8952 Switzerland


YEAR FOUNDED2013

COMPANY PROFILE

Inthera Bioscience is developing Helix Domain Mimetics (HDMs) as inhibitors of intracellular protein-protein interactions employing two proprietary technology platforms. HDMs merge the versatility of small-molecules with the specificity of biologics, a unique combination that is utilized to tackle intractable (“undruggable”) targets in a multitude of disease states. The broad applicability of the technology platforms has been illustrated against several targets in oncology and virology.

Initial in vivo data on Inthera’s lead compounds targeting hypoxia-induced signaling and KRas-activation indicate their potential to break new ground in the treatment of cancer types with poor prognosis such as pancreatic and triple negative breast cancer. HDMs easily penetrate cells, are well tolerated, exhibit very good pharmacokinetic properties and the manufacturing process is straightforward.

PRODUCT PIPELINE

KRas Inhibitor (various cancer types, preclinical)

Hypoxia-Induced Signaling Inhibitor (various solid tumors, preclinical)

OPPORTUNITIES

HDM (Helix Domain Mimetics) Technology Platform

KRas Inhibitor (cancer, preclinical)

Hypoxia-Induced Signaling Inhibitor (solid tumors, preclinical)

MANAGEMENT

Dr. Ulrich Kessler, CEOProf. Paramjit Arora, CTORoland Walder, CFO


ORGANISERSW

ELCOME


PANIES

t back :: next u

Isarna Therapeutics www.isarna-therapeutics.com

CONTACTMartina Fuchs Executive Assistant

ADDRESS Leopoldstrasse 254-256 Munich 80807 Germany

TELEPHONE +49 898 908310

FAX +49 8989 0831491

EMAIL [email protected] [email protected]

YEAR FOUNDED1998

COMPANY PROFILE

Isarna Therapeutics has an unmatched commitment to developing selective TGF-‐ inhibitors to fight cancer and to effectively treat ophthalmic and fibrotic diseases. We are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.

Isarna possesses an extensive pipeline of antisense compounds selectively inhibiting the TGF-‐ isoforms TGF-‐1, TGF-‐2 and TGF-‐3. The company’s most advanced next generation lead compounds will enter the clinic in 2015. The company’s investors include MIG Fonds, S-Refit, AT NewTec, and Bayern Kapital.

PRODUCT PIPELINE

OPPORTUNITIES

ASPH_0036

ASPH_1106

ASPH_1106

ASPH_1047

MANAGEMENT

Dr. Philippe Calais, CEOElizabeth Adkins Czerepak, CFO and CBODr. Michel Janicot, Head Preclinical Reserach and DevelopmentProf. Dr. Eugen Leo, Head Clinical Research and Development

9 | 2014-08-01 |

Current Development Status

OphthalmologyTGF-β2TGF-β1

OncologyTGF-β2TGF-β1TGF-β+vaccineTGF-β+chemoTGF-β3

FibrosisTGF-β1TGF-β2

Target Discovery Preclinical Development Phase 1

Since 2012


ORGANISERSW

ELCOME


PANIES

t back :: next u

Karus Therapeutics LTD www.karustherapeutics.com

CONTACTSimon Kerr CEO ADDRESS 93 Innovation Drive Milton Park ABINGDON OX14 4RZ United Kingdom

TELEPHONE +44 (0)1235 829140


YEAR FOUNDED2005

FINANCIAL SUMMARY

Series B investment secured 2012. Major investors include SV Life Sciences, New Leaf Venture Partners, Noco and IP Group.

COMPANY PROFILE

Karus Therapeutics is a leader in the development of innovative medicines that have breakthrough potential in treating inflammatory disease and cancer.

The Company’s scientific excellence is reflected in its proprietary PI3K and HDAC6 inhibitor programmes, from which innovative small molecule drugs with significant clinical and commercial potential have been developed.

PRODUCT PIPELINE

KA-2237 – PI3K-p110bd inhibitor for inflammatory disease (Prelinical)

KA-4000 – PI3K-p110bd inhibitor for cancer (Preclinical)

KA-3000 – HDAC6 inhibitor for inflammation (Lead selection)

KA-3000 – HDAC6 inhibitor for cancer (Lead selection)

OPPORTUNITIES

KA-2237 – PI3K-p110bd inhibitor for inflammatory disease (Prelinical)

KA-4000 – PI3K-p110bd inhibitor for cancer (Preclinical)

KA-3000 – HDAC6 inhibitor for inflammation (Lead selection)

KA-3000 – HDAC6 inhibitor for cancer (Lead selection)

MANAGEMENT

Simon Kerry, Chief Executive OfficerStephen Shuttleworth, Chief Scientific OfficerPenny Ward, Chief Medical OfficerSimon Jones, Finance Director


ORGANISERSW

ELCOME


PANIES

t back :: next u

LINDIS Biotech GmbH www.lindisbiotech.com

CONTACTDr. Horst Lindhofer CEO

ADDRESS Am Klopferspitz 19 Martinsried 82154 Germany

TELEPHONE +49 89 700 76624


YEAR FOUNDED2010

FINANCIAL SUMMARY

Raising Equity Capital in the amounts of 25-30 Mio Euros.

COMPANY PROFILE

Lindis Biotech GmbH is based on the former patent portfolio and know-how of Trion Pharma GmbH and its trifunctional antibody technology.

PRODUCT PIPELINE

Lymphomun (anti CD20 x anti CD3) - Phase 1/2

Ektomun (anti GD2 x anti CD3) - Late Preclinical

Rexomun (anti Her2 x anti CD3) - Phase 1/2

OPPORTUNITIES

Lymphomun

Ektomun

Rexomun

MANAGEMENT

Dr. Horst Lindhofer, CEODr. Dirk Pelster, COO


ORGANISERSW

ELCOME


PANIES

t back :: next u

Lixte Biotechnology Holdings, Inc. www.lixte.com

CONTACTJohn S Kovach, MD CEO

ADDRESS 641 Lexington Ave. 15th Floor New York 10022 United States

TELEPHONE +1 212-634-6474

FAX +1 (928) 982-5050


YEAR FOUNDED2006

FINANCIAL SUMMARY

The company has been and is supported by PIPEs at intervals based primarily on achieving milestones leading to its current Phase I trial and is now seeking partnerships or investments to evaluate the therapeutic effectiveness of its lead compound, LB-100, in randomized trials in one or more targeted cancers.

COMPANY PROFILE

Lixte Biotechnology Holdings, Inc. (Lixte) is a clinical-stage public (LIXT) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. The current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and DNA damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation. Lixte Biotechnology Holdings, Inc. (Lixte) is a clinical-stage public (LIXT) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. The current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and DNA damage repair and inhibitors of protein deacetylases and Hsp90 that regulate pathways of gene expression and protein degradation.

The phosphatase inhibitors enhance the effectiveness of cytotoxic anti-cancer drugs and radiation therapy making them potentially useful for the treatment of many cancers in combination with existing standard chemotherapy regimens and the evolving targeted cytotoxic therapies of personalized cancer medicine. The primary focus of the company is on its lead phosphatase inhibitor, LB-100, currently in Phase I trial (NCTO1837667).

The deacetylase inhibitors have anti-cancer activity but in model systems enhance the abundance of functional proteins whose deficiency is responsible for several inborn diseases including Gaucher and von Hippel-Lindau diseases and neurofibromatosis type 2. Also, one inhibitor significantly reduces the extent of tissue damage and neurologic impairment in a rat model of traumatic brain injury.

PRODUCT PIPELINE

MANAGEMENT

John S. Kovach, MD, President & CEO Directed 2 NCI Comprehensive Cancer Centers: Mayo Clinic, RST, MN 1986-1994 & City of Hope, LA, CA 1994-2000 and was Founding Director, SUNY Stony Brook Cancer Center 2000

Francis Johnson, PhD, Advisor President, Chem-Master International Inc., a research, development and manufacturing medicinal chemistry company.

Gil N. Schwartzberg, JD, ScD (hon), Advisor Former CEO and Chairman of the Board of Directors of the City of Hope National Medical center, an NCI-designated Comprehensive Cancer Center


ORGANISERSW

ELCOME


PANIES

t back :: next u

Lykera Biomed lykerabiomed.com

CONTACTJuan Ruiz CEO

Fernando Terrón Business Development

ADDRESS Calle de Innovacio, 2 Terrassa 08225 Spain

TELEPHONE +34 683 327 718 +34 915 344 314


YEAR FOUNDED 2010

FINANCIAL SUMMARY

The company aims at raising 4.8 M€ of private financing (disbursed in two tranches of 1.7 M€ and 3.1 M€, respectively) to perform additional in vivo and in vitro assays with the 3 mAbs candidates in different tumor models in order to compare and select the best candidate and the initial therapeutic indication to take it to Phase I.

COMPANY PROFILE

Lykera Biomed is a spin-off biotech company from Leitat Technological Center (Barcelona, Spain). The company’s mission is to develop innovative drugs targeting serious diseases, such as cancer.

Lykera currently has 3 first-in-class humanized monoclonal antibodies (mAbs) candidates targeting S100A4, S100P and S100A7, a potentially relevant target to diagnose and treat solid tumors such as pancreatic cancer and colorectal carcinoma.

PRODUCT PIPELINE

Lykera currently has 3 potentially first-in-class humanized monoclonal antibodies (mAbs) candidates targeting S100A4, S100P and S100A7 that belong to S100 protein family and have been widely related with different cancers. S100s are a familly of low-molecular-weight calcium binding intracellular and extracellular proteins that act as regulators in cellular physiological and pathological processes. Extracellular S100 proteins exert regulatory activities on different cell types, including tumor cells, fibroblasts, neutrophils and macrophages. Bibliography and experimental results suggest that S100A4, S100P & S100A7 proteins stimulate tumor proliferation, survival, invasion and metastasis through extracellular functions.

OPPORTUNITIES

Anti-S100 mAb for the treatment of cancer

MANAGEMENT

Juan Ruiz, CEO


ORGANISERSW

ELCOME


PANIES

t back :: next u

MaxCyte, Inc. www.maxcyte.com

CONTACTSMr. Douglas Doerfler President & CEO

Dr. Madhusudan Peshwa EVP Cellular Therapies

ADDRESS 22 Firstfield Road Suite 110 Gaithersburg, Maryland 20878 USA

TELEPHONE +1 301 944 1700

FAX +1 301 944 170


YEAR FOUNDED1998

FINANCIAL SUMMARY

Private.

COMPANY PROFILE

MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. MaxCyte is pioneering the use of mRNA for Chimeric Antigen Receptor (CAR) immunotherapies for solid cancers with Doctors Carl June and Dario Campagna.

Drawing on its cell therapy expertise, MaxCyte designed a portfolio of products including the MaxCyte® STX™ Scalable Transfection System and MaxCyte® VLX™ Large Scale Transfection System, ideal tools for use in drug discovery research and screening and protein production environments. These products provide for the rapid development and consistent production of 2e11 of (co)transfected primary cells, stem cells, and cell lines for protein and antibody production and for cell based assays with comparable results and Seamless Scalability™ from the bench to HTS and manufacturing. MaxCyte’s scalable cell transfection platform is used by pharmaceutical and biotechnology countries around the world to engineer cells for a wide range of applications, including recombinant vaccine production and cell therapy for oncology and other life threatening diseases.

PRODUCT PIPELINE

1. CAR T Modified with mRNA for Solid Tumours (Phase I II)

2. Gene Edited CD19 CAR (Preclin)

3. Rapid Manufacture CAR cells for solid tumours.

OPPORTUNITIES

Out License Oncology Programs for Co-Development.

MANAGEMENT

Douglas Doerfler, President & CEO


ORGANISERSW

ELCOME


PANIES

t back :: next u

Metys Pharmaceuticals www.metys-pharma.com

CONTACTSMichael Scherz, PhD Founder & CEO

Patrick Scherrer Lead Financial Advisor

ADDRESS Steinenring 8 Basel 4051 Switzerland

TELEPHONE +41 79 408 7982

FAX +41 61 568 4062


YEAR FOUNDED2013

FINANCIAL SUMMARY

Seeking Series A investors

CHF 18 million

COMPANY PROFILE

Metys Pharmaceuticals is developing dimiracetam for the prevention of cancer chemotherapy-induced painful peripheral neuropathy.

In the US alone, in a single year, more than 400’000 patients suffer from painful neuropathy caused by their cancer treatment. No drug has been approved to prevent or treat this neuropathy. Dimiracetam is an orally active, small molecule with more than 200 patients’ safety and tolerability data; and dimiracetam is highly effective in preventing and treating chemotherapy-induced neuropathy in rodents. Dimiracetam penetrates the brain and spinal cord, where it reverses the ramped-up signal transmission from damaged peripheral nerves by blocking glutamate-triggered glutamate release.

Metys Pharmaceuticals is preparing the first dedicated efficacy study of dimiracetam. The DISTALL study is a US-based, placebo-controlled, dose-ranging clinical trial of 3-months’ treatment duration in 180 patients scheduled to receive oxaliplatin; it has been designed in collaboration with world-leading expert neurologists and oncologists. We are preparing Phase III-enabling toxicology studies of dimiracetam, and we are advancing a back-up candidate through preclinical development. We seek CHF 18 million in Series A investment to finance these activities. We foresee a lucrative exit to a mid- or large-sized pharma company with successful completion of the DISTALL trial approximately 2.5 years after securing the Series A round. Peak sales forecasts for dimiracetam, in oxaliplatin-induced peripheral neuropathy alone, lie above CHF 1’000 million per annum.

Metys Pharmaceuticals comprises a team of seasoned drug developers, with a decade of shared drug development experience at Actelion. The company is based in Basel, Switzerland. It has been financed by its founder, Michael Scherz, PhD (formerly VP, Life Cycle Mgmt, Actelion), and nine seed investors, themselves largely former Actelion employees..

PRODUCT PIPELINE

dimiracetam

Phase II

OPPORTUNITIES

Series A investment, CHF 18 million

MANAGEMENT

Michael Scherz, PhD, Founder & CEOElisabet Lindberg, MD, Chief Medical OfficerCarlo Farina, PhD, Head of Chemistry & PatentsMaria Lindström, Head of Clinical Operations


ORGANISERSW

ELCOME


PANIES

t back :: next u

MC2 Biotek www.mc2biotek.com

CONTACTJesper J. Lange President

Lonni Goltermann Executive Assistant

ADDRESS Bøge Allé 5 Hørsholm 2970 Denmark

TELEPHONE +45 201 82222


YEAR FOUNDED2006

FINANCIAL SUMMARY

Privately held company in solid financial position.

COMPANY PROFILE

MC2 Biotek has developed a unique oil-in-water dispersion vehicle (PAD™ Technology) for ophthalmic and dermatological applications. Key features of the PAD™ topical vehicle are (i) superior penetration, (ii) improved solubility API’s, (iii) stability of difficult API’s, (iv) high tolerability, (iv) elegant and convenient to use and (v) patented.

MC2 Biotek has ongoing internal and partner-controlled clinical stage development PAD™ based projects in both ophthalmology (dry eye) and dermatology (psoriasis and AD).

MC2 Biotek is a privately owned biotech company based in Denmark and the UK.

PRODUCT PIPELINE

PADciclo™ (dry eye), PAD™-based cyclosporine product, large phase II upcoming.

PADcombo™ (psoriasis), PAD™-based combo of BDP and calcipotriene, phase II running.

PADmono™ (psoriasis), PAD™-based calcipotriene, phase II running.

MC2-07 (atopic dermatitis), pre-clinical.

Other pre-clinical projects.

OPPORTUNITIES

PADciclo™ (dry eye)

PADcombo™ (psoriasis)

PAD™ vehicle for topical drug development projects

MANAGEMENT

Jesper J. Lange, PresidentMorten Præstegaard, VP OperationsJon Bondebjerg, Project Leader, DermatologyJens Hansen, Scientific Advisor


ORGANISERSW

ELCOME


PANIES

t back :: next u

Minoryx Therapeutics www.minoryx.com

CONTACTMarc Martinell CEO

ADDRESS Av. Ernest LLuch 32, TCM2 Mataró (Barcelona) 08302 Spain

TELEPHONE +34 937 021975


YEAR FOUNDED2011

FINANCIAL SUMMARY

Since 2011, raised 2M€ from private investors (including 2 VCs - Caixa Capital Risc and Inveready) and public funds.

COMPANY PROFILE

Minoryx is committed to finding novel treatments Inborn Errors of Metabolism, a group of genetic and life threatening rare (orphan) diseases with highly unmet medical need. Minoryx develops a new generation of pharmacological chaperones non-competitive with natural substrate, through a proprietary technological platform (SEE-Tx). Such molecules are aimed to restore the protein deficiency which originates the corresponding diseases. As a complementary approach, Minoryx is also involved in progressing drugs which downstream correct the cellular dysfunction derived from the corresponding protein deficiency.

PRODUCT PIPELINE

1. Drug candidate for X-linked Adrenoleukodystorphy (ALD). Mechanism of action based on correction of cellular dysfunction found in ALD patients. Status: preclinical.

2. Lead optimization for GM1 Gangliosidosis and Morquio B. Mechanism of action based on non-competitive pharmacological chaperones identified through proprietary technology platform (SEE-Tx)

3. Discovery stage for congentital disorder of glycosylation type Ia (PMM2-CDG) and other Inborn Errors of Metabolism. Mechanism of action based on non-competitive pharmacological chaperones.

OPPORTUNITIES

INVESTMENT: Series A

OUT-licensing: Candidate for X-linked Adrenoleukodystrophy (ALD)

OUT-licensing: Non-competitive pharmacological chaperones for GM1 gangliosidosis and Morquio B

OUT-licensing/Alliance: SEE-Tx: Platform for identification of non-competitive pharmacological chaperones

MANAGEMENT

Marc Martinell, CEO and co-founderJoan Aymamí, Co-founderXavier Barril, Co-founderNigel Ten Fleming, non-executive chairman


ORGANISERSW

ELCOME


PANIES

t back :: next u

Mirna Therapeutics www.mirnarx.com

CONTACTCasi DeYoung Chief Business Officer

ADDRESS 2150 Woodward Street Austin 78744 USA

TELEPHONE +1-512-681-5200


YEAR FOUNDED2007

COMPANY PROFILE

Mirna Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering microRNA Replacement Therapy. MRX34, a first in class compound, is the first microRNA mimic drug candidate to advance into clinical testing in cancer patients. The ongoing MRX-34-101 study has now enrolled more than 50 patients in multiple cohorts including patients with primary liver cancer as well as hematological malignancies. Data are expected in 2015.

MRX34 was designed to deliver a mimic of the naturally occurring microRNA tumor suppressor, miR-34, which is under expressed in tumors of patients with a wide variety of cancers, including glioblastoma, ovarian, liver, colon and non-small cell lung cancer, and in cancer stem cells. The miR-34 mimic is encapsulated using an innovative liposomal formulation called SMARTICLES®.

Mirna Therapeutics, founded in 2007, is located in Austin, TX, has received significant funding from New Enterprise Associates, Pfizer Venture Investments, and Sofinnova Ventures. Mirna is also funded by the State of Texas, both the Emerging Technology Fund, and from CPRIT.

PRODUCT PIPELINE

MANAGEMENT

Paul Lammers, MD, CEOCasi DeYoung, CBOSinil Kim, MD, CMO


ORGANISERSW

ELCOME


PANIES

t back :: next u

Mucosis B.V.www.mucosis.com

CONTACTThomas Johnston CEO

COMPANY PROFILE

Mucosis B.V. is a clinical stage Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidate is SynGEM®, an intranasal vaccine to prevent respiratory syncytial virus infection. Our vaccines are based on the patented and validated Mimopath® technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in our proof-of-concept animal and human studies of our FluGEM® vaccine candidate.

PRODUCT PIPELINE

SynGEM – RSV vaccine

FluGEM – influenza vaccine

Mimopath delivery platform

OPPORTUNITIES

SynGEM

FluGEM

Mimopath

MANAGEMENT

Thomas Johnston, CEO


ORGANISERSW

ELCOME


PANIES

t back :: next u

Mymetics www.mymetics.com

CONTACTRonald Kempers CEO

ADDRESS Biopole Route de la Corniche 4 Epalinges 1066 Switzerland

TELEPHONE +41 21 653 4535

FINANCIAL SUMMARY

Listed on OTCQB: MYMX

Compliance with SEC filings and requirements

Quarterly Reports available on company website and SEC.

In Jan. 2014 signed License and Collaboration Agreement for RSV virosome vaccine with major pharma.

COMPANY PROFILE

Mymetics Corporation (OTCQB: MYMX) is a Swiss-based biotechnology company registered in the US and trades on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies.

Mymetics develops next-generation preventative vaccines for infectious diseases. Mymetics’ core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. The company’s vaccines are designed to induce protection against early transmission and infection, focusing on the mucosal immune response as a first-line defense, which, for some pathogens, may be essential for the development of an effective prophylactic vaccine.

Mymetics currently has 5 vaccines in its pipeline: HIV-1/AIDS, intra nasal Influenza, Malaria, Herpes Simplex Virus and the RSV vaccine (out licensed to ClearPath – Astellas). The company’s intra nasal Influenza vaccine and the HIV-1 vaccine have successfully completed Phase I clinical trials in healthy human volunteers. A Phase 1b clinical trial for its Malaria vaccine on children in Tanzania has been completed, while the HSV vaccine candidate is in the preclinical phase. For further information, please visit mymetics.com.

PRODUCT PIPELINE

OPPORTUNITIES

intranasal Influenza virosome vaccine

HSV (Herpes Simplex virus) vaccine

CMV virosome vaccine

MANAGEMENT

Ronald Kempers, CEOToon Stegmann, CSO R&DMario Amacker, Head Manufacturing and Quality


ORGANISERSW

ELCOME


PANIES

t back :: next u

nanobiotix SA www.nanobiotix.com

CONTACTPhilippe Mauberna CFO

ADDRESS 60 rue de Wattignies Paris 75012 France

TELEPHONE +331 4026 0424


YEAR FOUNDED2003

FINANCIAL SUMMARY

Nanobiotix completed a successful €28.1m capital raise based on a share price of €10.60, broadening the shareholder base in Europe. There was a significant demand for the shares and so the company provided an additional 15% of new equity over the initial offering. Even with the additional shares, the subscription was oversubscribed by 181%. The aim of the capital raise was to provide the company with additional resources to finance its development strategy for NBTXR3, principally in Soft Tissue Sarcoma (STS).

COMPANY PROFILE

Nanobiotix completed a successful ‐28.1m capital raise based on a share price of ‐10.60, broadening the shareholder base in Europe. There was a significant demand for the shares and so the company provided an additional 15% of new equity over the initial offering. Even with the additional shares, the subscription was oversubscribed by 181%. The aim of the capital raise was to provide the company with additional resources to finance its development strategy for NBTXR3, principally in Soft Tissue Sarcoma (STS).

PRODUCT PIPELINE

Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

MANAGEMENT

Laurent Levy, CEO & FounderElsa Borghi, CMOBernd Muehlenweg, BDO


ORGANISERSW

ELCOME


PANIES

t back :: next u

NBE-Therapeutics www.nbe-therapeutics.com

CONTACTSUlf Grawunder, PhD CEO

Roger Beerli, PhD VP R&D

ADDRESS Technology Park Basel Hochbergerstrasse 60C Basel 4057 Switzerland

TELEPHONE +41-61-633-2230


YEAR FOUNDED2012

FINANCIAL SUMMARY

Seed funding CHF 2.5 Mio raised.

COMPANY PROFILE

NBE-Therapeutics is a privately owned Swiss, Basel-based Biotech company that was founded in 2012 with the vision to develop next-generation ADCs improving treatment options for cancer patients. The company is financially backed by the Boehringer Ingelheim Venture Fund and additional private investors.

PRODUCT PIPELINE

In development

OPPORTUNITIES

Transpo-mAb® Technology (antibody discovery)

SMAC-Technology (conjugation technology)

MANAGEMENT

Ulf Grawunder, PhD, CEORoger Beerli, PhD, VP R&D


ORGANISERSW

ELCOME


PANIES

t back :: next u

NEOVACS neovacs.fr

CONTACTSMiguel Sieler CEO

Dr Pierre Vandepapeliere CMO

ADDRESS 5 impasse Reille Paris 75014 France

TELEPHONE +33 15 310 9300


YEAR FOUNDED1993

FINANCIAL SUMMARY

Company listed in Paris on Alternext, market cap of 75 mio € with 52 % floating.

Main institutional shareholders :

Truffel Capital (20%) and Novartis Venture Fund (15%)

COMPANY PROFILE

Neovacs SA is a listed french biotech company developping with a groundbreaking technology therapeutic vaccines to treat specific autoimmune diseases as RA, Crohn and Lupus.

PRODUCT PIPELINE

TNFa Kinoid against RA in Phase IIb, results in 11/2014.

TNFa Kinoid in Crohn disease, phase I/IIa completed in 2013

INFa Kinoid in Lupus Phase IIb trial to start mid 2015

4 preclinical programs in DMLA, solid tumors, chronic infections and allergy.

OPPORTUNITIES

Based on the expected positive results in RA, Neovacs is searching a global licensing partner for this indication TNF Kinoid in RA

TNF Kinoid in Crohn

INFa Kinoid in Lupus

MANAGEMENT

Miguel Sieler, CEODr Pierre Vandepapeliere, CMOBernard Fanget, Head of CMCGeraldine Vogel, Head of PreclinicNathalie Thomas, Head of Regulatory


ORGANISERSW

ELCOME


PANIES

t back :: next u

NovaHep AB www.novahep.com

CONTACTDr. Petter Björquist CEO

ADDRESS NovaHep AB Arvid Wallgrens Backe 20 Gothenburg 413 46 Sweden

TELEPHONE +46 705 979296


YEAR FOUNDED2005

FINANCIAL SUMMARY

Transaction: Capital increase/ new equity

Amount: SEK 13+ million

Stake: < 30 %

Closing: Q4, 2014

COMPANY PROFILE

NovaHep is a biotechnology company founded as a spin-off from the Karolinska Institute with a unique, proprietary technology in the field of regenerative medicine. NovaHep is developing the next generation of tissue-engineered products for replacement therapy. The pipeline consists of high quality, biocompatible products that are individualized with the patients’ own stem cells. Clinical proof-of-concept has been shown, when three individuals were transplanted with tissue-engineered veins.

PRODUCT PIPELINE

NovaHep’s first goal is to replace insufficient deep veins of the leg, veins damaged through trauma or deep vein thrombosis. Patients suffering from chronic vein insufficiency (CVI) of the leg have problems with swelling, a feeling of heaviness or pain, and bleeding venous (skin) ulcers. Replacement of the damaged veins including their faulty valves with NovaHep´s P-TEV will alleviate these symptoms. To bring this product to the market, a regulatory path has to be outlined for Europe and the US, the process of making engineered biological veins transferred from preclinical to GMP-grade and scaled-up, a clinical trial programme initiated, and a marketing plan established. NovaHep has initiated activities in all these areas.

NovaHep’s proprietary technology will subsequently be explored also in the following application areas:• Other vascular disorders, both veins and arteries will be considered• Other hollow organs and solid tissues, e.g. trachea, oesophagus and liver • In vitro applications such as predictive liver toxicity tests• Use of xenogeneic scaffold for all above

OPPORTUNITIES

NovaHep is intending to increase and speed up the company’s commercialisation of regenerative medicine, and is therefore looking for additional investments. The target for this series B round is USD 2-3M for Q4 2014.

In late 2015 another round of USD 4-5M will be raised.

MANAGEMENT

Petter Björquist, CEO, holds a PhD in Biology/Biochemistry from Gothenburg University. Ten years within AstraZeneca R&D in Cardiovascular Diseases, twelve years at Cellartis/Cellectis as VP Regenerative Medicine, responsible for e.g. the major collaboration with Novo Nordisk on development of a human embryonic stem cell derived beta cell treatment for diabetes.

Suchitra Sumitran-Holgersson, CSO and co-founder, Professor of Transplantation Biology, Sahlgrenska Academy, University of Gothenburg. She holds comprehensive experience with stem cell biology and transplantation biology. She is the co-inventor of the unique NovaHep technology.

Rickard Wright, CBO, MBA from the London School of Economics, and an Executive Masters Management of Technology with a focus on biotechnology from The Wharton School of Business & School of Engineering & Applied Sciences at the University of Pennsylvania. Eight years, Managing Director Newstock Capital, conducting licensing, M&A, and advisory services. Global healthcare fund manager for GE Technology Ventures, 5 years Co-founder & CEO of Therimunex. Three years Principal at Guardian Technology Partners, Chemical and Helathcare Intellectual Property Advisory.

Jannek Hagen, CFO, holds a M.Sc. in Finance & Strategic Management from Copenhagen Business School. He has worked in different positions within investment management in Denmark and in Switzerland for the past nine years and continues to work part-time as Project Manager for Alden Impact Capital AG.

Jan Holgersson, co-founder, Professor of Transplantation Immunology at Sahlgrenska Academy, University of Gothenburg, Director for the Tissue Typing and Stem Cell Labs at Sahlgrenska University Hospital. He is the co-founder of three biotech companies of which he is a board member.


ORGANISERSW

ELCOME


PANIES

t back :: next u

Novimmune SAwww.novimmune.com

CONTACTAdrian Mills Chief Business Office

ADDRESS 12 Chemin des Aulx 1228 Plans-les-Ouates Geneva 1228 Switzerland

TELEPHONE +41 22 839 7141

FAX +41 22 839 7142


YEAR FOUNDED1988

COMPANY PROFILE

Novimmune is a drug discovery and development company focused on the creation of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer.

The company was founded in 1998 by Dr. Bernard Mach, a world-renowned immunologist and inventor of cDNA cloning. After a lifetime of studying the intricate interactions between the human body and disease processes, he knew that much of the collateral damage caused by a great number of diseases occurred fairly late in the disease cascade. But, traditional drug therapy was then still largely focused on mitigating late-stage symptoms.

Dr. Mach’s vision, for Novimmune, was to create a cutting-edge biopharmaceutical company that would discover and create compounds which affected the disease process much further up the cascade. Instead of focusing on the consequences of the disease process, he wanted to go and attack the cause.

Bernard Mach

Dr. Bernard Mach founded Novimmune with the goal of creating compounds that would impact the underlying causes of disease rather than just treating a patient’s symptoms. Dr. Mach currently serves as the Chairman of the Scientific Advisory Board.

The Lombard Odier Venture Fund, and other angel investors, provided the company with its first round of seed capital and, by 2000, Dr. Jack Barbut had been recruited as the chief executive officer to execute on the vision and strategy. This effectively marked the turning point of Novimmune from a virtual company to an operational start-up.

Dr. Barbut, in turn, recruited a top-notch team which still forms the core of the company’s research and development efforts. Since then, the Novimmune family has grown to include a team of over 90 dedicated individuals representing more than 60 different fields of expertise.

To date, Novimmune has generated seven monoclonal antibodies designed to treat immune-related disorders. The pipeline is a balance of preclinical and clinical compounds, specific for clinically validated and novel targets. Each of these portfolio products has the potential of becoming a medicine for multiple medical conditions due to the intrinsic mechanism of action.

Five compounds are currently in early clinical development with the two most advanced in clinical Phase II.

In addition to these compounds, Novimmune has developed two unique and proprietary antibody generation platforms — a monoclonal antibody platform and a bispecific antibody platform — designed to streamline the identification, production, and characterization of fully-human antibodies. Two internal, bispecific antibody programs against undisclosed oncology targets have been initiated.

The company has also been purposefully targeting a number of orphan drug indications, with the express hope of eventually providing safe and effective treatment options to some of the often neglected populations suffering from rare diseases.

In 2009, Novimmune received the European Biotechnica Award in recognition of being the European biotechnology company with “the greatest future potential.” And, in 2010, the company signed an exclusive partnering agreement to co-develop its NI-1401 compound with Genentech / Roche. That compound completed Phase I clinical trials in 2013.

Novimmune is based in the Plan-les-Ouates suburb of Geneva, Switzerland, and maintains strong ties to a number of academic research institutions, including the University of Geneva.

Continued...


ORGANISERSW

ELCOME


PANIES

t back :: next u

Novimmune SAwww.novimmune.com

CONTACTAdrian Mills Chief Business Office

ADDRESS 12 Chemin des Aulx 1228 Plans-les-Ouates Geneva 1228 Switzerland

TELEPHONE +41 22 839 7141

FAX +41 22 839 7142


YEAR FOUNDED1988

...continued

PRODUCT PIPELINE

NI-0501 Fully Human IFN‐ Hemophagocytic lymphohistiocytosis (HLH) Phase II

NI-0401 Fully Human CD3‐ Transplant, other Phase II

NI-0801 Fully Human CXCL-10 (IP-10) Primary Biliary Cirrhosis (PBC), others Phase II

NI-1401 Fully Human IL-17 Autoimmunity — Partnered with Genentech Phase I

NI-0101 Humanized TLR4 Autoimmunity / Inflammation Phase I

NI-0701 Fully Human CCL5 (RANTES) Inflammation Phase I

NI-1201 Fully Human IL-6R Inflammation, other Pre-Clinical

NI-1701 ‐‐-body™ CD47/CD19 Acute lymphocytic leukemia (ALL)

Non-Hodgkin’s Lymphoma (NHL) Discovery

NI-1601 ‐‐-body™ Cancer Oncology — Kappa-Lambda Body (Bispecific) Discovery.

OPPORTUNITIES

NI-0101:TLR4 antibody, for RA, AKI, fibrosis

CD47+Tumour Associated Antgen bi-specific antibodies

NI-1701: CD47/CD19 B-cell antibody

NI-0401: CD3epsilon antibody, transplant GVH

MANAGEMENT

Jack Barbut, CEOAndrew Oakley, CFOChristina de Min, CMOMarie Kosco-Vilbois, CSOAdrian Mills, CBONatalie Mueller, Director Legal Affairs and IP


ORGANISERSW

ELCOME


PANIES

t back :: next u

Numab AG www.numab.com

CONTACTSOliver Middendorp Co-CEO, CBO

David Urech Co-CEO, CSO

ADDRESS Einsiedlerstrasse 34 Wädenswil 8820 Switzerland

TELEPHONE +41 445 330471


YEAR FOUNDED2011

COMPANY PROFILE

Numab’s lead program aims at developing an innovative antibody-based therapy for epithelial cancers and also carries a therapeutic promise for certain autoimmune diseases. This is done with a bi-specific antibody that specifically eliminates IL23R-positive cells through CD3-mediated recruitment of T killer cells. Numab’s CD3-binding moiety reveals best-in-class properties and is offered for licensing to interested parties.

Numab’s antibody fragment technology rapidly delivers highly potent antibody Fv fragments with excellent biophysical properties. These highly potent and stable Fv fragments are then used as modules to reproducibly assemble mono- or bi-specific antibody fragment-based therapeutics with predictably favorable CMC properties. Up to date Numab has modules against the following targets: IL23R, IL5R, TNF, CD3 and HSA (in progress).

PRODUCT PIPELINE

ND007 – preclinical bi-specific anti-IL23RxCD3 antibody fragment for the treatment of epithelial cancer with therapeutic promise in certain autoimmune diseases

ND003 – preclinical bispecific anti-IL5RxCD3 antibody fragment for the treatment of eosinophilic asthma

OPPORTUNITIES

ND007 – epithelial cancer and autoimmune diseases

ND003 – eosinophilic asthma

Effector Fv modules: anti-CD3, anti-HSA

Target Fv modules: anti-IL23R, anti-IL5R, anti-TNF

MANAGEMENT

David Urech, Co-CEO, CSOOliver Middendorp, Co-CEO, CBOTea Gunde, Head PharmacologySebastian Meyer, Head BiochemistryRoland Helfenstein, Head Finance & Administration


ORGANISERSW

ELCOME


PANIES

t back :: next u

Obexia AG www.obexia.com

CONTACTConrad Savoy, PhD, MBA CEO

ADDRESS Biozentrum, University of Basel Klingelbergstrasse 50 -70 Basel 4056 Switzerland

TELEPHONE +41 79 759 2089


YEAR FOUNDED2009

FINANCIAL SUMMARY

Open for investment of CHF 6.6 mio to move lead molecule OBX1201 from pre-clinical proof-of-concept to IND clearance.

COMPANY PROFILE

Obexia, “the weight switch company” (www.obexia.com) is a privately held spin-off from the Biocenter University of Basel. Obexia is dedicated to the development of innovative breakthrough therapies for cachexia (loss of body weight and muscle mass) and anorexia (appetite loss).

Obexia’s particular focus is on cancer cachexia and anorexia, also known as wasting syndrome, a frequent condition with a high unmet medical need. Cancer cachexia is associated with dramatically reduced quality of life and early death.

Obexia‘s lead compound OBX1201 is a single chain antibody fragment (scFv) which selectively blocks the melanocortin-4 receptor (MC4R), targeted to lead to appetite stimulation, increased body weight (muscle mass build-up) with the expected benefit for patients to improve quality of life and prolong survival. Pre-clinical proof-of-concept has been established in a relevant animal model.

Obexia is seeking investors to fund approx. CHF 6.6 million to accomplish the next development steps, leading to IND clearance.

PRODUCT PIPELINE

OBX1201, a monoclonal antibody fragment (scFv), a selective and potent melanocortin-4 receptor (MC4R) blocker;

pre-clinical proof-of-concept established

OPPORTUNITIES

OBX1201 (investment opportunity)

OBX1201 (outlicensing)

MANAGEMENT

Dr. Conrad Savoy, CEODr. Jean-Christophe Peter, CSODr. Pierre Vankan, Head of Development


ORGANISERSW

ELCOME


PANIES

t back :: next u

OCT www.oct-clinicaltrials.com

CONTACTSElena Startseva Head of Business Development

Anna Yanaeva Business Development Manager

ADDRESS 8/2 Bolshaya Moskovskaya str. St. Petersburg 191002 Russia

TELEPHONE +78124498635


YEAR FOUNDED2005

COMPANY PROFILE OCT is a leading mid-size contract research organization (CRO) in Europe and the US. With more than 90 people on staff, OCT provides drug development services to pharmaceutical, biotechnology, medical device and non-for-profit organizations.

Since 2005 OCT has been involved in a number of clinical trials programs which were placed in Russia, Ukraine, Bulgaria, Belarus, Latvia, Lithuania, Estonia, Georgia, Germany and the US. OCT provided program management and clinical development services for Phase I-IV clinical trials, as well as pre-clinical and bioequivalence studies. We advance a product through development and approval on time and within a client’s budget. Our experienced teams deliver quality results for our clients’ drug research and development needs which may vary from full clinical trial program to standalone CRO service like medical writing, consultancy, monitoring, data management or statistics.

OCT expertise includes more than 150 projects in a wide range of therapeutic areas, including but not limited to oncology, cardiology, pediatrics, endocrinology, ophthalmology and others.

MANAGEMENT

Dmitry Sharov, PresidentElena Startseva, Head of Business DevelopmentIrina Petrova, Clinical Operations Director


ORGANISERSW

ELCOME


PANIES

t back :: next u

Oncos Therapeutics Ltd oncos.com

CONTACTAntti Vuolanto COO

ADDRESS Saukonpaadenranta 2 Helsinki FI-00180 Finland

TELEPHONE +358 10 279 4000


FINANCIAL SUMMARY

The company’s lead investor is HealthCap. In addition, it has received significant non-dilutive funding.

COMPANY PROFILE

Oncos Therapeutics is a clinical stage cancer immunotherapy company with adenovirus-based platform technology. It’s lead product has recently obtained a clinical verification of an innovative mechanism of action. Due to synergistic action with other cancer therapies, (e.g. chemotherapies and checkpoint modulators) it will be developed as combination therapy rather than monotherapy. Unlike autologous tumor cell vaccines, Oncos products are off-the-shelf products and can be readily administered to the patient.

OPPOTUNITIES

Oncos is currently building a syndicate to raise $35M to take its lead asset through proof-of-concept in two indications and to make its follow-on product ready for clinic.

Oncos platform technology provides various partnering and out-licensing opportunities including co-development of certain assets.

MANAGEMENT

Frans Wuite MD MBA, President and Chief Executive Officer – ex Amgen Europe leadership team memberMagnus Jäderberg MD, Chief Medical Officer – ex CMO Bristol-Myers Squibb Europe Antti Vuolanto PhD, Chief Operations Officer – ex Mobidiag


ORGANISERSW

ELCOME


PANIES

t back :: next u

OncoSec Medical, Inc. oncosec.com

CONTACTDr. Robert H. Pierce Chief Medical Officer

ADDRESS 9810 Summers Ridge Road, Suite 110 San Diego 92121 USA

TELEPHONE +1 855 662 6732


COMPANY PROFILE

OncoSec is a biopharmaceutical company developing DNA-based intratumoral cancer immunotherapies. The company’s clinical programs currently include three Phase 2 trials targeting metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma, conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in these indications, it is also investigating additional indications and combination therapeutic approaches. For more information, please visit www.oncosec.com.

OPPORTUNITIES

Robust Pipeline

Strong Financial

Extraordinary Team

Comprehensive IP Portfolio

Broad Platform Applications

MANAGEMENT

Punit Dhillon, CEOVeronica Vallejo, CFODr. Robert Pierce, CMO


ORGANISERSW

ELCOME


PANIES

t back :: next u

Orphazyme ApS www.orphazyme.com

CONTACTAnders Hinsby CEO

ADDRESS Ole Maaløes Vej 3 Copenhagen 2200 Denmark

TELEPHONE +45 70 70 29 80

YEAR FOUNDED2009

COMPANY PROFILE

Orphazyme ApS (Copenhagen, Denmark) develops new therapies for the treatment of rare and genetic diseases.

The company is founded on the pioneering research from the laboratory of Professor Marja Jäättela, and with the aim of converting human chaperone proteins into effective therapies for degenerative diseases. Orphazyme’s novel technology also has the potential to address the neurodegenerative aspects of these devastating diseases.

Orphazyme’s core program is developing heat shock protein based therapies for the treatment of diseases caused by defects in the function and/or metabolism of proteins. The company focuses on severe and often fatal diseases with a very high unmet need.

PRODUCT PIPELINE

Lead project to start Phase II/III clinical Development in Niemann-Pick disease type C in Q1 2015.

MANAGEMENT

Anders Hinsby, CEOThomas Kirkegaard, CSOCarlos Camozzi, CMO


ORGANISERSW

ELCOME


PANIES

t back :: next u

ORYZON www.oryzon.com

CONTACTCarlos Buesa CEO

ADDRESS san ferran 74 cornella de llobregat Barcelona 08940 España

TELEPHONE +34 93 515 1313


FINANCIAL SUMMARY

Oryzon was founded in 2000 and has got 14M€ in different funding round plus 16 M€ in non refundable International and National Grants and soft public loans. In April 2014 inked a +526M USD deal with Roche to develop ORY-1001 for oncological diseases. the company is currently fully funded; however the company wants to use these resources as a platform to accelerate growth. With this goal, Oryzon has set up a more ambitious strategic plan 60M‐ (80M$) to accelerate ORY-2001 till Phase II-B, to broaden further our pipeline and to expand US operations with the idea of becoming a global leader in EPIGENETICS. This plan is opening new sequential rounds of funding and considering a transition from private to public in the next quarters and therefore we are welcoming American investors wanting to join a project with a huge upside.

COMPANY PROFILE

Oryzon is a Clinical Stage Biopharmaceutical company and the leader in EPIGENETICS in Europe. With one program in LSD1 in Phase I/IIA (ORY-1001) in oncology and other expected to enter in Clinical Phases in 2015 for Alzheimer’s Disease and other earlier programs in HMTs and KDMs. We are a global leader on Lysine Specific Demethylase-1 with a strong IP position (18 patent families, 4 already granted in US). LSD1/KDM1A has been proposed as a target for oncology, viral diseases and neurodegeneration. Our current Business model is to develop the assets till Phase II.

Oryzon is a dynamic, and capital efficient company with excellent know-how (28-30 people.) and it is considered the Biopharmaceutical company of reference in Spain. Its headquarters (2200sqm) in Barcelona have world class labs and offices. In 2014 the company sold its IVD Diagnostics affiliate concentrating its business in its therapeutic programs in epigenetics. The Company has a seasoned executive management with more than 120 years of overall experience in the industry at the CEO, CSO, BDO, IPO. MD and CFO positions.

The company is now developing ORY-2001 a dual bispecific LSD1-MAOB inhibitor for the treatment of Azheimer’s disease (a market of >11 Billion $/year) which has been able to stop the disease progression in animal models. Ory-2001 can also be develop for orphan indications as HD or Rett syndrom’s.

The company has incorporated an affiliate in the US (Cambridge, Massachusetts) in 2014.

PRODUCT PIPELINE

OPPORTUNITIES

ORY-2001 A program to enter in clinic next year for Ad

MANAGEMENT

Carlos Buesa, CEOTamara Maes, CSOEmili Torrell, BDONeus Virgili, IP DIRECTORCesar Molinero, CMO


ORGANISERSW

ELCOME


PANIES

t back :: next u

OssDsign AB www.ossdsign.com

CONTACTBo Qwarnstrom CEO

ADDRESS Virdings Allé 2 Uppsala 75450 Sweden

TELEPHONE +46 768 998587


YEAR FOUNDED2011

FINANCIAL SUMMARY

OssDsign is seeking investors in a third financing round, amounting to €7 M in two tranches (€2.5 and €4.5, respectively). Lead investor is Karolinska Development AB.

COMPANY PROFILE

OssDsign manufactures, develops and sells next generation products for better bone repair. The company is based in Uppsala, Sweden.

Based on its proprietary and disruptive platform technology, OssDsign´s vision is to make the company the cutting edge worldwide leader of solutions for better bone repair. OssDsign has started commercialization in Europe of its lead product A first US regulatory file has been submitted to the US FDA. The company is now raising capital in a third financing round to fund the next phase of the company´s commercial expansion.

PRODUCT PIPELINE

The first step in the company´s strategy is to establish a leading position for first product: OssDsign® Craniomosaic, the first implant allowing functional healing in cranioplasty, among neurological and craniofacial surgeons. Functional healing means integration between the synthetic implant material and surrounding tissues leading to better healing, less complication rates, higher quality of life for patients and reduced hospital costs.

The second step is to launch follow-up bone repair products, based on the company´s proprietary technology platform. Such follow-up products are currently in the regulatory process. Third step: together with strategic partners introduce OssDsign products on segments in general orthopedics and oral surgery.

OPPORTUNITIES

OssDsign is seeking investors in firms third financing round.

MANAGEMENT

Bo Qwarnstrom, CEOThomas Engstrand, CMOHåkan Engqvist, CSOEva Nicklasson, Manufacturing ManagerJonas Åberg, Development Manager


ORGANISERSW

ELCOME


PANIES

t back :: next u

OticPharma www.oticpharma.com

CONTACTOrna Palgi EVP R&D

ADDRESS 7 Oppenheimer St. Science Park Rehovot 7670107 Israel

TELEPHONE +972 73 290 5820


YEAR FOUNDED2008

FINANCIAL SUMMARY

Company established on 2008. Company backed by OrbiMed.

COMPANY PROFILE

Otic Pharma develops foam based products for ENT disorders. Clinical stage company. in preparation for Phase 3 with the lead product.

PRODUCT PIPELINE

1. FoamOtic Externa for the treatment of Otitis Externa. Phase 2 completed. in preparation for Phase 3.

2. FoamOtic Sinus for Chronic Sinusitis. research stage.

3. Foam-O-Vet for the treatment of Canine Otitis Externa. completed Phase 1.

4. FoamOtic Media for Otitis Media. at research stage.

OPPORTUNITIES

Invest in Otic Pharma

License out of FoamOtic Externa

License out of Foam-O-Vet

MANAGEMENT

Orna Palgi, PhD, Executive VP R&DRodrigo Yelin, PhD, Chief Operating OfficerAnat Nursella, CPA, Chief Financial OfficerGalit Itzhaki, B. Pharm, Clinical Director


ORGANISERSW

ELCOME


PANIES

t back :: next u

Palobiofarma S.L.www.palobiofarma.com

CONTACTDr. Julio Castro CEO

ADDRESS Tecnocampus Mataro, Avda Ernest Lluch 32 Barcelona 08302 Spain

TELEPHONE +34 93 169 6581


YEAR FOUNDED 2006

FINANCIAL SUMMARY

6 Mio € in equity raised so far in three financing rounds

COMPANY PROFILE

Palobiofarma discovers and develops novel drugs for different therapeutic indications based on the modulation of the adenosine receptors.

The company exhibit a very robust and diversified pipeline, with three compounds in clinical development for respiratory, oncological and CNS diseases.

PRODUCT PIPELINE

OPPORTUNITIES

PBF-680: A novel Adenosine A1 receptor antagonist for the oral treatment of asthma and COPD in Phase II

PBF-509: A novel adenosine A2a receptor antagonist for the treatment of lung cancer in Phase II

PBF-999: A dual A2a/PDE-10 inhibitor for the treatment of Huntington´s Disease in Phase I

MANAGEMENT

Dr. Julio Castro, CEODr. Juan Camacho, CSO


ORGANISERSW

ELCOME


PANIES

t back :: next u

PCI Biotech www.pcibiotech.no

CONTACTGael L’Heveder CBDO

ADDRESS strandveien 55 Lysaker N-1366 Norway

TELEPHONE +47 67 11 54 12


YEAR FOUNDED2008

COMPANY PROFILE

PCI Biotech is a clinical stage biopharmaceutical company developing products based on its patented photochemical internalization (PCI) platform technology. PCI is a triggered endosomal release technology. Photosensitive products are used to rupture endosomes to allow successful intracellular delivery of drugs.

PCI can enhance the delivery of all molecules taken into the cell by endocytosis. This includes most types of macromolecules, drugs carried by antibodies or nanoparticles, and some small molecule drugs.

The PCI technology is also a versatile and innovative vaccination platform, which may specifically increase the cytotoxic T-cell response of vaccines. This is important in therapeutic vaccination, when the immune system needs to recognise and destroy diseased cells (e.g. virus infected cells and cancer).

PCI Biotech follows a dual strategy to create value by realizing both the large potential of innovative therapeutics and untapped potential of existing cancer drugs.

PRODUCT PIPELINE

• Amphinex in two ongoing clinical oncology programs (phase II study in head & neck cancer and phase I/II study in bile duct cancer)

• The PCI technology is also a versatile and innovative vaccine immuno-potentiator, which may specifically increase the cytotoxic T-cell response of vaccines. This is important in therapeutic vaccination, when the immune system needs to recognise and destroy diseased cells (e.g. virus infected cells and cancer).

OPPORTUNITIES

PCI immuno-potentiator for cancer vaccination

Amphinex in head and neck cancer-phase 2

Amphinex in bile duct cancer-phase 1

MANAGEMENT

Per Walday, CEOAnders Hogset, CSORonny Skuggedal, CFOGael L’Heveder, CBDO


ORGANISERSW

ELCOME


PANIES

t back :: next u

PDC*Line Pharma www.pdcline-pharma.com

CONTACTSLaurent Levy CEO

Joel Plumas CSO

François Thomas Senior Advisor

ADDRESS c/o GATE1, Petite Halle 31 rue Gustave EIFFEL GRENOBLE 38000 FRANCE

TELEPHONE +33 6 34 36 77 47


YEAR FOUNDED2014

FINANCIAL SUMMARY

PDC*line Pharma was founded in April 2014 by Laurent LEVY and Joel PLUMAS.

PDC*line Pharma obtained 500 k€ in grants from 3 French awards obtained in 2014 (worldwide innovation challenge, national competition for innovative company creation, and “medical biotech” industrial plan).

PDC*line Pharma is seeking 2 m€ of equity capital (on top of grants) to reach significant milestones at the end of 2015:- Melanoma : phase 1 completed and ready to start phase 2- Lung Cancer : preclinical completed and ready to start phase 1 / 2

A total of about 10 m€ in grants and equity will be necessary to achieve proof of clinical activity in 2018, with a potential industrial deal with a pharma before that date.

COMPANY PROFILE

PDC*line Pharma SAS is a start-up that develops advanced therapeutic cancer vaccines based on a unique cell line of Plasmacytoid Dendritic Cells (PDC*line) with a first candidate in phase 1 clinical trial in melanoma. PDC*line Pharma is a spin-off of the French Blood Services (EFS).

Immunotherapy is revolutionizing cancer treatment and represents a global market potential of about 9 b‐ in 2023. Vaccines are an essential part of cancer immunotherapy strategy. Indeed they aim at inducing a potent T Cell immune response specifically targeted against tumor antigens in order to provide a safe and durable control of cancer disease. The only validated technology is based on Dendritic Cells (DC) with one approved drug, Provenge® (Dendreon) for prostate cancer. Present DC based vaccines are autologous cell therapies which face complex and costly logistics and lead to limited quantities of heterogeneous products.

PDC*vac is a breakthrough technology that overcomes autologous DC based cancer vaccine limitations thanks to PDC*line, a unique cell line of Plasmacytoid Dendritic Cells. PDC*line is fully qualified, safe, easy to expand and manipulate. It is loaded with peptides derived from a combination of tumor antigens expressed by the targeted cancer. The off-the-shelf vaccine is injected to induce a potent and targeted cytotoxic T Cell response against the tumor cells that express these antigens.

PDC*vac offers major advantages over conventional DC based vaccines in terms of scalability (production and logistics), versatility of application (loading of the tumour antigens according to the targeted cancer), and efficacy (higher potency of our PDC*line over classical DCs in preclinical models). PDC*vac also offers strong opportunities of synergies with other cancer therapies, especially immune checkpoint inhibitors such as anti-PD1.

The cancer opportunity is in the range 3 to 4,5 b‐ in US and EU for PDC*vac, including about 200 m‐ for advanced melanoma and 1,6 bn‐ for advanced lung cancer, our first 2 targeted markets.

PDC*line Pharma’s IP relies on 2 international patent families, PDC*line proprietary cell line, and the know-how accumulated since 2000 in R&D and manufacturing at the EFS.

PDC*line Pharma offers a unique investment opportunity:

– Very attractive market of cancer immunotherapy with potential synergies with non-specific immune activators (such as anti-PD1 monoclonal antibodies)

– Drug candidate already in clinical development in melanoma, a high-growth market.

– Spin-off from the EFS (French blood service) with access to its R&D and GMP infrastructures.

– Disruptive technology platform with broad IP protection and applicable to any cancer type.

– Small team of managers and experts with complementary academic and industrial experience.

– Proof of clinical activity in 2018 reachable with an about 10 m‐ in grant and equity should support an attractive return on investment for investors

Continued...


ORGANISERSW

ELCOME


PANIES

t back :: next u

PDC*Line Pharma www.pdcline-pharma.com

CONTACTSLaurent Levy CEO

Joel Plumas CSO

François Thomas Senior Advisor

ADDRESS c/o GATE1, Petite Halle 31 rue Gustave EIFFEL GRENOBLE 38000 FRANCE

TELEPHONE +33 6 34 36 77 47


YEAR FOUNDED2014

...continued

PRODUCT PIPELINE

PDC*line Pharma develops 2 programs:

– PDC*mel, our first clinical candidate is currently in phase 1 clinical trial in advanced stage melanoma. Phase 2 is forecast to start in 2016.

– PDC*lung, our next candidate is currently in early development for lung cancer. Phase 1 / 2 is forecast to start in 2016.

MANAGEMENT

Laurent Levy, MS, MBA, CEOJoel Plumas, PhD, CSOIsabelle Tabah-Fisch, MD, Senior Medical Advisor


ORGANISERSW

ELCOME


PANIES

t back :: next u

Pharmaco-kinesis Corporation www.pharmaco-kinesis.com

CONTACTFrank Adell CEO

ADDRESS 6053 West Century Boulevard Suite No. 1000 Los Angeles, California 90045 USA

TELEPHONE +1 310-641-2700

FAX +1 310-641-2702

EMAIL frank.adell @pharmaco-kinesis.com

YEAR FOUNDED2006

FINANCIAL SUMMARY

To date the company has raised $15,000,000. And, presently, is in process of raising additional $16,000,000.

COMPANY PROFILE

Metronomic Biofeedback Pump (MBP) - The Metronomic Biofeedback Pump (MBP) is a fully implantable smart infusion device, designed to locally deliver chemotherapies or medication over time to a target site. Current methods of treatment for brain cancer using chemotherapy require a patient to visit a doctor for twice weekly injections of relatively large quantities of the drug, causing spikes in the concentration present in the brain. The MBP seeks to improve on this by gradually delivering medication over time in smaller doses. This minimizes initial peak concentrations as well as maintains effective levels of the drug over the duration of the treatment. It has been shown in a recent study that continuous treatment with chemotherapy improves the therapeutic effect and reduces the complications that commonly occur during the course of treatment.

Nano-Impedance Biosensor Chip (NIB) - NIB chip is an extremely sensitive electrochemical Nano impedance spectroscopy-based biosensor which is capable to measure DNA, IRA, mRNA, protein, pathogen and various biomarkers related to diseases with sensitivity of measuring impedance signal 1.04 PicoAm when ten protein link to their anaylte.

PRODUCT PIPELINE

Metronomic Biofeedback Pump (MBP)

Nano-Impedance Biosensor (IB) chip

MANAGEMENT

Frank Adell, CEOJosh Shachar, Chief Innovation officerThomas Chen, MD, Ph.D., Chief Neuro-Oncology OfficerIan Welsford, Ph.D., Chief Regulatory and Compliance Officer Liangfang Zhang, Ph.D., Chief Nano-Engineering


ORGANISERSW

ELCOME


PANIES

t back :: next u

PhosImmune, Inc www.phosimmune.com

CONTACTThomas A. Haag, Ph.D., J.D. Acting CEO

ADDRESS 970 Old Ballard Rd. Charlottesville Virginia 22901 USA

TELEPHONE +1 202 706 7910


YEAR FOUNDED2012

FINANCIAL SUMMARY

PhosImmune has received an seed investment from the Virginia Center for Innovative Technology’s GAP BioLife Fund. PhosImmune is currently seeking additional investors and partners.

COMPANY PROFILE

PhosImmune, Inc. is a cancer immunotherapy company located in Charlottesville, VA and Birmingham, UK, founded to commercialize library of phosphopeptide tumor targets (PTTs) developed at the University of Virginia (UVa) and the University of Birmingham (UoB), UK. The Company was co-founded by Professors Donald Hunt and Vic Engelhard and Dr. Mark Cobbold. Phosphopeptide Tumor Targets are unique targets for cancer immunotherapy as they are highly expressed on cancer cells with low/no expression seen on normal cells, found on wide number of cancer types and derived from proteins involved in key pathways that underpin malignancy. Targeting them offers significant reduction in potential for tumor escape. A proprietary PTTs screening methodology allows for rapid identification and selection of PTTs for therapeutic applications. Existing/newly discovered PTTs may be exploited by mAb Therapy, TCR-based Therapy and PTT-based cancer vaccines.

PRODUCT PIPELINE

700+ Unique phosphopeptide tumor target (PTTs) expressed in melanoma, leukemia as well as colorectal, ovarian, breast, esophageal and lung cancers.

Six PTT specific cloned T cell Receptors.

OPPORTUNITIES

PhosImmune is interested in speaking with potential partners to collaborate on developing PTT-Specific mAbs and TCRs

PTT-specific cloned T cell receptors available for partnering

Participation in PhosImmune’s Advanced Seed Round

MANAGEMENT

Donald Hunt, Ph.D., PresidentThomas Haag, Ph.D., J.D., Acting Chief Executive OfficerKevin FitzGerald, Ph.D., MBA, Chief Business OfficerDean Fanelli, Ph.D., J.D., Acting Chief Operating OfficerJoyce Frey-Vasconcells, Ph.D, Regulatory consultant

Founders & Advisors:Dr. Victor Engelhard, Scientific FounderDr. Mark Cobbold, Scientific FounderDr. Drew Pardoll, AdvisorDr. Gary Middleton, Advisor


ORGANISERSW

ELCOME


PANIES

t back :: next u

PIQUR Therapeutics AG www.piqur.com

CONTACTSVladimir Cmiljanovic CEO

Gaudenz von Capeller CFO

ADDRESS Hochbergerstrasse 60C Basel 4057 Switzerland


YEAR FOUNDED2011

FINANCIAL SUMMARY

PIQUR has raised over USD 40 M in several financing rounds with private investors and Versant Ventures.

COMPANY PROFILE

Founded in 2011 in Basel (Switzerland), PIQUR is a biopharmaceutical company developing best-in-class, next generation cancer therapeutics targeting the PI3K-Akt-mTOR signal transduction network. The PI3K-Akt-mTOR cancer pathway is considered one of the three most important cancer pathways and is associated with many tumour types, including gliomas, thyroid, breast, non-small cell lung, gastric, gastrointestinal stromal, pancreatic and bile duct cancers. Challenges in this field have been the complexity of the inter-connections within the PI3K-Akt-mTOR pathway, drug-induced feedback loops, and pharmacological and galenic issues. Some 2nd generation agents have reached the clinic and have demonstrated that PI3K/mTOR inhibition is feasible – providing clinical proof of concept. However, these products have fallen short of efficacy and tolerance requirements and new generations of more effective and better tolerated agents are needed. PIQUR’s knowhow and leadership position, backed by its global network of PI3K development specialists, have been responsible for the creation of PIQUR’s novel 3rd and 4th generation cancer-fighting agents that have overcome the complex dual PI3K-mTOR inhibition and physico-chemical problems faced by other companies, providing optimal therapies, tailored to the unique needs of each cancer. . In January 2014 PIQUR launched the clinical Phase I study with the active ingredient PQR309; the first results of the study are anticipated in the fourth quarter of 2014.

PRODUCT PIPELINE

PQR309 Oncology Phase IA

MANAGEMENT

Vladimir Cmiljanovic, CEOGaudenz von Capeller, CFO


ORGANISERSW

ELCOME


PANIES

t back :: next u

ProFactor Pharma Ltd profactorpharma.com

CONTACTRichard Cruse CEO

ADDRESS BioCity Scotland Bo’ness Road Newhouse ML1 5UH Scotland

TELEPHONE +44 1698 537855

EMAIL richard.cruse @profactorpharma.com

YEAR FOUNDED2009

FINANCIAL SUMMARY

Founders 2009

Seed 2011 £200k

Angel investor and Scottish Investment Bank 2013/14 £900k

COMPANY PROFILE

ProFactor Pharma is developing a low cost production process for the manufacture of recombinant human Factor VIII using its patented, very high expressing cell line in modern single use/disposable technologies.

PRODUCT PIPELINE

Current sales of rhFVIII are ~$5BN. Plasma derived FVIII takes the total market to over $7BN.

And yet, three quarters of the world’s haemophiliacs receive inadequate or no treatment at all! The reason for this is two fold: it’s too expensive for many; but more importantly, there just isn’t enough to go around.

OPPORTUNITIES

Factor VIII production process

Factor VIII distribution

MANAGEMENT

Richard Cruse, CEODr Ian Garner, CSODr David Brown, NEChairDr John McVey, Chief Science AdvisorBruce Vernon, QP/QA/QCHigh Ilyine, BD


ORGANISERSW

ELCOME


PANIES

t back :: next u

: next u

RECARDIO GmbH www.recardio.eu

CONTACTDr. Roman Schenk CEO

ADDRESS Lakeside B01A Klagenfurt 9020 Austria


YEAR FOUNDED2011

COMPANY PROFILE

RECARDIO is an Austria based life science company. It is focusing on regenerative therapeutic modalities for the treatment of cardiovascular diseases. RECARDIO (REgenerative CARDIOvascularar Therapy) was founded in 2011. After establishing proof-of-principle in vivo and completion of the preclinical development, it has entered clinical stage and is developing multiple therapeutic leads as the future regenerative medication for patients with various cardiovascular diseases, with the potential of improving their cardiac function, quality of life and survival..

PRODUCT PIPELINE

Cardiogliptin (clinical)

REC-02 (pre-clinical)

REC-03 (pre-clinical)

OPPORTUNITIES

Cardiogliptin

MANAGEMENT

Roman Schenk, CEOMartin Fleckenstein, CMO


ORGANISERSW

ELCOME


PANIES

t back :: next u

RedHill Biopharma www.redhillbio.com

CONTACTAdi Frish Senior VP Business Development and Licensing

ADDRESS 21 Ha’arba’a St., Tel-Aviv 64739 Israel

TELEPHONE +972-3-541-3131

FAX +972-3-541-3144


YEAR FOUNDED2009

COMPANY PROFILE

RedHill Biopharma Ltd. (NASDAQ: RDHL) (TASE: RDHL) is an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers. RedHill’s current pipeline of proprietary products includes: (i) RHB-104 - an oral combination therapy for the treatment of Crohn’s disease, with an ongoing Phase III study; (ii) RHB-105 - an oral combination therapy for Helicobacter pylori infection, with an ongoing Phase III study; (iii) RHB-102 - a once-daily oral pill formulation of ondansetron for the prevention of nausea and vomiting in advanced stages of development for multiple indications, including a European marketing application for chemotherapy and radiotherapy-induced nausea and vomiting planned for the third quarter of 2014. In addition, a Phase III study for an undisclosed indication is planned to commence in the third quarter of 2014, (iv) RHB-106 - an encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v) MESUPRON® - a Phase II-stage uPA inhibitor, administered by oral capsule, targeting gastrointestinal and other solid tumor cancers; (vi) RP101 - currently subject to an option-to-acquire by RedHill, RP101 is a Phase II-stage Hsp27 inhibitor, administered by oral tablet, targeting pancreatic and other gastrointestinal cancers; (vii) RHB-103 - an oral thin film formulation of rizatriptan for acute migraines with a U.S. NDA under FDA review and a European marketing application planned for the third quarter of 2014; and (viii) RHB-101 – a once-daily oral pill formulation of the cardio drug carvedilol.

PRODUCT PIPLINE

RHB-103 – an oral thin film formulation of rizatriptan for acute migraines with a U.S. NDA under FDA review and a European marketing application planned for the third quarter of 2014

RHB-104 – an oral combination therapy for the treatment of Crohn’s disease, with an ongoing Phase III study in the U.S., Canada and Israel. RHB-104 is also undergoing a Phase IIa proof-of-concept study in multiple sclerosis.

RHB-105 – an oral combination therapy for Helicobacter pylori infection, with an ongoing Phase III study in the U.S.

RHB-102 – a once-daily oral pill formulation of ondansetron for the prevention of nausea and vomiting in advanced stages of development for multiple indications, including a European marketing application for chemotherapy and radiotherapy-induced nausea and vomiting planned for the third quarter of 2014. In addition, a Phase III study for an undisclosed indication is planned to commence in the third quarter of 2014.

RHB-101 – a once-daily oral pill formulation of the cardio drug carvedilol.

RHB-106 – an encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals, Ltd.

MESUPRON® – a Phase II-stage uPA inhibitor, administered by oral capsule, targeting gastrointestinal and other solid tumor cancers;

RP101 – currently subject to an option-to-acquire by RedHill, RP101 is a Phase II-stage Hsp27 inhibitor, administered by oral tablet, targeting pancreatic and other gastrointestinal cancers.

OPPORTUNITIES

RHB-101

RHB-102

RHB-103

RHB-105

MANAGEMENT

Dror Ben-Asher, CEOOri Shilo, Deputy CEO, Finance and OperationsReza Fathi PhD, Senior VP R&DGilead Raday, Senior VP Product and Corporate DevelopmentAdi Frish, Senior VP Business Development and LicensingGuy Goldberg, Chief Business OfficerIra Kalfus MD, Medical Director


ORGANISERSW

ELCOME


PANIES

t back :: next u

Re-pharm www.re-pharm.com

CONTACTDr. Robert Scoffin CEO

ADDRESS New Cambridge House Bassingbourn Road Litlington SG8 0SS UK

TELEPHONE +44 (0) 1223 858890


COMPANY PROFILE

We believe that there is unmet medical need that can be profitably treated by using a smart approach to drug re-profiling.

Our pharmacologists and chemists work with patented computational techniques to identify and evaluate re-profiling opportunities.

We have active projects across diverse therapeutic areas in varying stages of pre-clinical development.

PRODUCT PIPELINE

MANAGEMENT

Dr. Robert Scoffin, Co-Founder and Chief Executive OfficerDr. Alan Rothaul, Co-Founder and Chief Scientific OfficerDr. David Bardsley, Chief Business Officer


ORGANISERSW

ELCOME


PANIES

t back :: next u

Reviva Pharmaceuticals, Inc. www.revivapharma.com

CONTACTLaxminarayan Bhat, PhD Founder and CEO

ADDRESS 3900 Freedom Circle, Suite 101 Santa Clara, California 95054 USA

TELEPHONE +1-408-816-1454

FAX +1-408-904-6270


YEAR FOUNDED2006

COMPANY PROFILE

Reviva Pharmaceuticals, Inc., (Reviva) headquartered in Santa Clara, California, is a fast growing privately held, late-stage clinical development pharmaceutical company. Reviva is developing a portfolio of internally discovered next generation innovative therapies using chemical genomic driven approaches and proprietary technologies that addresses unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic and inflammatory diseases. Reviva has a strong patent portfolio and promising multiple products in the pipeline at various stages of development.

Speed without sacrificing quality is one of the hallmarks of Reviva’s product development model. Reviva leadership and management team comprised of highly successful and experienced professionals in the pharmaceutical industry and have a demonstrated track record of taking drugs through the development process to the global market. Some of our team members contributed to the development of blockbuster category drugs currently in the global market.

OPPORTUNITIES

Reviva is interested in partnering and/or licensing opportunities for its lead product, RP5063, a broad-spectrum antipsychotic currently in Phase 3 development for schizophrenia, for the US and/or global territories.

MANAGEMENT

Dr. Laxminarayan Bhat, Chief Executive OfficerMr. Partha R. R. Sarathy, Chief Financial OfficerDr. Marc Cantillon, Chief Medical OfficerDr. Sarath Kanekal, Vice President Regulatory and DevelopmentMs. Ellen M. Wallis, Vice President Business Development and Commercialization


ORGANISERSW

ELCOME


PANIES

t back :: next u

Rexahn Pharmaceuticalswww.rexahn.com

CONTACTVikas Sharma, Ph.D. Director, Business Development

ADDRESS 15245 Shady Grove Rd, Suite 455 Rockville 20878 USA

TELEPHONE +1 24 026 85300

COMPANY PROFILE

Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN) is a clinical stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. Rexahn’s cancer drugs have been shown to directly target cancer cells while bypassing healthy cells, demonstrating increased efficacy and reduced toxicity. These drug candidates are effective against multiple drug resistant cancers and show they can work together with FDA approved cancer treatments to increase efficacy. Rexahn is also developing specific biomarkers that identify which patients will be most responsive to its treatments. The Company’s nanotechnology-based drug delivery system has shown it can make FDA approved chemo drugs more effective.

PRODUCT PIPELINE

Archexin® is a unique anti-cancer drug candidate which inhibits the activated form of the cancer cell signaling protein phosphorylated-Akt1 which is only found in cancer cells and is involved in cancer cell growth, survival, angiogenesis, and drug resistance. Archexin has completed a Phase I clinical trial in cancer patients and was shown to be safe and well tolerated. The dose-limiting toxicity was grade three sedation. In a small Phase IIa trial in advanced pancreatic cancer patients, Archexin in combination with gemcitabine was shown to be safe and well tolerated and demonstrated a preliminary efficacy signal with a median survival of 9.1 months. Rexahn initiated an additional Phase IIa clinical trial in cancer patients with metastatic renal cell carcinoma in January 2014.

RX-3117 is a Next Generation cancer cell specific cytotoxic agent that inhibits DNA and RNA synthesis and induces apoptotic cell death specifically in cancer cells by a mechanism distinct from other DNA synthesis inhibitors. Preclinical studies have shown it be effective in inhibiting the growth of solid tumors in the pancreas, lung, colon, renal and others and to be effective in gemcitabine resistant cancer cells. An exploratory Phase I clinical trial in cancer patients was conducted in Europe in 2012 and demonstrated that RX-3117 is orally bioavailable and no adverse events were reported over the dose range tested. Rexahn initiated a Phase Ib clinical trial in cancer patients with solid tumors in December 2013.

RX-5902 (Supinoxin) is an orally administered highly potent first-in-class anti-cancer small molecule that eliminates cancer cells through inhibition of phosphorylated p68 which is found only in cancer cells. Studies to date have shown it to be effective in tumor progression and metastasis for melanoma, cancers of the ovary, kidney and pancreas. A Phase I clinical trial with Supinoxin in cancer patients began in August 2013. This trial is a multi-center study, designed to evaluate the safety, tolerability, dose-limiting toxicities and maximal tolerated dose (MTD) and preliminary efficacy in patients with solid tumors.

RX-21101 is a nano-polymer anticancer drug that combines its nano-drug delivery system with docetaxel, a widely used FDA approved chemo drug. RX-21101 may bolster efficacy while lowering toxicity of FDA approved chemo drugs by specific tumor targeting and increased stability in the body. Potential indications include breast, ovarian, prostate and lung cancer.

OPPORTUNITIES

RX-5902 - Phase I

RX-3117 -Phase I

Archexin - Phase II


ORGANISERSW

ELCOME


PANIES

t back :: next u

Russian Pharmaceutical Technologies LLCruspharma.com/eng.html

CONTACTIlya Tsimafeyeu Scientific Advisor

ADDRESS Griboyedov canal nab. 130 Liter A, off. 202 Saint Petersburg 190121 Russia

TELEPHONE +79265 646581


YEAR FOUNDED 2012

COMPANY PROFILE

Russian Pharmaceutical Technologies LLC is a research and development start-up company focused on transforming innovative scientific discoveries into novel therapeutic agents.

PRODUCT PIPELINE

RPT835, first-in-class allosteric inhibitor of fibroblast growth factor receptor 2

Indication: FGFR2-expressing tumors

Stage of development: Late-preclinical studies

Expected date of Phase I/II clinical study: February 2015

MANAGEMENT

Russian and World experts in oncology and drug development


ORGANISERSW

ELCOME


PANIES

t back :: next u

Sareum Ltdwww.sareum.co.uk

CONTACTDr Tim Mitchell CEO

ADDRESS 2a, Langford Arch Cambridge CB22 3FX UK

TELEPHONE +44 (0) 1223 497700


YEAR FOUNDED 2003

COMPANY PROFILE

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, with a focus on cancer and auto-immune disease.

Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers. Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum’s drug discovery technology platform that has so far produced the Company’s Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL® can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR.

PRODUCT PIPELINE

Chk1 kinase inhibitor, targeting solid tunmours, neuroblastoma, AML & lymphoma, in preclinical development

Aurora+FLT3 kinase inhibitor, targeting AML, in preclinical development

TYK2/JAK1 kinase inhibitor, targeting autoimmune diseases, in late lead optimisation.

OPPORTUNITIES

Chk1 kinase inhibitor, targeting solid tunmours, neuroblastoma, AML & lymphoma, in preclinical development

Aurora+FLT3 kinase inhibitor, targeting AML, in preclinical development

TYK2/JAK1 kinase inhibitor, targeting autoimmune diseases, in late lead optimisation.

Seeking co-development opportunities at late lead optimisation / preclinical / early clinical stages

Seeking investment, circa. $12M

MANAGEMENT

Dr Paul Harper, ChairDr Tim Mitchell, CEODr John Reader, CSO


ORGANISERSW

ELCOME


PANIES

t back :: next u

Scancellwww.scancell.co.uk

CONTACTDr Richard Goodfellow CEO

ADDRESS Scancell Ltd Dept Clinical Oncology Nottingham NG5 1PB United Kingdom

TELEPHONE +44 115 823 1863


PRODUCT PIPELINE

SCIB1

Cancer vaccine in Phase 1/2 clinical trials for melanoma

SCIB2 – preclinical cancer vaccine targeting NY-ESO-1

Moditope cancer vaccine platform


ORGANISERSW

ELCOME


PANIES

t back :: next u

Scil Proteins GmbHwww.scilproteins.com

CONTACTDr. Henning Afflerbach CEO

ADDRESS Heinrich-Damerow-Str. 1 Halle/Saale 06120 Germany

TELEPHONE +49 345 27996 330

FAX +49 345 27996 332


YEAR FOUNDED1999

FINANCIAL SUMMARY

Scil Proteins was founded in 1999 at the Technology and Founder Center in Halle/Saale, Germany. The company is fully owned by BioNet Ventures GmbH. In 2014 BioNet Ventures sold Scil Proteins’ sister company and microbial manufacturing specialist Scil Proteins Production to Wacker Biotech GmbH. Bionet Ventures remains the only shareholder of Scil Proteins.

COMPANY PROFILE

Scil Proteins is a private protein engineering company that is focused on generating and optimizing unique Affilin®-based protein therapeutics and non-therapeutic applications using its proprietary flexible and modular Affilin® platform for partners in the pharmaceutical, biotech and life science industries. Affilin®-based molecules are derived from human scaffold proteins and have high stability, affinity and specificity making them ideal for a range of applications that demand targeting and capturing of biomolecules. The unique properties of these Affilin®-based molecules overcome several of the limitations of antibodies, especially in specific niche applications.

The company’s core business areas include the development of drug conjugates and multi-specific protein binding molecules, as well as ligands for non-therapeutic applications. All of these core areas are underpinned by state-of-the-art protein engineering technologies and a team with an unrivalled depth of expertise and track record in this area, making Scil Proteins an attractive partner.

OPPORTUNITIES

Affilin Drug Conjugate Technology

Multispecific Affilin Technology

Affilin-Antibody Chimera Technology

Affinity Purification

Bead Based Cell Capturing

MANAGEMENT

Dr. Henning Afflerbach, CEODr. Ulrich Haupts, CSO


ORGANISERSW

ELCOME


PANIES

t back :: next u

Serodus ASAwww.serodus.com

CONTACTTrygve Gulbrandsen CSO

ADDRESS Gaustadalléen 21 Oslo N-0349 Norway

TELEPHONE +47 2295 8191


YEAR FOUNDED2008

COMPANY PROFILE

Serodus is a biomedical company listed on Oslo Stock Exchange (SER). The company is focusing on cardiovascular therapeutics with large unmet needs.

PRODUCT PIPELINE

SER100 clinical phase IIa completed in patients with isolated systolic hypertension.

SER150 phase IIa under initiation for the treatment of diabetic nephropathy.

SER130 in preclinical development, intended for cardiac infarction.

SER140 in pharmacology studies, intended for treatment of type 2 diabetes.

OPPORTUNITIES

SER100 open for outlicensing

MANAGEMENT

Eva Steiness, CEOTore Kvam, CFOTrygve Gulbrandsen, CSOTorben Skarsfeldt, Sen. PM


ORGANISERSW

ELCOME


PANIES

t back :: next u

Synthena AGwww.synthena.com

CONTACTDr. Wolfgang Renner CEO

ADDRESS Freiestrasse 3 Bern 3012 Switzerland

TELEPHONE +41 79 219 96 70


YEAR FOUNDED 2012

FINANCIAL SUMMARY

CHF 10 million series A

COMPANY PROFILE

Synthena AG is a privately held, Swiss biopharmaceutical company focused on the development of new tricycloDNA based oligonucleotide drugs for the treatment of severe neuromuscular diseases. Its lead product SYN01 is in preclinical development for Duchenne muscular dystrophy, where it has shown unprecedented efficacy in restoring skeletal muscle, respiratory, cardiac and cognitive functions in different animal models. Further research programs are ongoing in Spinal Muscular Atrophy, Steinert’s disease, and Pompe disease. Synthena has raised over CHF 10 million in series A financing.

PRODUCT PIPELINE

SYN01: DMD exon 51, preclinical



OPPORTUNITIES

Partnering our DMD franchise

Partnering our lead compound for Pompé disease

MANAGEMENT

Wolfgang Renner, CEOLuis Garcia, CSOBrano Dugovic, CTOAdrian Häberli, Head QC


ORGANISERSW

ELCOME


PANIES

t back :: next u

Takis s.r.lwww.takisbiotch.it

CONTACTLuigi Aurisicchio, Chief Executive and Scientific Officer

ADDRESS via Castel Romano, 100 Rome 00128 Italy

TELEPHONE +39 06 50576077

FAX +39 06 50576710


YEAR FOUNDED 2009

FINANCIAL SUMMARY

Takis currently acts as a CRO and employes 11 FTEs. The company is in a growing phase and the estimated annual turnover will be around 1.5M‐.

Takis financing need to develop its pipeline for a Round A (first two year plan) is of approximately 4.7 million euros.

These financing needs should be covered through capital injection paid in 2 instalments:• 1st capital injection of Euro 2.2M: at the positive conclusion of the investment deal (beginning of the 1st year

of the plan);• 2nd capital injection of Euro 2.5M: at the end of year 1 of the plan

Takis financing need for the Round B (3rd and 4th year of the plan) is of approximately 4.9 million euros.

COMPANY PROFILE

Takis is a biotech Company created In November 2009 as a spin off from IRBM (Istituto di Ricerche di Biologia Molecolare P. Angeletti), a Research Center in Italy near Rome, formerly part of the global network of Merck Research Laboratories (MRL).

The group has more than 10 years experience and an established track record in drug discovery, having contributed to the development of new drugs for the treatment of viral diseases and cancer and to a number of IND/CSA filings in the areas of virology and oncology. The team is also recognized for the conception and implementation of a number of innovative technologies.

Takis as a Biotech pursues the discovery and development of innovative Therapeutic Cancer Vaccines based on a proprietary Adeno vector-prime DNA-boost platform technology, leveraging on its strong track record in drug discovery. Takis’ frontline candidates are three therapeutic cancer vaccines targeting distinct tumor antigens. The vaccine candidates have completed pre-clinical development and are ready for translation to the clinic.

One of the main assets of Takis is the expertise in in vivo electro-gene-transfer, which can be used for a variety of clinically useful applications, from vaccine development to somatic gene therapy. Takis is actively involved in the generation of humanized monoclonal antibodies for use in Oncology and Infectious Diseases.

PRODUCT PIPELINE

TK-001: cancer vaccine targeting a well-known oncogene overexpressed in a significant proportion of frequent tumors such as breast, ovarian, gastric cancers. Major therapeutic indications for this product are: breast, ovarian and gastric cancers.

TK002: cancer vaccine targeting a tumor stromal antigen overexpressed in a high percentage of several tumor types such as gastric, breast, lung, pancreatic. Albeit we believe this to be a universal tumor antigen, prioritized indications for development will be colon, gastric and pancreatic cancers.

TK003Mab: a family of monoclonal antibodies targeting a transmembrane receptor with a significant role in the tumor resistance to chemotherapy agents and in the biology of cancer stem cells.

TK004: a veterinary Cancer Vaccine targeting Telomerase, an Universal tumor associated antigen. Trials are ongoing with canine B cell and T cell lymphomas and other solid tumors.

Continued...


ORGANISERSW

ELCOME


PANIES

t back :: next u

Takis s.r.lwww.takisbiotch.it

CONTACTLuigi Aurisicchio, Chief Executive and Scientific Officer

ADDRESS via Castel Romano, 100 Rome 00128 Italy

TELEPHONE +39 06 50576077

FAX +39 06 50576710


YEAR FOUNDED 2009

...continued

OPPORTUNITIES

TK001

TK002

TK003Mab

TK004

MANAGEMENT

Luigi Aurisicchio, CEO/CSOGiuseppe Roscilli, Director, Drug Testing and Monoclonal Antibodies.Emanuele Marra, Director, Cancer Vaccines and Biomarkers


ORGANISERSW

ELCOME


PANIES

t back :: next u

Targeted Medical Pharma, Inc.tmedpharma.com

CONTACTSDr. William Shell Chairman of the Board Chief Executive Officer Chief Scientific Officer

Cassandra Evans Executive Assistant

ADDRESS 2980 Beverly Glen Circle, Ste. 301 Los Angeles 90077 USA

TELEPHONE +31 0474 9809


YEAR FOUNDED 1999

FINANCIAL SUMMARY

The Company posted increased revenues, gross profit and an increase in net income before interest, taxes, depreciation and amortization, and stock based compensation (Adjusted EBITDA*) on a quarter-over-quarter basis.

A copy of Targeted Medical Pharma’s quarterly report on Form 10-Q for the three months ended June 30, 2014, filed with the Securities and Exchange Commission on August 14, 2014, is accessible on the Company’s website at www.tmedpharma.com and at the SEC’s website at www.sec.gov.

COMPANY PROFILE

Targeted Medical Pharma, Inc. (“TMP”; OTCQB: TRGM) is a publicly traded, Los Angeles-based biotechnology company that is committed to drug discovery and development. The company currently develops and distributes amino acid based medical foods, a rapidly growing sector of medication technology, for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders using the patented system of Targeted Cellular Technology.

The company also develops a line of dietary supplements designed to support health and wellness. TMP currently manufactures 10 proprietary amino acid based medical foods, and recently launched its first dietary supplement, Clearwayz™. The products are sold directly to physicians and pharmacies in the U.S. The Company is also developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.

Targeted Medical Pharma and its subsidiary companies, Complete Claims Processing and Physician Therapeutics, provide healthcare practitioners and patients with clinically proven therapies required to safely and effectively manage disease without harmful side effects.

We are committed to delivering long-term value to investors by maintaining disciplined cost controls, optimizing capital investment and adhering to the highest standards of corporate governance.

PRODUCT PIPELINE

Product Indication

ASD-AA – Autism

ESS-1818 – Chronic Anemia

Pulmona New Asthma

Oral IGF1 – Diabetes

PARK -AA – Parkinson’s Disease

ALZ- AA – Alzheimer’s Disease

MANAGEMENT

William Shell M.D., Chairman of the Board, CEO and Chief Scientific Officer David Silver, M.D. Board Member, President and Chief Operating Officer William B. Horne, Chief Financial OfficerDouglas Gintz, Chief Technology and Information Officer


ORGANISERSW

ELCOME


PANIES

t back :: next u

Themis Bioscience GmbHwww.themisbio.com

ADDRESS Muthgasse 11/2, 1190 Vienna Austria

TELEPHONE +43 1 236 7151


COMPANY PROFILE

Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases.

We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.

Themis’ core lead technology, Themaxyn™ – a highly novel, patent-protected, and innovative vaccine platform which originates from a world-leading European vaccine research institute – will be used to create novel vaccines. The Company’s first vaccine targets are emerging tropical and travelers diseases, including dengue, chikungunya and yellow fever virus, and there is clear potential to expand the Themaxyn™ technology to further indications.

Themis was founded in September 2009 and is based in Vienna. The founders and management team includes experienced vaccine experts with successful, established track records in the biotechnology industry and have worked alongside each other for a number of years.


ORGANISERSW

ELCOME


PANIES

t back :: next u

To-BBBwww.tobbb.com

CONTACTDr. Carlos de Sousa Chief Business Officer

ADDRESS J.H. Oortweg 19 Leiden 2333 CH The Netherlands

TELEPHONE +31 71 332 2255


YEAR FOUNDED 2003

FINANCIAL SUMMARY

Investors in to-BBB include Aescap Venture, Antea Participaties, Jonghoud International and the Industrial Bank of Taiwan Management Corporation (IBTM).

COMPANY PROFILE

to-BBB is a clinical stage biotechnology company developing novel treatments for devastating brain disorders, such as brain cancer and neuroinflammatory diseases. The Company combines existing drugs with to-BBB’s proprietary G-Technology® for enhanced drug delivery across the blood-brain barrier.

to-BBB currently has two products in clinical trials: its lead product 2B3-101 is in a Phase IIa trial in Europe and the US for the treatment of primary brain tumors as well as brain metastases; the second product 2B3-201 for MS relapses and other neuroinflammatory diseases is completing a Phase I clinical study.

to-BBB is headquartered in the Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan.

PRODUCT PIPELINE

• 2B3-101: brain-targeted liposomal doxorubicin, currently in a Phase IIa trial for the treatment of breast cancer brain metastases and malignant glioma (incl. glioblastoma multiforme), with subsequent pivotal studies to the market planned in these indications.

• 2B3-201: brain-targeted liposomal methylprednisolone, currently in a Phase I trial in healthy volunteers, with a subsequent fast development path to the market for MS acute relapses and other neuroinflammatory diseases (incl. uveitis and neuropathic pain) under a 505(b)(2) submission.

• Additional product propositions for devastating brain diseases are in early preclinical development, based on combining existing drugs with the G-Technology.

OPPORTUNITIES

Mezzanine round H2 2014

Licensing 2B3-101 for Brain Cancer

MANAGEMENT

Leonard Kruimer, CFO, acting CEOPieter Gaillard, CSOCarlos de Sousa, CBOPericles Calias, Senior VP Translational Medicine


ORGANISERSW

ELCOME


PANIES

t back :: next u

ugichem GmbHwww.ugichem.com

CONTACTHolger Bock CEO

ADDRESS Mitterweg 24 Innsbruck 6020 Austria

TELEPHONE +43 512 282285 10

FAX +43 512 282285 11


YEAR FOUNDED 2003

FINANCIAL SUMMARY

Funding to date: €12M

COMPANY PROFILE

ugichem GmbH designs and develops antisense therapeutics called Ugimers® that reach targets in tissues not accessible by competing technology and that have the potential to reach targets considered otherwise undruggable. Ugimer® tissue targeting can be customised through the use of our proprietary modular chemistry, discovered and refined by ugichem to 3rd generation sophistication with bulk production protocols in place.

Proof of concept has been demonstrated with Ugimers® in several animal disease models and human cells. In kidney, for example, Ugimers® have a 10-fold increased efficacy and a 20-fold higher potency comparing to standard antisense. Customising the modular Ugimer chemistry furthermore enables several-fold tissue specific improvements of efficacy profiles. These results have been achieved without the need for transfer agents and demonstrate a good safety profile with no overt signs of immunogenicity nor hepatotoxicity recorded to date.

ugichem is progressing its own R&D pipeline, is conducting studies with big pharma and biotech partners (undisclosed) and seeks additional R&D collaborations. ugichem invites participation from investors in its ongoing C-round.

OPPORTUNITIES

R&D collaborations: Antisense Drug Development Platform: Ugimers®

Immune-cell based diseases: Inflammation, autoimmune diseases, disorders associated with T cell regulation

Rare genetic diseases

MANAGEMENT

Holger Bock, CEOThomas Lindhorst, CSOJürgen Soutschek, CTOLynn Butler-David, CBOBirgit Werner, Head Chemistry


ORGANISERSW

ELCOME


PANIES

t back :: next u

VBI Vaccineswww.vbivaccines.com

CONTACTJeff Baxter CEO and President

ADDRESS 222 Third Street, Suite 2241 Cambridge MA 02142TELEPHONE +(617) 830-3031


YEAR FOUNDED 2001

FINANCIAL SUMMARY

VBI Vaccines is a publicly traded company, listed on NASDAQ (ticker symbol: VBIV). VBI recently completed private placements totaling $16.25M and entered into a credit agreement for a secured debt facility up to $6M. The latest financial statements are available under the Investor section of the VBI Vaccines website.

COMPANY PROFILE

VBI Vaccines is an emerging stage vaccine development company based in Cambridge, MA with research and development in Ottawa, Canada.

PRODUCT PIPELINE

Prophylactic CMV eVLP Vaccine: • Stimulates a potent neutralizing antibody response against CMV in clinically relevant cell types• Currently in late stage preclinical development• GMP tech transfer underway for Phase I clinical trials

This asset is financed through to the end of Phase I clinical trials.

Thermostable LPV™ Technology for Vaccines & Biologics:

LPV™ technology has an established safety profile including relevant preclinical toxicology and phase I clinical results. Key proof of concept data includes:• Stabilization of Flu (split virus) for 12 months at 40C• Stabilization of Rabies (whole killed) for 18 months at 40C• Stabilization of MMR (live attenuated virus) for 8 weeks at 37C• Stabilization of Her2 mAb (monoclonal) for 8 weeks at 40C

LPV™ technology enables differentiated product offerings & unique attributes:• Patient Access - enables safe storage & transfer outside of cold-chain• Patient Safety - reduced risk of spoilage & out-of-spec vaccination• Patient Convenience & Adherence - Portable, convenient dosing regimens for biologics

This technology is available for evaluation with a partners’ proprietary pipeline products.

HCV eVLP Vaccine

The vaccine is envisioned as a therapeutic vaccine that could replace use of interferons in regions (Southeast Asia/China, Russia) with high HCV incidence rates where recently approved HCV therapies are cost prohibitive.

Key accomplishments include:• Pan-genotype HCV neutralizing responses (suitable for Southeast Asia/China, Russia)• Induction of both cellular and humoral immune responses

OPPORTUNITY

Pan-genotype HCV neutralizing responses (suitable for Southeast Asia/China, Russia)

MANAGEMENT

Jeff Baxter, CEO and PresidentEgidio Nascimento, CFODavid E. Anderson, PhD, Senior Vice President, ResearchMarc Kirchmeier, PhD, Vice President, FormulationAdam Buckley, Vice President, Business Development


ORGANISERSW

ELCOME


PANIES

t back :: next u

Verona Pharma plcwww.veronapharma.com

CONTACTJan-Anders Karlsson, PhD Chief Executive Officer

ADDRESS Verona Pharma plc Suite 21 – Alpha House 100 Borough High Street London SE1 1LB UK

TELEPHONE +44 (0) 20 7863 3300

EMAIL jan-anders.karlsson @veronapharma.com

YEAR FOUNDED 2006

FINANCIAL SUMMARY

As per first 6 months 2014:

Completed a £14.02m (gross) share placing, subscription and open offer in March 2014. All existing institutional shareholders participated together with a number of new healthcare-focused investors.

Loss after tax for the period of £1.40 million (2013: £1.02 million) or 0.19 pence (2013: 0.31 pence) per ordinary share.

Net cash outflows from operating activities during the six month period of £1.47m (2013: £1.29m),

Cash and cash equivalents as at 30 June 2014 of £12.10 million (2013: £0.93 million).

COMPANY PROFILE

“First-in-class” differentiated drugs, addressing high unmet needs in the respiratory market

Focused on the commercially attractive hospital market

RPL554 for patients with COPD and asthma exacerbations

Shorter time lines and less costly clinical trials

Opportunity to access community / out-patient settings through partnerships

DPI / pMDI inhalers provide convenient maintenance treatment

Multiple near-term value inflection points

Highly experienced management team and board of directors supported by global key opinion leaders

Verona Pharma is well financed.

PRODUCT PIPELINE

RPL554, inhaled PDE3/PDE4 inhibitor for respiratory diseases, Ph 2

VRP700, inhaled anti-tussive, Ph 2

OPPORTUNITES

RPL554

VRP700

MANAGEMENT

Dr. Jan-Anders Karlsson, Chief Executive OfficerDr. Grahaem Brown, Clinical Development and Clinical OperationsDr. Peter Spargo, SVP Chemistry, Manufacturing and ControlsDr. Kathy Banner, Senior Scientist, Development


ORGANISERSW

ELCOME


PANIES

t back :: next u

Vironova ABwww.vironova.com

CONTACTMohammed Homman Chief Executive Officer

ADDRESS Gävlegatan 22 Stockholm 11330 Sweden

TELEPHONE +46 (0)8-702 67 90.


YEAR FOUNDED 2005

COMPANY PROFILE

Vironova focuses on the development of novel antiviral therapeutics and virus identification products to combat and prevent the spread of viral diseases. Based on proprietary software the company also offers image analysis services of nanoparticles that is able to cut time and costs in viral related R&D, drug delivery and production of biologicals. Vironova’s goal is to create shareholder value by building a strong portfolio of drug development projects and generating a growing positive cash flow from analysis services of nanoparticles and virus identification products. In a longer perspective Vironova strives to become the most productive and profitable company within the viral disease area.

MANAGEMENT

Mohammed Homman, Chief Executive Officer Charlotta Hjerpe, Chief Operating OfficerJosefina Nilsson, Head of SalesIda-Maria Sintorn, Head of Image Analysis


ORGANISERSW

ELCOME


PANIES

t back :: next u

VTU Technology GmbHwww.vtu-technology.com

CONTACTSDr Thomas Purkarthofer Head of Business Development

Dr Michael Koncar CEO

ADDRESS Parkring 18 Grambach 8074 Austria

TELEPHONE +43 316 4009 4000

FAX +43 316 4009 4010


YEAR FOUNDED2008

COMPANY PROFILE

VTU Technology is a leading and globally recognized Austrian Biotech company with a well-established business in developing and licensing proprietary protein production technologies and processes to different industries (such as pharma, diagnostics, food & feed, chemical, agro).

VTU strives to ambitiously leverage its cutting-edge, exclusive technologies and expertise of a highly skilled team in highly promising growth segments in order to quickly establish and grow an attractive, short and long term revenue protein production & distribution business enabling the company to multiply its annual revenues.

VTU´s technological leadership position is based on its cutting-edge and most productive Pichia pastoris protein production platform backed by a strong IP position. The VTU team has an established track record in providing contract research. The company has already granted and is negotiating further revenue generating commercial licenses with prime companies from different industries.

MANAGEMENT

Dr. Michael Koncar, CEODr. Thomas Purkarthofer, Head of Business DevelopmentDr. Roland Weis, Head of OperationsDr. Iskandar Dib, Principal R&D Manager



ORGANISERSW

ELCOME

SPEAKERS

t back :: next u

Host Sponsor

Reception Sponsor



ORGANISERSW

ELCOME

SPEAKERS

t back :: next u

Silver Sponsor

t back :: next u

www.venturefund.novartis.com

Investing in innovative life sciences concepts for patient benefit creating

attractive returns for entrepreneurs and investors.

NVF supports innovative companies that strive to create significant patient benefit,

have strong management, and are capital efficient.

Novartis Venture Funds



ORGANISERSW

ELCOME

SPEAKERS

t back :: next u

Silver Sponsor

Roche www.roche.com

Headquartered in Basel, Switzerland, Roche is a leader in research-focused

healthcare with combined strengths in pharmaceuticals and diagnostics.

Roche is the world’s largest biotech company, with truly differentiated

medicines in oncology, immunology, infectious diseases, ophthalmology

and neuroscience. Roche is also the world leader in in vitro diagnostics and

tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Roche’s personalised healthcare strategy aims at providing medicines and

diagnostics that enable tangible improvements in the health, quality of life

and survival of patients. Founded in 1896, Roche has been making important

contributions to global health for more than a century. Twenty-four medicines

developed by Roche are included in the World Health Organisation Model

Lists of Essential Medicines, among them life-saving antibiotics, antimalarials

and chemotherapy.

In 2013 the Roche Group employed over 85,000 people worldwide, invested

8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs.

Genentech, in the United States, is a wholly owned member of the Roche Group.

Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more

information, please visit www.roche.com.



ORGANISERSW

ELCOME

SPEAKERS

t back :: next u

Silver Sponsors

Torreya Partners LLC www.torreyapartners.com

Torreya Partners LLC is a leading boutique advisory firm that provides strategic

advice and assistance with Mergers & Acquisitions, Partnering and Financings

to life science companies worldwide. Torreya Partners provides the long-term

thinking and objective advice required for life science companies to create lasting

value. We take great pride in handling complex financial and strategic matters

for some of the most sophisticated private and public life science companies

in the world. Our reputation has been built on quality advice, excellence in deal

execution and good outcomes for our clients. We bring the caliber of people and

quality of relationships found in some of the largest investment banks along with

the attentive, detailed service you expect from a boutique advisory firm. Torreya

Partners has offices located in New York, Philadelphia and San Francisco.

Supporting Organisations



ORGANISERSW

ELCOME

SPEAKERS

t back :: next u

www.biopharminsight.com

BioPharm Insight is your definitive guide to the global life sciences community. Subscribers take action on forward-looking intelligence uncovered by an independent team of investigative journalists, and make strategic business decisions using the most comprehensive and powerful real-time database of market analytics and key contacts. Featuring an intuitive online interface and exclusive Active Intel™ relational content technology, BioPharm Insight provides an unrivaled capability to segment and analyze the industry with detailed and searchable profiles.

Global Headquarters100 River Ridge Drive, Suite 204Norwood, MA 02062Tel: +1 781 762 9450Fax: +1 781 762 9400

New York330 Hudson Street, 4th FloorNew York, NY 10013Tel: +1 212 686 5606

London80 StrandLondon WC2R 0RL UKTel: +44 (0) 207 059 6307

BioPharm Insight



ORGANISERSW

ELCOME

SPEAKERS

t back :: next u


www.biotechgate.com

Your source for life science companies and licensing information.

If you are about to negotiate a licensing deal between a Biotech and a Pharma company. Or you are looking for a big Pharma company to out-license your Biotech product. Or you are active in the medical technology (Medtech) sector and just want to identify potential cooperation partners or customers. Or you are an investor looking for investment opportunities - or you just want to know about historical financing rounds and valuations in the life sciences, Biotech, Pharam and medical device field. This portal can solve all of these problems - and even more.

Biotechgate




ORGANISERSW

ELCOME

SPEAKERS

t back :: next u

www.citigatedr.co.uk

Citigate Dewe Rogerson is the leading international consultancy specialising exclusively in financial and corporate communications across the UK, Europe, North America and Asia.

Citigate has a dedicated Pharma & Biotech team with more than 60 years combined experience in the sector and a unique mix of skills: corporate and financial PR and investor relations, finance, journalism and academic science. The team provides sector expertise and forms an integrated part of Citigate Dewe Rogerson, benefiting from the company’s overall strength and from the cross-fertilisation of ideas across sectors.

The Citigate Pharma & Biotech team has an established track record in working with biotechnology companies at all stages in development. As well as core skills in financial calendar work, transactions support, financial PR and media relations, the team has extensive experience in branding, design and new media consultancy. Recent clients include global top-five biotechs, listed companies in the UK and Europe, and numerous emerging businesses in the UK, France, Germany, the Netherlands, and Scandinavia.

Citigate’s Pharma & Biotech team has been involved in major corporate transactions such as IPOs, other public and private fundraisings, and M&As. We have advised on a number of IPO transactions across Europe including; METabolic EXplorer (Euronext Paris - €52 million), Algeta (Oslo Stock Exchange - €30 million), Santhera Pharmaceuticals (SWX – CH88.5 million), ThromboGenics (Euronext Brussels - €35 million), Hutchison China MediTech (AIM - £40 million), Zentiva (LSE and PSE – US $211 million), Arpida (SWX - €63 million), Inion (LSE - £35 million), TopoTarget (CSE - €30 million), BioFusion (AIM - £8.2 million) and ExonHit (Alternext - 7.3 million).

Citigate Dewe Rogerson3 London Wall BuildingsLondon WallLondon EC2M 5SY

Tel: +44 (0)-207-638-9571

Citigate Dewe Rogerson




ORGANISERSW

ELCOME

SPEAKERS

t back :: next u

www.edisongroup.com

Edison is a UK-based investment intelligence firm. It employs more than 70 equity analysts operating from offices in London, New York, Sydney, Wellington and Frankfurt that provides research coverage on more than 700 publicly traded companies, making it one of the largest dedicated small and mid-cap research providers worldwide. Healthcare is the largest industry group within Edison with 12 analysts covering some 150 biotech/medical device companies located in UK, Continental Europe, North America and Australia.

Edison




ORGANISERSW

ELCOME

SPEAKERS

t back :: next u

FreeMind www.freemindconsultants.com

FreeMind is a consulting group whose goal is to assist its clients in maximizing their potential to receive funding from non-dilutive sources. Established in 1999, FreeMind is the largest consulting group of its kind with over 400 active clients, academics and Industry alike. FreeMind’s proven long-term strategic approach has garnered its clients over 1.5 billion dollars to date.

Our expertise in applying for grants and contracts extends throughout every government mechanism open to funding the life sciences including all NIH institutes, DoD, NSF, FDA, CDC, BARDA, etc., as well as private foundations such as Michael J Fox, Bill and Melinda Gates and Susan G Komen.

FreeMind’s knowledgeable and experienced team of Analysts and Project Managers are dedicated to guiding its clients non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award. Our team of experts will assist our clients in making non-dilutive funding a key tool in their long-term financial strategy.

Tel: (617) 648-0340 Fax: (617) 904-1767 Email: [email protected]

BostonFreeMind Group423 Brookline Ave. #124Boston, MA 02215

Washington DCFreeMind Consultants4094 Majestic lane # 269Fairfax, VA 22033

JerusalemFreeMind GroupHi - Tech CenterHebrew UniversityJerusalem 95702Israel




ORGANISERSW

ELCOME

SPEAKERS

t back :: next u

www.healthaptial.de

The Healthcare Industries Cluster Berlin-Brandenburg – HealthCapital – is one of the leading life sciences and healthcare centers in the world. The unique research and clinic landscape, which is the region’s major strength, is supported by a close network of key players from industry, start-ups, finance, clinics and politics. Here, numerous technology parks and networks in different fields, above all biotechnology and medical technology, create an excellent infrastructure for transforming the latest scientific findings into innovative products and services for the healthcare sector. Berlin Partner for Business and Technology is responsible for managing the cluster in cooperation with ZAB Brandenburg Economic Development Board.

HealthCapital




ORGANISERSW

ELCOME

SPEAKERS

t back :: next u

Invest in Israel /www.investinisrael.gov.il

Invest in Israel, the Investment Promotion Agency of Israel ,part of the Ministry of Economy, promotes foreign direct investment into Israel and works to foster investment growth across Israel’s industries. Accompanying potential investors through the entirety of the investment process, Invest in Israel works to accelerate local industry while offering an array of professional services to potential and current foreign investors, who include multinational companies, foreign industrial companies, venture capitalists, private equity investors, investment bankers, angels and others.




ORGANISERSW

ELCOME

SPEAKERS

t back :: next u

Israel Advanced Technology Industrieswww.iati.co.il

Israel Advanced Technology Industries (IATI) is the largest umbrella organization in Israel for the high tech and life science sectors. IATI’s mission is to strengthen the Israeli high tech and life science industries across the whole value chain and create global, technological and innovational leadership. IATI researches, develops and advocates policies and actions that promote all of Israel’s high tech, increasing awareness of its strengths and innovations worldwide.

Our members come from every level and aspect of the industry: Entrepreneurs, start-ups, incubators, accelerators, R&D centers, multi-national companies, local and international venture capital funds, private investors, tech transfer companies and service providers.




ORGANISERSW

ELCOME

SPEAKERS

t back :: next u

www.lifesciences.instinctif.com

Instinctif Partners is an international business communications consultancy. With a track record of delivering truly creative programmes, the Life Sciences practice focuses on enhancing the value proposition for companies seeking investment, partnerships or customers. Our core skill is working with clients to communicate the value of their science and innovation to key stakeholders through the most relevant channels: crafting communications solutions that showcase each company, product or technology. Specifically, we are unique in offering specialist expertise seamlessly across corporate, financial, healthcare and marketing communications with outreach programmes to media, industry, professional, public, financial and investment communities. Our service offering covers all communications disciplines including strategic counsel, PR, IR, media relations, public affairs, crisis communications, internal communications, marketing, advertising, copywriting, design, research and event management. Our globally integrated and dedicated life sciences team serves clients around the world from our bases in London, Manchester, Munich, Boston, Melbourne and Sydney.

For more information please visit www.lifesciences.instinctif.com

Instinctif Partners




ORGANISERSW

ELCOME

SPEAKERS

t back :: next u

Life Science Austria www.lifescienceaustria.at

Life Science Austria – LISA – is a program acting as a hub for people from all over the world who are interested in the life science sector in Austria. Together with its associates in the Austrian regions, LISA is the first point of contact for anyone with questions about scientific collaboration, setting up an operation, or funding and sponsoring projects and businesses in Austria.

Working with all existing life science clusters in the Austrian regions – ecoplus, human.technology.styria, Life Science Austria Vienna Region, Health Technology Cluster, and Life Science Cluster Tirol - LISA is able to build on their expertise and services. The aims of LISA and its partners are: contribute to the success of life science enterprises in Austria by helping to introduce scientific discoveries to the market, assist in the search for funding, and provide general business consultancy and support to ensure healthy commercial development.

Austria Wirtschaftsservice GesmbH (aws), is responsible for running this program on behalf of the Austrian Federal Ministry of Economics, Family and Youth (BMWFJ).

Austria Wirtschaftsservice Gesellschaft mbH, Ungargasse 37, 1030 Wien, Austria

Tel.: +43 (1) 501 75 - 0 • Fax: +43 (1) 501 75 - 900 • Email: [email protected]




ORGANISERSW

ELCOME

SPEAKERS

t back :: next u

One Nucleus

About One Nucleus: One Nucleus is a membership organisation for international life science and healthcare companies. We are based in Cambridge and London UK, the heart of Europe’s largest life science and healthcare cluster.

Vision: For One Nucleus and our members to be the top European life science and healthcare network.

Mission: We will achieve this by maximising the global competitiveness of our members.

Organisation History: Established in 1997, and formerly known as ERBI, One Nucleus is a not-for-profit, membership organisation and located in Cambridge and London – the centre of Europe’s leading life science and healthcare cluster.

The company has over 470 organisations as members including pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial service providers.

One Nucleus’s mission is to maximise the global competitiveness of our members. For our science and technology-based members, that means being global leaders in the research, development and commercialisation of healthcare innovations that radically improve the quality of people’s lives around the world. For our business and professional services members, it means delivering exceptional services that significantly enhance the business performance of their clients.

www.onenucleus.com




ORGANISERSW

ELCOME

SPEAKERS

t back :: next u

Swiss Biotech www.swissbiotech.org

SwissBiotech – One Nation – One Biotech Cluster

Swiss Biotech unites the four leading biotech regions of Switzerland (BioAlps, BaselArea, Biopolo Ticino and Greater Zurich Area). The regions have early on combined efforts with the SWX Swiss Exchange which holds a leading position in terms of life-science listings and services.

The National Industry Association named Swiss Biotech Association Represents more than 150 companies to date and acts as the operational arm for the marketing alliance. Swiss Biotech raises Switzerland’s profile as an economic center in Europe and profiles the biotech industry with its key research institutions and companies.

Swiss Biotechs’ mission is to spread the message of Switzerland as one of the top biotech locations in the world. This will be achieved by presenting a comprehensive picture of the drivers of biotechnology including research, education, economics, finance and industry. The bases for success in biotechnology are the critical mass of research institutes and accelerated technology transfer. The early integration of industry and well-trained workforce is another critical success factor for rapid economic growth. More than 40 technology parks throughout the country support the increasingly important and successful TechTransfer process.

Further inquiries:SwissBiotech, Executive OfficeTel. +41 (0)44 455 56 78 [email protected]




ORGANISERSW

ELCOME

SPEAKERS

t back :: next u

www.tiberendstrategicadvisors.com

Tiberend Strategic Advisors, Inc. is a corporate communications firm providing media strategy and execution for life science companies – biotech (therapeutics), medical devices and diagnostics. We work with both public and private emerging growth companies.

1. To enhance valuation

2. To build visibility for partnerships and strategic alliances

Tiberend Strategic Advisors, Inc.35 W. 35th Street, 5th Floor, New York, NY 10001-2205

Tel: 212.827.0020 Fax: 212.827.0028 Fax

Tiberend Strategic Advisors, Inc.


ORGANISERSPRESENTING COM

PANIESW

ELCOME

SPEAKERS

t back :: next u

Exhibitors

With its more than 110 offices in over 70 countries, provides a broad range of

intelligence and business development services for both Austrian companies

and their international business partners. Our 750 employees and 40

consultants around the world can assist you in locating Austrian suppliers

and business partners. We organize more than 1,000 events every year to

bring business contacts together. Other services provided by ADVANTAGE

AUSTRIA offices range from introductions to Austrian companies looking for

importers, distributors or agents to providing in-depth information on Austria

as a business location and assistance in entering the Austrian market.

Advantage Austria www.advantageaustria.org/ch



PANIESW

ELCOME

SPEAKERS

t back :: next u

Exhibitors

Bachem is an independent, technology-based, public biochemicals company

providing full service to the pharma and biotech industry.

Bachem is specialized in the process development and the manufacturing of

peptides and complex organic molecules as active pharmaceutical ingredients

(APIs), as well as innovative biochemicals for research purposes.

Bachem has more than 40 years of experience in peptide research

Excellent know-how in peptide chemistry and organic synthesis (technology

leadership)

Efficient manufacturing processes (cost leadership)

Bachem sets industry standards

With headquarters in Bubendorf, Switzerland and affiliates in Europe and the US,

Bachem works on a global scale and holds a leading position in the field of peptides.

Bachem AG www.bachem.com



PANIESW

ELCOME

SPEAKERS

Exhibitors

t back :: next u

BIA Separations is the leading developer and manufacturer of CIM®

(Convective Interaction Media) monolithic chromatographic columns for

production, purification, and analytics of large biomolecules. BIA Separations

is headquartered in Austria, with a research and production facility in

Slovenia and sales offices in the US and China. Our mission is to develop and

produce CIM® monolithic columns of highest quality and provide superior

research and method development services for purification and analytics of

biomolecules.

Products

CIM® monolithic columns stand for elaborate design providing high efficiency, high

speed, and high yield in downstream processing of viruses, VLP, phages, pDNA and

large proteins. Large flow-through channels and high surface accessibility of binding

sites entail binding capacities exceeding those of resin-based columns and rapid

mass transfer based on convection. CIM® monolithic columns are distinguished

for their flow independent performance, resulting in fast separation, concentration,

purification, removal, and analytics of your biopharmaceuticals. CIM® monolithic

columns are available in different product lines to suit your different needs.

BIA Separations www.biaseparations.com



PANIESW

ELCOME

SPEAKERS

t back :: next u

Exhibitors

Chelatec provides customized services in the specific fields of radiolabeling

and preclinical research. Our mission is to assist the pharmaceutical and

biotechnology industry in the identification and selection process of drug

candidates using the radioactive tracer.

The principle of radioactive labeling consists of combining a radioisotope with a

molecule. The analysis of the radiolabelled molecule is then quantitative, based

on the emission of gamma or beta rays. From the in vitro analyses to the in vivo

studies, measurement remains simple because it is direct and independent of the

matrix. Radioactive labeling remains by far the most competitive method throughout

the numerous stages of the selection and validation process of your molecules.

Chelatec www.chelatec.com



PANIESW

ELCOME

SPEAKERS

t back :: next u

Exhibitors

Here are some of the key ways our clients apply our intelligence and

forecasts to support their strategic objectives.

· Using consensus forecasts in strategic planning, strategic market assessments, or

as comparators

· Targeting M&A and licensing assets and conducting valutation activities and due

diligence

· Identifying strategic partners to help them reach their objectives

· Monitoring pipeline products and the competitive landscape

· Evaluating growth opportunities via industry trends and emerging technologies

· Assessing regulatory & clinical trial pipeline activity and requirements

· Benchmarking against peers to measure performance

· Making strategic business decisions that help drive value for their company

· Collaborating and improvng productivity by utilizing the same trusted information

across the organization

· Getting daily need-to-know commentary and analysis with custom data and news

alerts

· Understanding key future events that could impact their products and company

Evaluate Ltd. www.evaluategroup.com



PANIESW

ELCOME

SPEAKERS

t back :: next u

Exhibitors

InnoMedica is a Swiss biotech startup company based in Bern (management,

administration), Marly (production), Zug (headquarters) and Ibaraki (Japan;

Yamazaki-DDS Co., Ltd.). In January 2013, InnoMedica initiated the project

Targeted Liposomal Doxorubicin (TLD-1, Talidox®) and started operating as

an independent pharmaceutical company. Originally established in 2000,

InnoMedica was a private equity company focused on investments in the

fields of biochemistry and medicine. The vast experience in the Life Science

sector combined with broad expertise in capital markets are an optimal

foundation for the successful development of the product pipeline.




PANIESW

ELCOME

SPEAKERS

t back :: next u

Exhibitors

Invest in Israel; the Investment Promotion Agency of the Ministry of Economy

operates as the international marketing arm of the Ministry.

We offer foreign companies diverse services. Firstly we operate as a scouting arm

for companies looking for technological partners in Israel. We have hosted these last

few years companies such as: Roche, Baxter, Bayer, Takeda, Pfizer… to mention a

few.

Much can be said about Israel’s capacity for innovation. Here is just one statistic

relevant to you: Israel has the highest number of R&D workers in the world: 27 per

1,000 employees and the highest number of Doctorates are in the L.S. sector.

Invest in Israel also serves as a focal point for foreign based companies interested in

investigating direct investment and joint venture opportunities.

Israel offers attractive business incentives through the Investment Law (investment

grants of 20%, corporate tax rates than can go as low as 9%).

The Industrial R&D Law( conditional grants of 40%, 50% & 60% for approved

projects) and an extensive network of international R&D collaboration programs.

Also a program offering Employment Grants. I’ll be happy to explain all the details.

Israel is a hotbed of innovation. The numerous M&A’s by foreign companies is proof

of this. Many have been hundred million and billion $ ones. At the very least you

should explore the potential.

Israel Trade & Economics Officewww.investinisrael.gov.il



PANIESW

ELCOME

SPEAKERS

t back :: next u

Exhibitors

We are the Young Scientist Network, a non-profit organization created and

run by a group of graduate students/post-docs of the University and the

ETH Zurich. Young Scientist Network operates under the wing of Life Science

Zurich culminating in our acronym LSZYSN.

We strive to reduce the existing gap between academic research and the life

science industry.

We host events to allow young academics to explore the world of biotechnology

and to stimulate constructive interactions between people from various life science

sectors.

We envision that our efforts will contribute to the formation of a well-informed,

competitively skilled and well-connected local and global life science community.

Life Science Zurich Young Scientist Networkwww.lifescience-youngscientists.uzh.ch



PANIESW

ELCOME

SPEAKERS

t back :: next u

Exhibitors

The Ohio Clinical Trial Collaborative OCTC performs clinical drug trials Phase

I-IV for industry drug and device companies. The collaborative represents

the hospitals of the State of Ohio and consists of several thousand principal

investigators. Just a few of the areas of expertise are infectious disease,

neuroscience, neuro-oncology, pediatrics(all diseases), and oncology, and

otolaryngology/head and neck, respiratory, gastro-intestinal, women’s health,

musculoskeletal disorders, endocrine disorders, diabetes, bone marrow

transplant, sickle cell and cystic fibrosis. The collaborative also provides

support in areas such as our bio repository (human tissues).

Ohio Clinical Trials Collaborativeohioclintrials.org



PANIESW

ELCOME

SPEAKERS

t back :: next u

www.sharpservices.com

Exhibitors

Sharp Clinical Services is a leading provider of specialist clinical supply

chain services, from drug product development and manufacturing services

through to increasingly complex clinical supplies packaging, clinical labeling

and clinical distribution services.

Our experienced project management and operational teams bring together years

of unparalleled experience in producing and managing your clinical supply chain

across the globe. All projects are compliant with the highest quality standards

spanning Good Manufacturing Practices (cGMP), Good Distribution Practices, and all

international regulatory requirements.

With Sharp Clinical Service’s experience of managing local and global clinical supply

chains, access to the world markets just became easier from clinical production,

labeling & distribution to comparator sourcing & EU Qualified Person (QP) audit and

release services. We are big enough to deliver your global project while remaining

small enough to care for your product like our own.

Value Added Services

· Clinical Supply Chain Optimisation

· QP Consultancy

· Project Management

· Design Engineering

· Kit/Tooling Design

· Primary/Secondary Packaging Consultation

· Protocol Review and Breakdown

· Import/Export Consultation/Assistance

· International Shipping Consultation

· Study Design

· Drug Forecasting

· Validation Studies Design

· Stability Protocol creation

· R&D Specifications

· Formulation selection

· Formula Development Consultation

Sharp Clinical Services



Organisers


WELCOM

ESPEAKERS

www.sachsforum.com

Sachs Associates is a London based international conference organiser which produces high profile events for the bio-pharmaceutical and financial community. These events are held In Europe and the USA; currently in Boston and Zurich.

The company was established in 1992 and ran emerging growth and emerging market investor forums in association with Dow Jones and then Bloomberg LP over a ten year period.

The benefits of conference participation with Sachs Associates may be summarised as follows:

Multimedia ExposureSachs Associates is uniquely able to provide its conference sponsors maximum exposure across extremely well focused electronic and print media. Regular extensive coverage of all the Company’s conferences is carried out through video streaming and extensive events coverage through major international financial news agencies,including Bloomberg, Dow Jones and Reuters. In addition, Sachs Associates has a number of long establishedrelationships with other financial press organisations globally, which allow further effective distribution onbehalf of its clients.

Eminent SpeakersSachs Associates is committed to ensuring that its events continue to provide forums with the participation ofthe most eminent speakers from the public and private sectors. Through its reputation and its long-establishedlocal relationships, the Company has attracted the very senior political and economic personalities as speakersat its events.

Sponsorship and Marketing Opportunities for forthcoming eventsSachs Associates has developed an extensive knowledge of the key individuals operating within the Europeanand global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at theforefront of the industry and provides a powerful tool by which to increase the position of your company in thismarket.

Sponsorship of any of our events allows you to raise your company’s profile directly with your potential clients.All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most outof attending our industry driven events.

The following sponsorship and marketing opportunities are available at future conferences:• Conference Sponsor – including workshops and social events• Exhibition stands• Distribution of Promotional Material

If your company is interested in exhibiting or sponsorship opportunities please callMina Orda on +44 203 463 4890.

Sachs Associates



PANIESW

ELCOME

SPEAKERS

www.sachsforum.com

BI

OT

EC

H

IN

E

UR

OP

E

IN

VE

ST

OR

F

OR

UM

27 Belsize LaneLondon

NW3 5QS

Tel: +44 203 463 4890Fax: +44 (0) 207 691 7919

We look forward to seeing you at:

2nd AnnualMEDTECH & DIAGNOSTICS INNOVATIONS SUMMIT

13th November 2014 • Düsseldorf

3rd Annual CANCER BIO PARTNERING and INVESTMENT FORUM

Promoting Public & Private Sector, Collaboration & Investment in Drug Development

23rd February 2015 • New York

8th Annual EUROPEAN LIFE SCIENCE

CEO FORUM & EXHIBITIONPartnering & Investing in Biotech & Pharma Industry

3rd – 4th March 2015 • Zurich

14th annual biotech in europe investor forumsachs associates are delighted to welcome you to the...

Documents